Sudan Communicable Disease Profile

WHO/CDS/2004.
COMMUNICABLE DISEASE TOOLKIT
SUDAN
1. COMMUNICABLE DISEASE PROFILE
2004
FINAL DRAFT
Communicable Disease Working Group on Emergencies, WHO/HQ

The WHO Regional Office for Eastern Mediterranean (EMRO)
WHO Office, Khartoum
World Health Organization 2004
All rights reserved.
The designations employed and the presentation of the material in this publication do not imply the
expression of any opinion whatsoever on the part of the World Health Organization concerning the legal
status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or
boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full
agreement.
The mention of specific companies or of certain manufacturers products does not imply that they are endorsed
or recommended by the World Health Organization in preference to others of a similar nature that are not
mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital
letters.
The World Health Organization does not warrant that the information contained in this publication is complete
and correct and shall not be liable for any damages incurred as a result of its use.
Further information is available at: CDS Information Resource Centre, World Health Organization, 1211
Geneva 27, Switzerland; fax: (+41) 22 791 4285, e-mail: [email protected]
ACKNOWLEDGMENTS
Edited by Dr Michelle Gayer, Dr Albis Gabrielli, and Dr Mire Connolly of the Programme on Communicable
Diseases in Complex Emergencies, WHO/CDS.
This Profile is a collaboration between the Communicable Disease Working Group on Emergencies (CD-
WGE) at WHO/HQ, the Division of Communicable Disease Prevention and Control (DCD) at WHO/EMRO
and the Office of the WHO Representative for Sudan. The CD-WGE provides technical and operational
support on communicable disease issues to WHO Regional and Country Offices, MoHs, other UN agencies,
NGOs and international organizations. This Working Group includes the Departments of Control, Prevention
and Eradication (CPE), Surveillance and Response (CSR) in Communicable diseases (CDS), Roll Back
Malaria (RBM), Stop TB (STB) and HIV/AIDS (HIV) in HTM; and the Departments of Child and Adolescent
Health and Development (CAH), Immunizations, Vaccines and Biologicals (IVB) and Health and Action in
Crisis (HAC).
The following people were involved in the development and review of this document and their contribution is
gratefully acknowledged:
The following persons in HQ, EMRO and WHO Country Office in Khartoum contributed to the development of
this document and their technical input is gratefully acknowledged:
Dr Samira Aboubaker (FCH/CAH), Dr Roberta Andraghetti (CDS/CSR), Dr Hoda Atta (EMRO/DCD), Dr Samiha
Baghdadi (EMRO/DCD), Dr Andrew Ball (FCH/HIV), Ms Rachel Bauquerez (CDS/CSR), Dr Claudio Beltramello
(CDS/CPE), Dr Eric Bertherat (CDS/CSR), Dr Julian Bilous (HTP/VAB), Dr Sylvie Briand (CDS/CPE), Dr Philippe
Calain (CDS/CPE), Dr Claire-Lise Chaignat (CDS/CPE), Dr Kabir Cham (CDS/MAL), Ms Claire Chauvin
(HTP/VAB), Dr Ottorino Cosivi (CDS/CSR), Dr Denis Coulombier (CDS/CSR), Dr Philippe Desjeux (CDS/CPE),
Dr Dirk Engels (CDS/CPE), Dr Suzanne Farhoud (EMRO/DHP), Dr Pierre Formenty (CDS/CSR), Dr Malgosia
Grzemska (CDS/STB), Dr Zoheir Hallaj (EMRO/DCD), Dr Bradley Hersh (HTP/VAB), Prof. Martin Hugh-Jones
(WHO Collaborating Center for Remote Sensing and Geographic Information Systems for Public Health,
Louisiana State University), Dr Yvan Hutin (HTP/BCT), Dr Frdrique Marodon (CDS/CPE), Mrs Gill Mayers
(HTP/VAB), Dr Franois-Xavier Meslin (CDS/CPE), Dr Abraham Mnzava (EMRO/DCD), Dr Ezzeddine Mohsni
(EMRO/DCD), Dr Antonio Montresor (CDS/CPE), Mr Altaf Musani (EMRO/EHA), Ms Kathy ONeill (CDS/CSR),
Dr Salah-Eddine Ottmani (HTM/STB), Dr Brian Pazvakavambwa (FCH/HIV), Dr William Perea (CDS/CSR), Dr
Sergio Piche (EMRO/DHP), Ms Claire Preaud (CDS/CSR), Dr Aafje Rietveld (HTM/MAL), Dr Mike Ryan
(CDS/CSR), Dr Guido Sabatinelli (WHO/Khartoum), Dr Maria Santamaria (CDS/CSR), Dr Lorenzo Savioli
(CDS/CPE), Dr Khalid Shibib (SDE/HAC), Dr Nadia Teleb (EMRO/DCD), Dr Williamina Wilson (CDS/CSR), Dr
Nevio Zagaria (CDS/CPE).
We would like thank the Government of Ireland and the Office of US Foreign Disaster Assistance (OFDA) of
the US Agency for International Development for their support in development of this document.

Acknowledgments 3
1. Introduction5
2. Acute lower respiratory infections (ALRI) 6
3. African trypanosomiasis (African sleeping sickness) 10
4. Bacillary dysentry (shigellosis) 15
5. Cholera 17
6. Diarrhoeal diseases (others) 20
7. Diphtheria 23
8. Dracunculiasis (Guinea worm infection/disease) 26
9. Ebola Haemorrhagic Fever 30
10. HIV/AIDS 33
11. Leishmaniasis (cutaneous and mucosal) 40
12. Visceral leishmaniasis (kala azar) 44
13. Leprosy 48
14. Lymphatic filariasis 51
15. Malaria 55
16. Measles 59
17. Meningococcal disease (meningitis and septicaemic form) 63
18. Onchocerciasis (river blindness) 69
19. Pertussis (whooping cough) 74
20. Poliomyelitis 77
21. Rabies (Sudan) 81
22. Schistosomiasis 84
23. Soil - transmitted helminthiases (ascariasis, hookworm infection, trichuriasis)88
24. Tuberculosis 92
25. Typhoid fever 97
26. Yellow fever 99
Annex 1: Flowcharts for the diagnosis of communicable diseases 102
Annex 2: Steps for management of a communicable disease outbreak 107
Annex 3: Safe water and sanitation 108
Annex 4: Injection safety 109
Annex 5: Key contacts for Sudan 110
Annex 6: List of WHO guidelines on communicable diseases 113
Annex 7: Immunization schedule for Sudan 116
Annex 8: Map of Sudan 117
Annex 9: Population of Sudan,2000 118
Annex 10: Basic health indicators in Sudan 119

INTRODUCTION
The purpose of this document is to provide public health professionals working in Sudan with up to date information on the
major communicable disease threats faced by the population. The list of endemic and epidemic diseases has been
selected on the basis of the burden of morbidity and mortality. Diseases which have global eradication or elimination
goals are also included. The document outlines the burden of communicable diseases in Sudan for which data are
available, provides data on recent outbreaks in the country, and presents disease-specific guidelines on the
prevention and control of these diseases.
The control of communicable represents a major challenge to those providing health care services in Sudan. It is
hoped that this document will facilitate the co-ordination of communicable disease control activities between all
agencies working in the country.

1. ACUTE LOWER RESPIRATORY INFECTIONS (ALRI)
CHILDREN BELOW FIVE YEARS OF AGE
DESCRIPTION
Infectious agent
Bacteria: the most common are likely to be Streptococcus pneumoniae and
Haemophilus influenzae (and Staphyloccus aureus to a less extent).
Several respiratory viruses
Case definition Clinical case definition

"Pneumonia" is used at government facilities as an action-oriented classification for
management purposes according to both the ARI and IMCI guidelines. It is therefore
likely to include lower ARI clinically presenting with similar signs and symptoms, such
as pneumonia, bronchiolitis, bronchopneumonia.
The classification of cases below five years old according to the national IMCI
guidelines - that differ slightly from the ARI guidelines - is reported below.
Children 2 months up to 5 years old

Pneumonia
Symptoms: Cough or difficult breathing; and
Signs: 50 or more breaths per minute for infants age 2 months up to 1 year, or
40 or more breaths per minute for children age 1 up to 5 years old;
and
No general danger signs, chest indrawing or stridor in calm child.
Severe Pneumonia or Very Severe Disease

Symptoms: Cough or difficult breathing and: any general danger signs or
Chest indrawing or stridor in a calm child.
General danger signs: unable to drink or breast feed; vomiting everything;

convulsions; lethargic or unconscious
Infants below 2 months of age
Severe cases in young infants are classified broadly as "Possible serious bacterial
infection", based on the presence of any of 16 signs or symptoms, among which
are also respiratory signs such as fast breathing (60 or more breaths per minute),
severe chest indrawing, nasal flaring, grunting and wheezing. Other signs include also
fever or low body temperature, typical signs of infection (ear and skin), danger signs
and feeding problems.
[Source: National guidelines on Integrated Management of Childhood Illness - IMCI

-, revised in 2001]
Mode of Airborne .
transmission
Incubation Depends on the infective agent. Usually 2-5 days.
Period of Depends on the infective agent. Usually during the symptomatic phase.
communicability

EPIDEMIOLOGY
Burden Pneumonia is reported as one of the leading causes of death in children less than
five years of age throughout the country.
Acute respiratory infections represented 20% of outpatient visits in children under
five years old and were responsible for 41 % of hospital admissions for the same
age group in 1997, according to data from the Federal Ministry of Health.
Pneumonia caused 16% of deaths in paediatric hospitals in 1996, while acute
respiratory infections were responsible for 19% of hospital deaths in under-fives
in 1997.
(Source: "Report on IMCI Early Implementation Phase in Sudan", Primary Health
Care, Federal Ministry of Health, November 1999)
Geographical Throughout the country .
distribution
Seasonality Should be checked with the country. An ARI peak is likely to occur in the colder
months, December through February.
Alert threshold An increase of the number of cases above what is expected
Recent epidemics
in the country Should be checked with the country.
RISK FACTORS FOR INCREASED TRANSMISSION

Population Yes Influx of non-immune population / infected individuals into areas of new
movement pathogens. War in Sudan has caused the displacement of significant number of
people from war-torn areas to safer areas, including Khartoum. Crowding
situations of internally displaced people in the new areas may put them at
higher risk of developing ARI.
Overcrowding Yes Likely to be important
Poor access to Yes Access to services and drugs varies considerably between areas,
health services especially in rural areas. High attrition rates of government health
providers including those trained in child health (IMCI) are high and
represent a major concern. Immunisation coverage is low, with rates of 51
% for measles, less than 50% for DPT3 and 27% for fully immunized child in
2001 (Source for immunization rates: Multiple Indicator Cluster Survey,
Sudan, 2000).
Prompt identification and treatment of the cases by appropriate providers is
the most important control measure
Without proper treatment fatality rate is high (20 % or more in
emergency situations) - To be checked with country if data available
on refugees .

Food shortages Yes Food insecurity is likely to occur in war-torn areas and among displaced people.
Additional risk factors include: poor breastfeeding practices (less than 20% of
infants less than 4 months old are exclusively breastfed), likely high
malnutrition indicators (low birth weight, malnutrition, vitamin A deficiency),
and poor feeding practices during illness (Source: Multiple Indicator
Cluster Survey, Sudan, 2000).
Lack of safe water Yes 58% of the population has access to sanitary means of excreta disposal, the
and poor percentage being less than 20% for the poor households. Access to sources
sanitation of safe water varies considerably especially by standards of living, with the
Poor having very limited access to them. (Source: Multiple Indicator Cluster
Survey, 2000).
Others Yes Indoor air pollution. Low temperatures may increase the relative risk of
children's acquiring pneumonia.
Risk assessment
ALRI represent one of the top leading causes of death in children under 5 in
conclusions Sudan. Inadequate feeding practices, food insecurity and overcrowding among
displaced people, low immunization coverage, limited access to quality health
care (trained staff and drugs) are likely to increase children's risk to illness and
death, especially among rural populations and the Poor.
PREVENTION AND CONTROL MEASURES

Case Management
Priority is early recognition and adequate treatment of cases
First-line antibiotic for cases in under-fives classified as pneumonia is
cotrimoxazole; second-line antibiotic is amoxicillin. Pre-referral antibiotics for
severe cases that cannot take oral antibiotic or treatment for severe cases that
cannot be referred are: intramuscular chloramphenicol for children 2 months up to 5
years old, and intramuscular benzylpenicillin and gentamicin for infants under 2
months of age.
Children with fever, in addition to cough or difficult breathing, may be treated also for
malaria, according to their exposure to malaria risk (high Vs low malaria risk areas)
and laboratory results (blood film) if these services are available.
Supportive measures such as continued feeding to avoid malnutrition, vitamin A if
indicated, antipyretics to reduce high fever and protection from cold (especially
keeping young infants warm) are part of integrated case management.
Prevention of low blood glucose is carried out for severe cases.
Integrated management of illness is practiced in any sick child seen by a provider trained
in IMCI.
Proper advice is given to caretakers of non-severe cases on home care, including
compliance with antibiotic treatment instructions.
Signs of malnutrition are assessed as this increases the risk of death due to
pneumonia. Severely malnourished children are referred to hospital.
Prevention
Health education on good ventilation of housing &avoid over crowedness .
Adequate feeding, including exclusive breastfeeding, to avoid malnutrition
Improved immunization coverage

Immunization
Measles, diphtheria and whooping cough immunization are effective to reduce impact of
ALRI. Immunization coverage rates for these antigens are currently sub-optimal in
Sudan.
2. AFRICAN TRYPANOSOMIASIS (AFRICAN SLEEPING SICKNESS)

DESCRIPTION
Infectious agent Protozoan: Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense .
Case definition Clinical description:
1st stage (haemolymphatic involvement):
A painful chancre (papular or nodular) at the primary site of Tsetse fly bite (rare in
T.b. gambiense infection).
Possibly fever, intense headache, insomnia, painless lymphadenopathy, anemia,
local oedema and rash.
2nd stage (neurological involvement):
Parasites cross the blood-brain barrier and attack the central nervous system
Cachexia, somnolence and signs of central nervous system involvement.
Possible protracted course of several years in T.b. gambiense infection.
Rapid and acute evolution in T.b. rhodesiense infection.
Both diseases are always fatal without treatment.
Laboratory tests available:
Serological:
Card Agglutination Trypanosomiasis Test (CATT): for T. b. gambiense only.
Immunofluorescent assay: for T. b. rhodesiense mainly and possibly for
T. b. gambiense.
Parasitological:
Detection (microscopy) of trypanosomes in blood, lymph node aspirates or
cerebro-spinal fluid (CSF).
Case classification:
Suspected*: any case without direct demonstration of the parasite

that is compatible with the clinical description
and/or
with a positive serology
Confirmed: a case with direct demonstration of the parasite, compatible or not
with the clinical description.
1St stage: parasite seen in blood and/or lymph nodes, with CSF containing no
detectable trypanosomes and a leukocyte count <_5/l.
2" d stage: CSF containing trypanosomes and/or a leukocyte count >5/l.
NOTE: in the 1s` stage or early in the 2i0 stage of the disease there are often no clinical signs
or symptoms classically associated with the disease. Suspicion is then based on local risk of

Mode of The disease is transmitted primarily by the bites from infected Tsetse flies (Genus
transmission Glossina). Transmission is also possible through contamination with infected blood or
through the placenta (congenital).
Incubation
In T.b. rhodesiense infection: 3 days to a few weeks
In T.b. gambiense infection: longer incubation period that can take several months
or even years
Period of The disease is communicable to the Tsetse fly as long as the parasite is present in the
communicability blood of the infected person or animal (from 5-21 days after the infecting bite).
Parasitaemia occurs in waves of varying intensity in untreated cases during all stages
of the disease. Once infected, Tsetse fly remains infective for life (life span: 1 to 6
months).
EPIDEMIOLOGY
Burden From January 2000 to November 2002, the figures collected from various and
incomplete sources show that about 138,800 people were screened and about 6,155
cases were identified. Among them about 48% were already in the neurological phase
of the disease.
The average prevalence rate calculated for these figures is 3.7%. The prevalence can
reach more 20% in some areas such as Ibba village.
About 5 million people are at risk from African trypanosomiasis in Sudan, and 50,000
are estimated to be already infected.
Due to the focal nature of the disease, prevalence should refer only to the areas at
risk. Aggregation: of datato the national level is misleading and obscures the problem.
It is almost impossible to measure incidence rates of T. b. gambiense sleeping
sickness, because the variable and long asymptomatic period of the disease makes it
impossible to know with any accuracy when infection began. There is little or no
information on mortality available outside hospital records, since most of the deaths
take place in rural areas with poor or non-existing civil registration systems. In
particular, mortality in infants is difficult to measure, even with systematic screening,
because of the well known systematic underreporting of infant deaths. In addition, it is
very difficult to obtain age/sex breakdowns.
Seroprevalence of 10-30% has been found in certain villages of southern Sudan .
Geographical Foci of T.b. gambiense form are located in the southern part of Sudan, west of
distribution the Nile, within 100 km of the borders with Central African Republic, Democratic
Republic of Congo and Uganda. The main foci are Juba, Kato-Keji and Yei counties in
Bahr-alJabal state, and Maridi-Mundri-Ibba, Tambura, Yambio and Yei counties in
Western Equatoria state.
Very little information is available on the current status of African trypanosomiasis
in Bahr-EI-Gazal and Eastern Equatoria states, but the area around Torit (Eastern
Equatoria) is known to be heavily affected.
Small foci of T.b. rhodesiense form are located in southern Sudan on the East side of
the Nile river, along the border with Ethiopia.
An important feature of African trypanosomiasis is its focal nature. It tends to occur
in circumscribed zones, and observed prevalence rates vary greatly from one
geographical area to another, and even between one village and another within the
same area
Seasonality The disease has no clearly evident seasonal pattern.

Recent Several major outbreaks have been observed periodically in southern Sudan since the
epidemics in early part of the 20th century. The first outbreak lasted from 1920 to 1929, the
the country second from 1953 to 1961, the third from 1975 to 1985. The 1975 epidemic affected
primarily the Li-Rangu, Yambio and N'zara areas. In 1977 Yambio district alone
reported 614 new cases, all of which were self-reporting.
After the resurgence of the disease in the late 1970s, a bilateral Sudanese-Belgian
Sleeping Sickness Control Programme limited the incidence of the disease, which
had been nearly eliminated by 1983. However, control activities collapsed in 1990
when fighting in the civil war intensified. The disease has gained epidemic
proportions since mid-1990s: today Sudan is included among the four worst-hit
countries (with Angola, Democratic Republic of Congo and Uganda), where African
trypanosomiasis is epidemic due to a high prevalence and an important transmission
level.
Population
Yes Risk of settlement in a high-transmission area.
movement Good organization and efficient health structures are essential to diagnose and
treat the disease.
Overcrowding No Tsetse density is not related to the density of population.

Poor access to Yes The complex nature of the disease requires efficient health structures and
health services trained personnel for diagnosis and treatment.
Food shortages No
Lack of safe water No The Tsetse fly is not attracted by dirty water.
and poor
sanitation
Others Yes It is a neglected disease.
Risk assessment Southern Sudan is experiencing a resurgence of epidemic sleeping sickness:
conclusions transmission rate and prevalence are increasing rapidly. War has played a
major role in causing the breakdown of surveillance, case-detection and
treatment. Access to populations in epidemic areas has been so far extremely
difficult, and health capacity has almost collapsed.
The number of people living in areas at risk for sleeping sickness in southern
Sudan can be estimated at 1-2 million, but reliable data are not available.
Prevalence of confirmed Trypanosoma brucei gambiense infection in
humans now exceeds 5% in several foci.

Case Management Early screening and diagnosis are essential, as treatment is easier in the 1st stage
of the disease (less injections required, no psychiatric disorders), at lower-risk
and can be administered on an outpatient basis.
Diagnosis and treatment require trained personnel and self-treatment is not
possible. All confirmed cases must be treated as soon as possible.
Most available drugs are old, difficult to administer in poor conditions and by no
means always successful.
T. b. gambiense infection:
1St stage:
Pentamidine (4 mg/kg/day) IM for 7 consecutive days on an outpatient basis.
2nd stage:
Melarsoprol. Hospitalization with 3 series of injections administered with a
rest period of 8 to 10 days between each series. A series consists of one
injection of 3.6 mg/kg/day Melarsoprol IV for 3 consecutive days.
In case of Melarsoprol treatment failure, use Eflornithine 400 mg/kg/day
administered in four daily slow infusions (lasting approximately 2 hours).
Infusions are given every 6 hours, which represents a dose of 100 mg/kg per
infusion.
T. b. rhodesiense infection:
1 St stage:
Suramin - The recommended dosage is 20 mg/kg/day with a maximum dose of
1 g per injection. The drug is administered intravenously at the rate of one
injection per week. The treatment course is 5 weeks for a total of five
injections.
2nd stage:
Melarsoprol. Hospitalization with 3 series of injections administered with a
rest period of 8 to 10 days between each series. A series consists of one
injection of 3.6 mg/kg/day Melarsoprol IV for 3 consecutive days.
Note: Melarsoprol causes reactive encephalopathy in 5-10% of patients, with fatal
outcome in about half the cases. The treatment has a 10-30% rate of treatment
failure, probably due to pharmacological resistance. Increasing rates of resistance to
Melarsoprol (as high as 25%) have been reported from various countries,
including Angola.
A Human African Trypanosomiasis Treatment and Drug Resistance Network has
been established by WHO. Four working groups are dealing with: (a) Drug availability
and accessibility; (b) Coordination of drug development and clinical trial; (c) Research
on resistance and treatment schedules; (d) Surveillance of resistance.
Procurement of Drugs:
Since 2001, a public-private partnership signed by WHO has made all drugs
widely available. The drugs are donated to WHO. Requests for supplies are made to
WHO by governments of disease-endemic countries and organizations working in
association with these governments. Stock control and delivery of the drugs
are undertaken by Medecins sans Frontieres in accordance with WHO
instructions. All the drugs are provided free of charge: recipient countries pay only for
transport costs and customs charges.
Prevention Routine Preventive Measures: Public education on the following measures should
be encouraged:
Avoidance of known foci of sleeping sickness and/or Tsetse infestation
Wearing suitable clothing (including long sleeves and long trousers) in endemic
areas
Routine use of insect repellents and mosquito nets
Case Detection: containment of the human reservoirs through periodical population
screening and chemotherapy of cases remains the cornerstone of disease control
for gambiense sleeping sickness. Active periodical screening (active case-finding) of
the population of endemic foci by mobile screening teams is the best option, since
infected subjects can remain asymptomatic and contagious for months or years
before developing overt symptomatology. Screening usually comprises CATT-testing
of the complete population visited by teams.
Because rhodesiense sleeping sickness is an acute disease, passive case-finding by
fixed posts is more appropriate, since symptoms are severe and patients will tend to
look for health care voluntarily.
Vector Control: Tsetse fly control programmes:
Application of residual insecticides or aerosol insecticides
Use of insecticide-impregnated traps and screens
Destruction of Tsetse habitats by selective clearing of the vegetation: clearing
bushes and tall grasses around villages is useful when peridomestic transmission
occurs. Indiscriminate destruction of vegetation is NOT recommended.
From 1997, a community-based vector trapping project has been implemented in
Tambura county (Western Equatoria): more than 3,000 pyramidal traps made locally
and maintained by volunteers have been placed at sites where people is likely to
come into contact with Tsetse flies. Between 1997 and 1999, the seroprevalence of
African trypanosomiasis in Tambura county villages in which screening, drug
treatment, and vector control activities were being conducted, dropped from
almost 9% to less than 2%.
Prohibition of blood donation from those who live (or have stayed) in endemic
areas.
The Government of Sudan has established a National Committee for Tsetse and
Trypanosomiasis Control (NCTTC) to enhance human trypanosomiasis management
activities and to effectively mobilize and manage resources allocated for the control
or the eradication of the disease from Sudan. The NCTTC includes the Federal
Ministry of Health, the Bahr-al-Jabal Regional Ministry of Health, the Tropical
Medicine Research Institute and the Central Veterinary Research Laboratories.
These institutions are involved in surveillance and case-detection activities,
hospitalization of cases, drug resistance monitoring, training of sleeping sickness
staff, vector surveys and studies on the animal reservoir.
Unfortunately, control activities are currently hampered by lack of adequate funding.
Epidemics control Mass surveys to identify affected areas.
Early identification of infection in the community, followed by treatment.
Urgent implementation of Tsetse fly control measures (e.g. aerosol insecticides
sprayed by helicopter and fixed wing aircraft)

3. BACILLARY DYSENTARY (SHIGELLOSIS)
DESCRIPTION
Infectious agent Bacterium: Genus Shigella, of which Shigella dysenteriae type 1 causes the most
severe disease and is the only strain responsible for epidemics
Case definition Suspected case (clinical case definition)
Diarrhoea with visible blood in the stools
Confirmed case
A case corresponding to the clinical case definition with isolation of Shigella from
stools
Mode of Fecal-oral route, particularly contaminated water and food
transmission
Incubation Incubation period is usually 1-3 days. May be up to one week for S. dysenteriae type
1
Period of During acute infection and until 4 weeks after illness (without treatment). With
communicability appropriate treatment 2-3 days. Asymptomatic carriers exist
EPIDEMIOLOGY
Burden Although there is many suspected cases but there is no confirmed one .
Geographical There is scattered cases(there is no difenitive areas ) .
distribution
Seasonality Cases are distributed all over the year. Seasonal incidence patterns are not constant
over years.
Alert threshold Five or more linked cases must be investigated further.
Recent 2001 February: 7 deaths were reported from Acumcum (western Bahr-al-Gazal).
epidemics in the Many cases were also reported but figures are not available. Shigella dysenteriae
country was isolated from stool samples.
March- April 1999- During an outbreak of recurrent fever in Rumbek county (Lakes
state), cases of bloody diarrhoea were observed and confirmed as shigellosis.

Population Yes Spreading of the infectious agent .
movement
Overcrowding Yes Very important for transmition of the disease .
Poor access to Yes Early detection and containment of the cases are paramount to reduce
health services transmission
In absence of proper treatment, case fatality rate with S. dysenteriae type 1
can be as high as 10% in children under 10 years-old.
Food shortages No However, malnutrition increases gastrointestinal tract susceptibility to
invasiveness of the organism and severity of disease
Lack of safe Yes The most important risk factor.
water and poor
sanitation
Others No

Risk assessment Risk of epidemics of S. dysenteriae type 1 is high in the refugee camps (up to one
conclusions third of the population at risk may be affected)
In the general population the risk is strictly related to the availability of safe water

Case Management Early and appropriate therapy is very important: treatment with an effective
antimicrobial can reduce the severity and duration of shigellosis. Selection
depends on resistance patterns of the bacteria and drug availability.
The problem of rapid acquisition of antimicrobial resistance in the treatment of
Shigella dysentery in Africa is a cause of concern. It is therefore important to
confirm the sensibility of Shigella dysenteriae to nalidixic acid in the early stages
of an outbreak of shigellosis, in order to avoid the use of ciprofloxacine and
decrease the risk of an early development of resistance to this antibiotic.
Supportive treatment using ORS, continued feeding (frequent small meals) and
antipyretics to reduce high fever are also essential.
S. dysenteriae type 1 is often more severe or fatal in young children, the elderly, and
the malnourished, and prompt treatment with antibiotics is essential. If in short
supply, antibiotics should be reserved for such high-risk groups.
Epidemic control Inform the Health Authorities if one or more suspected cases are identified. Early
detection and notification of epidemic dysentery, especially among adults, allows
for timely mobilization of resources needed for appropriate case management
and control.
Confirm the outbreak, following WHO guidelines.
Rectal swabs from suspected cases should be collected and shipped refrigerated to
laboratories in an appropriate medium (e.g. Cary Blair medium) for culture to
confirm the diagnosis of Sdl. It is recommended that at least 10 cases be used to
confirm the cause, identify antibiotic sensitivity and verify the outbreak. Once
confirmed, it is not necessary to obtain laboratory confirmation for every patient.
Testing of Sdl isolates for antimicrobial sensitivity should be done at regular
intervals to determine whether treatment guidelines remain appropriate.
International referral laboratories are available to assist in identification of the
organism and confirmation of the anti-microbial resistance pattern.
Do not wait for laboratory results before starting treatment/control activities.
Prevention See:
Section on Diarrhoea) Diseases and Annex 3: Safe Water and Sanitation
Guidelines for the Control of Epidemics due to Shigella dysenteriae type 1.
(available online at: http://www.who.intlemc-documents/cholera/whocdr954c.html)

4. CHOLERA
DESCRIPTION
Infectious agent Bacterium: Vibrio cholerae
Case definition A cholera outbreak should be suspected if:
A person older than 5 years develops severe dehydration or dies from acute
watery diarrhoea (clinical case definition); or
There is a sudden increase in the daily number of patients with acute watery
diarrhoea, especially patients who pass the "rice water" stools typical of cholera
Confirmed case
Isolation of Vibrio cholerae 01 or 0139 from stools in any patient with diarrhoea
Mode of Fecal oral route.

transmission
Main modes of transmission:
Drinking contaminated water
Eating food (fruits and vegetables) contaminated through:
Water
Nightsoil
Contamination during preparation (rice, millet, food from street vendors)
Contaminated seafood
Indirect contamination (hands)
Incubation Incubation period is usually a few hours to 5 days
Period of During the symptomatic phase until 2-3 days after recovery. Very rarely for months.
communicability
EPIDEMIOLOGY
Burden Even if no official data is available, cases of cholera are known to occur in the
country.
Geographical No definite geographical distribution for the disease .
distribution
Seasonality All the outbreaks mentioned below occurred between March and June
Alert threshold Any suspected case must be investigated.

Recent epidemics No official data available.
in the country
2002 - February-April: as of 18 April, 109 cases of "acute watery diarrhoea" including
1 death have been reported from Kerker, in the Nuba mountains (STATE). All cases are
children under 5 years of age.
2001 - April-May: a total of 65 cases of "acute watery diarrhoea" including 5 deaths
was reported from Wudier and Beih (Upper Nile). (Source: WHO SS Health Update)
1999 - Since early March 1999, the areas of Padak, Mading, Wanding, Lankien,
Akobo and Burmat have reported a total of 892 cases of "acute watery diarrhoea
with 24 death up to 27 April 1999. The outbreak mainly affected the Jungoli state in
areas south of river Sobat.(source WHO)
1996 - In April an outbreak of cholera and severe diarrhoeal diseases spread rapidly
through rebel-held areas in southern Sudan with over 12,000 cases reported after six
weeks. The outbreak resulted in at least 1,800 deaths. Although exact numbers are
unknown, as several locations which reported outbreaks were inaccessible, case
fatality rates were extremely high in those locations where data could be confirmed.
(source: UN)
1985 - May-June: 1,175 cases of cholera with 41 presumed home deaths and 13
inpatient deaths are registered among Ethiopian refugees settled in two adjacent
camps near Khashm-el-Girba in eastern Sudan (Kassala state)

Population Yes Spreading of the infectious agent.
movement
Overcrowding Yes Very important
Food shortages No
Lack of safe Yes The most important risk factor .
water and poor
sanitation
Others No
Risk assessment In camp situations, diarrhoeal diseases can account for between 25%
conclusions and 40% of deaths in the acute phase of an emergency. Over 80% of
deaths usually occur among children under 2 years old.all this cases not
reported as cholera because all cases under 5years &no isolatin of
vibrio .

Case management
The mainstay of the case management of cholera is the treatment of dehydration,
using ORS or i.v. fluids (ringer lactate)
Use of antibiotics (doxicycline/tetracycline) is not essential for disease
treatment but may be used to reduce the volume of diarrhoea (and of the
rehydration solutions required), shorten its duration and the period of vibrio
excretion. Antimicrobial sensitivity pattern should be assessed in order
to select the appropriate antibiotic.
Case fatality rate can be extremely high (from 5% up to 40%) in absence
of a proper treatment
Epidemic control
Inform the Health Authorities immediately if one or more suspected cases
are identified
Confirm the outbreak, following WHO guidelines. Stool samples must be
taken with a rectal swab and transported in Cary Blair medium. If a
transport medium is not available, a cotton-tipped rectal swab can be
soaked in the liquid stool, placed in a sterile plastic bag, tightly sealed,
and sent to the laboratory. It is recommended that at least 10 cases be
used to confirm the cause, identify antibiotic sensitivity and verify the
outbreak. Once confirmed, it is not necessary to obtain laboratory
confirmation for every patient.
Do not wait for laboratory results before starting treatment/control
activities
Ensure prompt treatment and confirm the diagnosis
Isolate cases in cholera treatment centres
Provide adequate health education
Ensure access to safe water and proper sanitation
Prevention See:
Prevention in Diarrhoea) Diseases section
Annex 3 : Safe Water and Sanitation
Guidelines for cholera control, WHO 1993
Immunization Two oral vaccines are currently available:
killed cholera vaccine (WC/rBS, two doses); and
live attenuated vaccine (CVD103- HgR, single dose)
They are licensed in a few countries only. Both might be used in carefully
evaluated emergency situations, such as refugee camps or slum residents.
Cholera vaccines can complement, but cannot replace conventional control
measures.
See also: Potential use of cholera vaccines in emergency situations. WHO,
1999 (WHO/CDS/EDC/99.4)

5. DIARRHOEAL DISEASES (OTHERS)
DESCRIPTION
Infectious agent Bacteria: such as Salmonellae (commonly S. enteritidis, S. typhimurium) and
Escherichia coli. The bacteria that cause the most severe outbreaks are Shigella
dysenteriae type 1 and Vibrio cholerae (see Bacillary dysentery and Cholera)
Protozoa: such as Entamoeba histolytica, Giardia lamblia and Cryptosporidium
parvum
Viruses: such as Rotavirus and Norwalk virus
Three or more abnormally loose or fluid stools over 24 hours
Mode of Fecal-oral route, particularly contaminated water and food
transmission
Incubation Salmonella generally requires an 8-48 hour incubation period, whereas E, coli is
typically longer at 2-8 days (median of 3-4 days). Both usually last between 2-5 days
The average incubation period is 2-4 weeks for E. histolyica, 7-10 days for G.lamblia
and 7 days for C. parvum
The incubation period for Rotavirus is about 48 hours, and symptoms may last for up
to one week
Period of During the acute stage of the disease and for duration of faecal excretion.
communicability Temporary Salmonella carriers can continue to exist for several months
EPIDEMIOLOGY
Burden Year number of cases percentage
2000 3248423 13%
2001 2709955 13%
2002 1066893 21%
Geographical Throughout the country.
distribution
Seasonality Diarrhoea rates are higher in summer than in winter.

Alert threshold An increase in the number of cases above what is expected compared to previous
years
Recent epidemics 1999: an outbreak in Maywut (Upper Nile) caused 65 cases and 1 death. A non
in the country typhoid Salmonella was found to be the responsible micro-organism.

Population Yes Importation
movement
Food shortages No However, malnutrition increases gastrointestinal tract susceptibility to
invasiveness of the organism and severity of disease

Lack of safe Yes The most important risk factor: prevention of diarrhoeal diseases depends on
water and poor the provision and use of safe water, adequate sanitation and health education.
sanitation The supply of adequate quantities of water should be one of the highest
priorities for camp planners. The emergency requirement is 20
litres/person/day.
Common sources of infection in emergency situations are:
Contaminated water sources (e.g. by faecally-contaminated surface water
entering an incompletely sealed well) or during storage (e.g. by contact with
hands soiled by faeces)
Shared water containers and cooking pots
Others Yes Lack of soap
Risk assessment In camp situations, diarrhoeal diseases can account for between 25% and
conclusions 40% of deaths in the acute phase of an emergency. Over 80% of deaths
usually occur among children under 2 years old.

Case Management
Prevention - using home fluids and Oral Rehydration Salts (ORS) and treatment
of dehydration - with ORS or i.v. fluids (Ringer lactate) for severely dehydrated
patient - is the mainstay of the management of diarrhoeal illness, together with
continuing feeding especially in children.
Reduction of mortality due to diarrhoeal disease is primarily related to effective
management of dehydration particularly in children.
Use of antibiotics is dependent on the infectious agent
Resume feeding with a normal diet when vomiting has stopped. It is important to
separate those who are eating from those who are not. Food should be cooked on
site. Continue breast feeding infants and young children
Epidemic control
Inform immediately the Health Authorities if an increase in the number of cases
above what is expected is identified
Confirm the diagnosis and ensure prompt treatment
Confirm the outbreak following WHO guidelines
Prevention Safe drinking water
Provision of an adequate supply, collection and storage system
Provision of information on the importance of clean water, also covering system
maintenance and household storage
See Annex 3 : Safe Water and Sanitation
Safe disposal of human excreta

Provision of an adequate facilities for the disposal of human waste
Provision of information on the importance of human waste disposal, also covering
use and maintenance of the facilities

Food safety
Provision of adequate food storage facilities, (both uncooked and cooked), cooking
utensils, adequate quantity of water and fuel to allow for cooking and reheating
Health education on the importance of food safety and safe food handling
Hand washing with soap

Provision of soap, allowing for hand washing, bathing and laundry
Health education on the relationship between diseases spread and lack of or
poor hand washing. Demonstration on the importance of good hand washing
Breastfeeding
Provision of information on: the protective qualities of breast-feeding, and the
importance of breast feeding ill children
Practical support for breast feeding ill children
6. DIPHTHERIA
DESCRIPTION
Infectious agent
Bacterium: Corynebacterium diphtheriae
Upper respiratory tract illness with laryngitis or pharyngitis or tonsillitis
plus
adherent membranes of tonsils or nasopharynx.
Laboratory confirmation: isolation of C. diphtheriae from a clinical specimen
Suspected case: not applicable
Probable case: a case that meets the clinical description
Confirmed case: probable case confirmed by laboratory or epidemiologically linked
to a laboratory-confirmed case
Carrier: presence of C. diphtheriae in nasopharynx, no symptoms
NOTE: persons with positive C. diphtheriae identification but who do not meet the clinical
description (e.g. asymptomatic carriers) must not be reported as probable or confirmed cases
Mode of
Contact (usually direct, rarely indirect) with the respiratory droplets of a case or
transmission carrier
In rare cases, the disease may be transmitted through foodstuffs (raw milk has
served as a vehicle)
Incubation Usually 2-5 days, occasionally longer
Period of Until virulent bacilli have disappeared from discharges and lesions; usually 2 weeks or
communicability less and seldom more than 4 weeks. The rare chronic carrier can shed bacilli for 6
months or more. The disease is usually not contagious 48 hours after antibiotics are
instituted.

EPIDEMIOLOGY
Burden Number of cases reported:
2001: 28 cases 1997: 15 cases
2000: 26 cases 1990: 1,342 cases
1999: 21 cases 1980: 587 cases
1998: 67 cases
Geographical Throughout the country .
distribution
Seasonality Seasonal incidence patterns are not constant over years.
Alert threshold One suspected, probable or confirmed case must be investigated.
Recent epidemics There is no recent outbreaks reported .

Population Yes Importation
movement
Overcrowding Yes Crowded conditions facilitate transmission
Poor access to Yes No access to routine immunization services
health services
Early detection and containment of the cases are paramount to reduce
transmission
Food shortages No
Lack of safe No
water and poor
sanitation
Others No
Risk assessment Outbreaks can occur when social or natural conditions lead to overcrowding
conclusions of susceptible groups, especially infants and children. This frequently occurs
when there are large-scale movements of non-immunized populations.
DTP3 coverage:
2001: 71 % (official country estimates); 46% (WHO-UNICEF estimates)
2000: 65% (official country estimates)
1980: 1 % (official country estimates)

Introduction The control of diphtheria is based on 3 measures:
Ensuring high population immunity through vaccination (primary prevention).
Rapid investigation and treatment of contacts (secondary prevention of spread).
Early diagnosis and proper case management (tertiary prevention of
complications and deaths).

Immunization
Immunize the population at risk as soon as possible. In an epidemic involving
adults, immunize groups that are most affected and at highest risk. Repeat
immunization procedures 1 month later to provide at least 2 doses to recipients
Diphtheria-toxoid-containing vaccine (preferably Td) should be given
To ensure safety of injection during immunization, auto destructible syringes and safety
boxes are recommended. Safe disposal of used sharps should be ensured
Case Management Diphteria antitoxin and antibiotic therapy are the cornesrstone of therapy for diphteria.
The antibodies only neutralize toxin before its entry into cells, and is therefore
critical that diphtheria antitoxin be administered s soon as a presumptive
diagnosis has been made.
Antibiotic therapy, by killing the organism, has three benefits:
The termination of toxin production
Amelioration of the local infection
Prevention of spread of the organism to uninfected persons
Patients
Diphtheria antitoxin i.m. (20,000 to 100,000 units) in a single dose, immediately
after throat swabs have been taken.
Plus
Procaine penicillin i.m. (25,000 to 50,000 units/kg/day for children; 1.2 million
units/day for adults in 2 divided doses) or parenteral erythromycin (40-50
mg/kg/day with a maximum of 2 g/day) until the patient can swallow; then
Oral penicillin V (125-250 mg) in 4 doses a day, or erythromycin (40-50
mg/kg/day with a maximum of 2 g/day) in 4 divided doses.
Antibiotic treatment should be continued for a total period of 14 days
Isolation: strict (pharyngeal diphtheria) or contact (cutaneous diphtheria) for 14
days.
NOTE: Clinical diphtheria does not necessarily confer natural immunity, and patients should
therefore be vaccinated before discharge from a health facility
Close Contacts*
Surveillance for 7 days for all persons with close contact, regardless of
vaccination status, and throat culture.
All must receive a single dose of benzathine penicillin G i.m. (600 000 units for
children < 6; 1.2 million units for 6 or older). If culture is positive, give antibiotics as for
patients above.
Carriers
All must receive a single dose of benzathine penicillin G i.m. (600 000 units for
children < 6; 1.2 million units for 6 or older).

Epidemic control Inform the Health Authorities if one or more suspected cases are identified.
Confirm the suspected outbreak, following WHO guidelines. Investigate any
probable case: check if it fulfils the case definition, record date of onset, age
and vaccination status.
Investigate any probable case: check if it fulfils the case definition, record date
of onset, age and vaccination status.
Confirm the diagnosis: collect both nasal and pharyngeal swabs for culture and
swabs from any wounds or skin lesions. If appropriate facilities are
available, determine the biotype and toxigenicity of C. diphtheriae.
Identify close contacts and define population groups at high risk. Adult contacts
must avoid contact with children and must not be allowed to undertake
food handling until proven not to be carriers.
Implement outbreak response measures. Give priority to case management and
immunization of population in areas not yet affected where the outbreak is likely
to spread.
Immunize the population at risk as soon as possible, especially children. In an
epidemic involving adults, immunize groups that are most affected and at highest risk.
Repeat immunization procedures 1 month later to provide at least 2 doses to
recipients.
In endemic situations, preferably Td vaccine (a combination of diphtheria and
tetanus toxoids with reduced diphtheria content) should be given.
To ensure safety of injection during immunization, auto-disable syringes and
safety boxes are recommended. Safe disposal of used sharps should be
ensured.
Close contacts include household members and other persons with a history of direct contact with a case, as well
as health care staff exposed to oral or respiratory secretions of a case

7. DRACUNCULIASIS (GUINEA WORM INFECTION/DISEASE)
DESCRIPTION
Infectious agent Dracunculus medinensis, a worm belonging to the Phylum of Nematodes.
Case definition Clinical description: Diagnosis is usually easy and unambiguous: the gravid female
worm (up to 1 meter long) emerges through the skin of any part of the body about
one year after infection. When the anterior part of the worm reaches the surface of
the skin an intensely painful oedema and a papule are formed. The papule is
succeeded (within 1 to 3 days) by a blister which ruptures (after 3 to 5 days)
leaving a small superficial ulcer. Systemic symptoms include fever, nausea and
vomiting. Functional lesions of the affected limb are frequent: lower extremeties are
involved in 90% of the cases with resulting crippling. Secondary bacterial infections
are also of major concern. No immunity to infection develops, and people in
endemic areas suffer from infection year after year. Each infection lasts about one
year.
Case definition: Anyone exhibiting or having a history of a skin lesion with the
emergence of a Guinea worm within the curent year.
Mode of Swallowing of water containing minute crustacean copepods (Cyclops or "water
transmission fleas", which measure 1-2mm) that have ingested larvae of D. medinensis discharged
by the adult female worm into stagnant water bodies. There is no known animal
reservoir of the infection.
Incubation The female gravid worm emerges through the skin (most frequently of the legs) about
12 months after larvae have been introduced into the human body.
Period of 12 to 50 days after rupture of vesicle. This results from the sum of the following
communicability periods:
2-3 weeks: the period from rupture of vesicle until larvae have been completely
evacuated from the uterus of the gravid worm.
About 5 days: the period during which larvae are infective for the copepods in
water.
12-14 days to about 3 weeks after ingestion by copepods: the period during which
the larvae become infective for people (at temperatures more than 25C).
EPIDEMIOLOGY
Burden 2001: Sudan reported 49,471 cases, equivalent to 78.0% of all cases reported
worldwide (63,717).
2000: Sudan reported 54,890 cases, equivalent to 72.9% of all cases reported
worldwide (75,223).
worldwide (96,293).
worldwide (78,557).
1997: Sudan reported 43,596 cases, equivalent to of 55.9% of all cases reported
worldwide (77,863)
NOTE: Dracunculiasis transmission is confined to Africa from 1998 (last indigenous cases
outside Africa were reported from Yemen in September 1997)

Geographical Almost all Sudan's cases come from southern states. Moreover, southern Sudan is a
distribution concern for neighbouring areas, since it exports cases to other Sudan states and
abroad. 28, 175, 7, 16 and 32 cases have been exported annually to adjacent
countries (Ethiopia, Uganda, Kenya, and the Central African Republican) in 1997
2001.
Within Sudan, the northern states already have almost interrupted transmission
of dracunculiasis. Only 85 indigenous cases were reported from 7 of the 16
northern states in 2001, compared with 4,053 cases reported from the northern
states in 1995.
Seasonality The disease is seasonal occurring with patterns depending on climatic factors,
especially rainfall. In the Sahelian zone, transmission generally occurs in the rainy
season, when surface water is available (May to August). In the humid savanna zone, the
peak usually occurs in the dry season, when drinking water sources are most
scarce and heavily contaminated. (November to January).
In Sudan, the majority of cases are reported between May and October, during the
rainy season. As the worm emerges on an annual cycle, this is also the period
during which infection occurs (transmission season).
Recent epidemics Dracunculiasis is an endemic disease, with little likelihood of rapid changes in
in the country incidence. However, in hyperendemic situations, field surveys can be performed to
determine prevalence of infection, discover high-risk sources of water, and apply
control measures (see below).proper surveillance &interventions will eliminate
all sourse of infection .

Population
Yes Infected individuals can "export" the disease to non-endemic areas provided
movement the disease cycle can complete itself.
Overcrowding Yes Overcrowding can lead more people to share the same water body where
D. medinensis larvae have been discharged.
Poor access to Yes The difficulties of implementing any public health programme in Sudan due to the
health services civil conflict are responsible for high disease transmission in the country.
Food shortages No
Lack of safe water Yes Among the most important factors, leading to fetch drinking water and wash
and poor sanitation one's body in the same water body.
Others No

Risk assessment Sudan reported 78% of all cases of dracunculiasis in 2001, and virtually all of
conclusions Sudan's cases are in the southern states, where the civil war has limited for long
time accessibility to endemic areas.
The country's proportion of global dracunculiasis cases has steadily increased over
the past seven years as cases are reduced in all other endemic countries. The
number of reported cases decreased in the last three years despite intensive
campaign to reduce under-reporting. However, this decrease cannot be considered a
valid reduction owing to inaccessibility of many endemic villages in the South due
to civil disturbance.
Although dracunculiasis is rarely fatal, it is of great socio-economic importance.
Persons with this disease are incapacitated because of pain caused by the primary
wound at the exit point of the worms and by associated secondary infections.
Temporary disability usually lasts periods averaging almost three months (usually
10-11 weeks), mainly because:
Several worms can be expelled successively
The migration and emergence of the worms occur in sensitive parts of the body,
e.g. the sole of the feet
Serious secondary bacterial infection frequently sets in subsequent to the accidental
rupture of the worm.
The emerging of the worm often happens at the busiest time of the year when people
need to plant or harvest their crops, and half or more of a village population may
be affected at the same time. In addition to its impact on agricultural productivity,
dracunculiasis also is a major cause of absenteeism from school. Moreover, it has
been observed that when disabled adult members of a household are prevented from
fully performing their agricultural or domestic activities due to dracunculiasis, the
nutritional status of children in the same household will deteriorate in the following year
due to both lack of food and negligence in the care of children.
Man-made water-catchment ponds such as ha firs are,shallow wells &ponds are
the main source of transmission in Sudan, and the epidemiology of the disease is
determined largely by the use of these open water sources.

Case Management No drugs are currently available to kill the adult worm, and antibiotics &bandages
slow extraction of the emergent guinea worm is usually the most effective:
Once a worm emerges, use a matchstick to roll it out gently a few centimetres a
day until the worm has been removed. Never break the worm, and never pull it.
Bandage the wound after applying an antibiotic ointment to prevent superinfection of
the lesion, and 24 hours later remove the bandages and roll the part of the worm that
has emerged. Repeat until the whole worm is removed (this usually takes 10-
20 days).&controlled measured may reduce it to 5-7 days and as either as 2
days .
Although practised in certain endemic countries, surgical extraction is NOT
recommended.
Prevention Provision of safe water sources: this is the most expensive, and the most durable,
intervention. It also has the advantage of providing other important benefits besides
eliminating the guinea worm.
Control of copepod populations in ponds, tanks, reservoirs and step wells.
Insecticide of choice for stagnant sources of water: Temephos (Abate), which is
effective and safe.
Formulation and dosage: based on the estimated amount of water present.
Time of application : at amaximam interval of 28days in ponds of less
than 500m during transmition season of known endemic village &in
village newely reporting cases , especially after a flood has receded.
Health education: programmes should be focused on the three following messages:
Villagers with blisters or ulcers should not enter any source of drinking water. It is well
known that infected persons try to relieve the burning sensation by immersing the
affected part of the body in local water sources. This should be discouraged.
Guinea worm infection comes from drinking water. Therefore water should be:
Boiled (this is usually impractical because of the scarcity or high cost of wood or
other fuel); or
Chlorinated; or
Filtered to remove copepods. Systematic filtering of drinking water derived
from ponds, shallow unprotected wells or from surface water should be
encouraged: use of finely-meshed cloth filter, straw filter, or, better still, a filter
made from a 0.15mm nylon mesh is the recommended option.
Immunization of high risk population against tetanus.

8. EBOLA HAEMORRHAGIC FEVER
DESCRIPTION
Infectious agent Ebola virus, belonging to the Filovirus group
Presentation may be very aspecific. Initial symptoms include acute fever, diarrhoea
that can be bloody (referred to as diarrhee rouge in francophone Africa) and vomiting.
Headache, nausea and abdominal pain are common. Conjunctival injection,
dysphagia and haemorrhagic symptoms (nosebleeds, bleeding gums, vomiting of
blood, blood in stools, purpura) may further develop. Some patients may show a
maculopapular rash on the trunk. Dehydration and significant wasting occur as the
disease progresses. At a later stage, there is frequent involvement of the central
nervous system, manifested by somnolence, delirium or coma. The case-fatality rate
ranges from 50% to 90%.
Laboratory criteria:
Confirmatory:
Positive ELISA antigen detection or IgM capture, or
Positive virus isolation (only in a laboratory of biosafety level 4), or
Positive skin biopsy (immunohistochemistry), or
Positive PCR with sequence confirmation.
Case Classification*:
Suspected: a case that is compatible with the clinical description.
Probable (in epidemic situation):
Any person having had contact with a clinical case and presenting with acute
fever, or
Any person presenting with acute fever and 3 of the following: headache,
vomiting/nausea, loss of appetite, diarrhoea, intense fatigue, abdominal pain,
general or articular pain, difficulty in swallowing, difficulty in breathing,
hiccoughs, or
Any unexplained death
Confirmed: Any suspected or probable case that is laboratory-confirmed.
Contact (in epidemic situation): An asymptomatic person having had physical
contact within the past 21 days with a confirmed or probable case or his/her body
fluids (e.g. care for patient, participation in a burial ceremony, handling of
potentially infected laboratory specimens.
(*) Case classification should be tailored according to circumstances locally identified on
the field (e.g. including contact with sick animals or animals with abnormal
behaviour).
Mode of Person to person transmission by direct contact (spread of droplets onto mucous
transmission membranes) or indirectly by infected blood, secretions, organs, semen and fomites.
Risk is highest during the late stages of illness when the patient is vomiting, having
diarrhoea or haemorrhaging. Risk during the incubation period is low. Under natural
conditions, airborne transmission among humans has not been documented.
Nosocomial infections have been frequent.
Incubation Incubation period is usually 2 to 21 days
Period of As long as blood, saliva, faeces and other secretions contain virus.
communicability

EPIDEMIOLOGY
Burden No confirmed cases reported since 1979 they were 34cases ,mortalitiy rate 65 %
Geographical .
Both Ebola outbreaks in Sudan occurred in the southernmost area of the country,
distribution close to the border with the Democratic Republic of Congo
Seasonality No clearly evident seasonal pattern .
Alert threshold One suspect case must lead to an alert.
Recent epidemics EBOLA:
in the country
1976 June-November - The first case of Ebola in Sudan was detected in N'zara
(West Equatoria, close to the border with Democratic Republic of Congo) and then spread
to Maridi, Tembura and Juba. On June 27, 1976, a N'zara Cotton
Manufacturing Factory cloth room worker became ill with a haemorrhagic febrile
disease and died in the N'zara hospital on July 6, 1976. Disease was introduced to Maridi,
128 km away, by a case admitted to Maridi hospital. Spreading occurred mainly
through close personal contact within hospital. Many medical care personnel were
infected, as transmission was usually associated with the act of nursing a patient. The
viral subtype identified was named Ebola-Sudan (EBO-S). The total number of cases
was 284 (the largest part in Maridi) and the percentage of deaths among cases (case-
fatality rate) was 53%.
1979 July-October - On 2 August 1979, a 45 year-old man was admitted to the
N'zara hospital with a fever that had lasted for three days and recent onset of diarrhoea
and vomiting. While at the N'zara hospital, he developed gastrointestinal haemorrhaging
and died on August 5. No precautionary isolation measures were taken or barrier
nursing techniques practiced. Three of his relatives who had cared for him during his
illness had developed haemorrhagic fever and were hospitalized. All cases occurred
among five families in a rural district in the remote savanna of southern Sudan. The
district was later quarantined. The total number of cases was 34, 22 of which were fatal
(CFR=65%). Every case had direct link to the index case who was employed at the
N'zara Cotton Manufacturing Factory.

Population Yes In case of outbreak, population movement can contribute to the spreading of
movement infection to non-affected areas. Contacts under daily follow-up should be
encouraged to limit their movements through community sensibilization and
social mobilization.
Overcrowding Yes Prompt isolation of suspect case is a key point among control strategies.
All conditions favouring contact with a sick person, his cloths and his bedding
constitute a risk factor for increased transmission.
Poor access to Yes Health centres are essential as alert network, not for providing treatment. Prompt
health services identification of the cases is paramount to rapidly implement the control
measures.
Food shortages No
Lack of safe water and No
poor sanitation
Others No Hunting-related activities have been indicated as a risk factor for acquiring the
infection in several occasions.

Risk assessment The reservoir of Ebola haemorrhagic fever is not known, and is therefore difficult to
conclusions evaluate the risk of transmission. The implementation of control measures can be
difficult due also to cultural reasons, such as the custom of eating primate meat.
With the exception of Uganda, Ebola outbreaks have always occurred in ecologically
similar areas: these areas could represent the biotope of the reservoir. Moreover,
there are indications that similar climatic patterns are associated with Ebola outbreaks.
Monitoring climatic variables could help in the identification of high-risk areas.
Future priorities include the identification of the reservoir, in order to better target
public health measures

Case Management
Specific therapy: not currently available for filoviral infections
Supportive treatment:
Analgesic drugs
Antimicrobial drugs (to avoid secondary infections)
Fluid replacement
Implementation of barrier nursing practices:
In order to prevent secondary infections contact with the patient's lesions and body
fluids should be minimized using standard isolation precautions:
Isolation of patients
Restriction of access to patients wards
Use of protective clothing
Safe disposal of waste
Disinfection of all non-disposable supplies and equipment
Safe burial practices
These can be implemented despite problems due to limited resources (see WHO/CDC.
Infection control for viral haemorrhagic fevers in the African care setting. Geneva:
WHO, 1998. WHO/EMC/EST/98.2)
Epidemic control Epidemics of the disease in health care institutions with poor hygiene standards can
be dramatically amplified through contact with patients or body fluids from infected
patients (blood, vomitus, urine, stools, semen, saliva). The potential for explosive
nosocomial infections constitutes the main threat to public health posed by the
disease. Strict adherence to isolation precautions with all patients has been shown to
reduce the risk of transmission: during the 1995 Ebola haemorrhagic fever outbreak
in Kikwit, no new cases were reported among health workers who used these
precautions consistently.
Prevention The following will help prevent explosive epidemics in areas potentially subject to
Ebola disease:
Mobilization and education of the community.
advance training for the use of isolation precautions.

9. HIV/AIDS
DESCRIPTION
Infectious Human Immunodeficiency Virus (HIV). Two types have been identified: HIV-1 and HIV-2,
agent with similar epidemiological characteristics. HIV-2 is less pathogenic than HIV-1.

Case definition AIDS case definition
Acquired Immunodeficiency Syndrome (AIDS) is the late clinical stage of HIV infection,
defined as an illness characterised by one or more indicator diseases.
WHO Staging System for HIV Infection and Disease in Adults and Adolescents
Stage 1
1. Asymptomatic
2. Persistent generalized lymphadenopathy (PGL)
Performance Scale 1: asymptomatic, normal activity
Stage 2
3. Weight loss, <10% of body weight
4. Minor mucocutaneous manifestations (seborrheic dermatitis, prurigo, fungal nail
infections, recurrent oral ulcerations, angular cheilitis)
5. Herpes zoster within the last 5 years
6. Recurrent upper respiratory tract infections (e.g. bacterial sinusitis)
And/or Performance Scale 2: symptomatic, normal activity
Stage 3
7. Weight loss, >10% of body weight
8. Unexplained chronic diarrhoea, >1 month
9. Unexplained prolonged fever (intermittent or constant), >1 month
10. Oral candidiasis (thrush)
11. Oral hairy leukoplakia
12. Pulmonary tuberculosis within the past year
13. Severe bacterial infections (i.e. pneumonia, pyomyositis)
And/or Performance Scale 3: bedridden, <50% of the day during the last month
Stage 4
14. HIV wasting syndrome, as defined by the Centers for Disease Control and
Prevention (CDC)a
15. Pneumocystis carinii pneumonia
16. Toxoplasmosis of the brain
17. Cryptosporidiosis with diarrhoea >1 month
18. Cryptococcosis, extrapulmonary
19. Cytomegalovirus (CMV) disease of an organ other than liver, spleen or lymph nodes
20. Herpes simplex virus (HSV) infection, mucocutaneous >1 month, or visceral any
duration
21. Progressive multifocal leukoencephalopathy (PML)
22. Any disseminated endemic mycosis (e.g. histoplasmosis, coccidiomycosis)
23. Candidiasis of the oesophagus, trachea, bronchi or lungs
24. Atypical mycobacteriosis, disseminated
25. Non-typhoid Salmonella septicaemia
26. Extrapulmonary tuberculosis
27. Lymphoma
28. Kaposi's sarcoma
29. HIV encephalopathy, as defined by CDCb
NOTE: both definitive and presumptive diagnoses are acceptable
(a) HIV wasting syndrome: weight loss of >10% of body weight, plus either unexplained chronic diarrhoea (>1 month), or
chronic weakness and unexplained prolonged fever (>1 month). (b) HIV encephalopathy: clinical finding of disabling
cognitive and/or motor dysfunction intefering with activities of daily living, progressing over weeks to month,
in the absence of aconcurrent illness or condition other than HIV infection that could explain the findings

Expanded WHO case definition for AIDS surveillance*
An adult or adolescent ( > 12 years of age) is considered to have AIDS if a test for HIV
antibody gives a positive result, and one or more of the following conditions are present:
>10% body weight loss or cachexia, with diarrhoea or fever, or both, intermittent
or constant, for at least 1 month, not known to be due to a condition unrelated to
HIV
Cryptococcal meningitis
Pulmonary or extrapulmonary tuberculosis
Kaposi sarcoma
Neurological impairment that is sufficient to prevent independent daily activities,
not known to be due to a condition unrelated to HIV infection (e.g. trauma or
cerebrovascular accident)
Candidiasis of the oesophagus (which may be presumptively diagnosed based on
the presence of oral candidiasis accompanied by dysphagia)
Clinically diagnosed life threatening or recurrent episodes of pneumonia, with or
without aetiological confirmation
Invasive cervical cancer
* WHO. Weekly Epidemiological Record. 1994. 69:273-275.
Laboratory evidence of HIV

This is most commonly done by detecting HIV antibody in serum samples using
enzyme-linked immunoassay (ELISA or EIA). When this test is positive, it must be
confirmed with another test of higher specificity such as the Western blot, the indirect
fluorescent antibody (IFA) test or a second ELISA test that is
methodologically and/or antigenically independent
The rapid tests, which are recommended by WHO, have been evaluated at WHO
collaborating centres and have levels of sensitivity and specificity comparable to
WHO recommended ELISA tests. The use of rapid HIV tests may afford several
advantages in emergency and disaster settings including
Rapid tests that do not require refrigeration will be more suitable for remote
and rural areas and sites without a guaranteed electricity supply. Long shelf life
is also important especially for remote areas and sites performing smaller
numbers of tests
Many rapid tests require no laboratory equipment and can be performed in
settings where electrical and water supplies need not be guaranteed
Rapid tests can detect HIV antibodies in whole blood (finger prick samples) as
well as serum/plasma and testing therefore may be performed by non

Mode of
Sexual intercourse (vaginal or anal) with an infected partner, especially in
transmission presence of a concurrent ulcerative or non-ulcerative Sexually Transmitted
Infection (STI); or
Contaminated needles, syringes, other injecting equipment and injecting
solutions (contamination often occurs when drug solutions are mixed or when
multiple users draw up solutions from a single container); or
Transfusion of infected blood or blood products; or
Infected mother to her child during pregnancy, labour and delivery or through
breastfeeding
Incubation Variable. On average, time from HIV infection to clinical AIDS is 8 to 10 years, though AIDS
may be manifested in less than 2 years or be delayed in onset beyond 10 years
Incubation times are shortened in resource poor settings and in older patients. They
can be prolonged by provision of primary prophylaxis for opportunistic infections or
antiretroviral treatment
Period of Any person who is infected with HIV may pass the infection to another through the
communicability routes of transmission described above.
Infectiousness is observed to be high during the initial period after infection. Studies
suggest it increases further with increasing immune deficiency, clinical symptoms and
presence of other STIs
EPIDEMIOLOGY
Burden Estimated number of adults and children living with HIV/AIDS, end of 2001:
(including all people with HIV infection, whether or not they have developed symptoms
of AIDS)
Adults (15-49) 410,000 (2.6% of all adults)
Women (15-49) 230,000
Children (0-15) 30,000
Estimated number of deaths due to AIDS in 2001: 23,000
Reported AIDS cases in 2001: 492
(Mode of Transmission: Heterosexual: 348: Perinatal: 6; Unknown: 138)
Estimated number of living orphans (2001): 62,000
Geographical No data available; HIV median prevalence among ANC attendees in 1998 was about
distribution 0.5% in urban areas and about 3.75% in rural areas.
Seasonality Not applicable
Alert threshold One suspected case must be investigated
Recent epidemics Number of AIDS cases by year of reporting:
in the country
1979: 0 1987: 2 1995: 257
1980: 0 1988: 64 1996: 221
1981: 0 1989: 122 1997: 270
1982: 0 1990: 130 1998: 511
1983: 0 1991: 188 1999: 517
1984: 0 1992: 184 2000:652
1985: 0 1993: 191 2001: 492
1986: 2 1994: 201
Total (end 2001): 4004

Population movement Yes
In emergency situations, population movement can:
Cause breakdown in family and social ties
Erode traditional values and coping strategies. This
can result in higher risk sexual behavior which increases
risk of HIV spread
Influence illicit drug trafficking and drug use, increasing risk
of HIV transmission through injecting drug use
Overcrowding Yes Groups with differing levels of HIV awareness, and differing
rates of infection, are often placed together in temporary
locations, such as refugee camps, where there is greater
potential for sexual contact.
Overcrowding can also influence injecting drug use patterns and
result in increased risk of sharing contaminated injecting
Poor access to health Yes Without adequate medical services STIs, if left untreated in
services either partner, Greatly increase the risk of acquiring HIV
Important materials for HIV prevention, particularly condoms,
are likely to be lacking in an emergency situation
In emergency situations services for drug dependence
treatment usually do not exist. It is more likely to be difficult
to access sterile injecting equipment.
Food shortages Yes The need for food is paramount in emergency situations, and
exchanging sex for money to buy food and other essentials can
occur (see Sex work)
Lack of safe water and No
poor sanitation

Others Yes Sexual violence
Refugees and IDPs are often physically and socially
powerless, with women and children at particular risk of
sexual coercion, abuse or rape
Sexual violence carries a higher risk of infection because the
person violated cannot protect herself or himself from unsafe
sex, and because the virus can be transmitted more easily if
bodily tissues are torn during violent sex
Sex work
Exchange of sexual favours for basic needs, such as money,
shelter, security, etc, is common in or around refugee
camps, and inevitably involves both the refugee and host
communities. Both sex workers and clients are at risk of HIV
infection if unprotected sex is practised
Injecting drug use
In Sudan, no AIDS cases officially reported from the
beginning of the epidemics to the end of 2001 had
contracted the disease by injecting drugs.
In the typical conditions of an emergency, it is highly likely
that the drug injectors will be sharing needles, a practice that
carries a very high risk of HIV transmission if one of the
people sharing is infected
Unsafe blood transfusions
Transfusion with HIV-infected blood is a highly efficient
means of transmitting the virus. In emergency situations,
when regular transfusion services have broken down, it is
particularly difficult to ensure blood safety
Adolescent Health

Risk assessment HIV has recently grown to become a major health problem in Sudan. Although the
conclusions surveillance system is limited to 4 sites only, it is feared that Sudan is
facing a generalized epidemic.
HIV prevalence among pregnant women was reported to be 2.94% in 1997.
Based on recent HIV surveillance data in Khartoum State in 2000, 2.5% of
women attending gynaecology clinics were found to be HIV seropositive,
compared to HIV seropositivity rates of 1.86% in pregnant women attending
antenatal clinics.
HIV rated among blood donors increased from 0.15% in 1993 to 1.4% in 1999 and
2000 respectively.
There is a clear link between HIV and TB. In 1999, HIV prevalence among TB
patients varied between 7.7% and 20% depending on the regions.
Women attending both gynaecological and antenatal clinics in Khartoum state
showed a curable STI incidence of 10.5% and 34%.
AIDS cases by mode of transmission (from the beginning of the
epidemics* up to end 2001):
Heterosexual contacts 3758 (93.9%)
Blood and blood products 12 (0.3%)
Perinatal 96 (2.4%)
Unknown 138 (3.4%)
All AIDS cases reported 4004 (100%)
* the earliest AIDS cases in Sudan (2) were reported in 1986
All stakeholders involved in humanitarian activities must be sensitized to the

importance of addressing HIV in tandem with all other activities. Activities
should include HIV prevention (promotion of safer sexual behaviours,
treatment of Sexually Transmitted Infections, blood safety) and care and
support for people living with HIV/AIDS. They must reach vulnerable
populations and address the needs of women and children.
All stakeholders must also be sensitized about HIV risks associated with
injecting drug users and the need for drug dependence treatment and risk
reduction education and counselling.

Case Management
Provide high quality care and support to all people living with HIV/AIDS (PLHA) that
includes counselling, psychosocial support, treatment for opportunistic
infections (e.g. TB), palliative care and access to antiretroviral therapy where
feasible
Support PLHA to live normal and productive lives that are free of stigmatization
and discrimination
Prevention Reduce sexual and mother-to-child transmission
Awareness and life skills education, especially youth, ensuring that all people are
well informed of what does, and does not, constitute a mode of transmission; of
how and where to acquire free condoms and medical attention if necessary; and
information on basic hygiene
Condom promotion which would ensure that good-quality condoms are freely
available to those who need them, using culturally sensitive instructions and
distribution
STI control, including for sex workers, using the syndromic STI management
approach, with partner notification and promotion of safer sex
Reduce mother-to-child transmission of HIV by
the primary prevention of HIV among women, especially young women
avoiding unintended pregnancies among HIV infected women and promoting
family planning methods, particularly in women who are infected with HIV
preventing the transmission of HIV from infected pregnant women to their
infants by:
using an antiretroviral prophylaxis regimen;
avoiding unnecessary obstetrical invasive procedures, such as
artificial rupture of membranes or episiotomy; and
modifying infant feeding practices (replacement feeding given with a
cup when acceptable, feasible, affordable, sustainable and safe.
Otherwise exclusive breastfeeding for the first months of life is
recommended)
Blood safety
HIV testing of all transfused blood
Avoid non-essential blood transfusion
Recruitment of safe blood donor pool
Prevention among injecting drug users
Ready access to sterile needles, syringes and other injecting equipment (and
disposal of used equipment)
HIV risk reduction education and counselling for injecting drug users (including peer
outreach when possible)
Drug dependence treatment services, including substitution treatment (e.g.
methadone) where possible
Access to STI and HIV/AIDS treatment for injecting drug users.

Universal precautions
Washing hands thoroughly with soap and water, especially after contact with body
fluids or wounds
Using protective gloves and clothing when there is risk of contact with blood or other
potentially infected body fluids
Safe handling and disposing of waste material, needles, and other sharp instruments.
Properly cleaning and disinfecting medical instruments between patients
Physical protection
The protection of the most vulnerable, especially women and children, from violence and
abuse is not only an important principle of human rights but is also essential for reducing
the risk of HIV infection
Protecting health In order to reduce nosocomial transmission, health workers should strictly adhere to
care workers Universal Precautions with all patients and laboratory samples - whether or not
known to be infected with HIV.
Health care workers should have access to voluntary counseling, testing and care.
Often health workers deployed in complex emergencies experience significant
occupational stress and those tested, as part of the management of occupational
exposures, will require additional support.
Counselling and The establishment of voluntary testing and counseling services to help individuals
voluntary testing make informed decisions on HIV testing should be considered when relative stability is
programmes restored. Often refugees are coerced into testing, or are required to make decision with
regard to testing when they are suffering acute or post traumatic stress disorders
As refugees are often tested prior to resettlement in other countries, it is critical that they
receive counseling on the legal and social implications of the test. Often migration or
temporary residency status is contingent on the applicant having HIV antibody
seronegative status
Post-test counseling is essential for both seronegative and seropositive results.
Refugees and conflict survivors who are already traumatized will require additional
psychosocial support if they test seropositive. Typically the support networks of
displaced persons are disrupted and suicide risk assessment forms an important part of
post-test counseling in a refugee or conflict context.
Testing of orphaned minors should be done with the consent of their official guardians
only where there is an immediate health concern or benefit to the child. There
should be no mandatory screening prior to admittance to substitute care
Immunization
Asymptomatic HIV-infected children should be immunized with the EPI vaccines.
Symptomatic HIV-infected children should NOT receive either BCG or yellow fever
vaccine.

10. LEISHMANIASIS (CUTANEOUS AND MUCOSAL)
DESCRIPTION
Infectious agent Protozoan, belonging to the genus Leishmania:
L. major, agent of cutaneous leishmaniasis (and, less frequently, of mucosal
leishmaniasis)
L. donovani, agent of mucosal leishmaniasis .
Case definition Clinical description
Appearance of one or more skin lesions, typically on uncovered parts of the body.
The face, neck, arms and legs are the most common sites. A nodule may appear at the site
of inoculation and may enlarge to become an indolent ulcer. The sore may remain in
this stage for a variable time before healing - it typically leaves a depressed scar. Other
atypical forms may occur. In some individuals, certain strains can disseminate and
cause mucosal lesions. These sequelae involve nasopharyngeal tissues and can
be very disfiguring (see below).
Sudanese mucosal leishmaniasis is a chronic infection of the upper respiratory tract and/or
oral mucosa caused mainly by L. donovani, or, less frequently, by L. major. The disease
occurs in areas of the country endemic for visceral leishmaniasis. The condition may
develop during or after an attack of visceral leishmaniasis, but in most cases it is a primary
mucosal disease. It is not preceded or accompanied by a cutaneous lesion. The duration of
the disease can vary between a few months and many years.
Laboratory criteria
Positive parasitology (stained smear or culture from the lesion)
Positive serology (immunofluorescent assay, ELISA, Direct Agglutination Test)
for mucosal leishmaniasis only
WHO operational definitions:
A case of cutaneous leishmaniasis can be defined as a person showing clinical signs
(skin lesions) with parasitological confirmation of the diagnosis (positive smear or
culture).
A case of mucosal leishmaniasis can be defined as a person showing clinical signs
(mucosal lesions with parasitological confirmation of the diagnosis and/or serological
diagnosis.
Mode of From the reservoir host through the bite of infective female phlebotomines (sand
transmission flies).
Phlebotomus papatasi is the vector of L. major in Sudan. The highest vector population
density is usually found when the temperature is high, humidity is medium and rainfall is
low. The vector is domestic and peridomestic in the villages. Humans are the preferred
hosts, and daily biting activity is highest in the evening.
There is limited information on the animal reservoir of cutaneous leishmaniasis in
Sudan. It is probably represented by the Nile rat Arvicanthus niloticus
Phlebotomus orientalis is the vector of L. donovani in Sudan, most abundant where
Acacia seyal and Balanites aegyptiaca vegetation is common and where the soil is rich
in clay.

Incubation Cutaneous leishmaniasis: usually 2-4 weeks but may be longer. It is inversely
proportional to the size of the inoculum.
Mucosal leishmaniasis: difficult to establish. Patients usually give no history of
cutaneous leishmaniasis. Some patients give a past history of treated visceral
leishmaniasis and others may have had mucosal and visceral leishmaniasis
concurrently.
Period of An infected subject is susceptible to transmit the parasite as long as it remains in lesions;
communicability in untreated cases, usually a few months to 2 years.
EPIDEMIOLOGY
Burden Year number of cases deathes
2000 204 2
2001 351 32
2002 258 ---__
Geographical Darfur and Kordofan Provinces are known to be endemic for zoonotic cutaneous
distribution leishmaniasis. Epidemics in recent years have occurred in Northern, Eastern,
Khartoum, and Central Province.
Most of mucosal leishmaniasis patients come from areas of endemic visceral
leishmaniasis (DESCRIPTION)
Seasonality During the epidemics occurred in Sudan in recent years, the peak of infection was
believed to occur in August and December, dropping sharply in March, April and May.
Recent epidemics 1976 Shendi-Atbara area (Northern Province)
in the country 1985-1987 Khartoum Province: about 10 000 recorded cases. Peak incidence in
September 1986.
1990-1992 Dongola and Mahas areas (Northern Province)

Population Yes Movements of population such as internal migration (displaced people) or
movement movements of refugees (repatriation programme) contribute to the
maintenance of epidemics, bringing non immune people in endemic areas and
infected people in non-endemic areas where the vector is widespread.
The characteristics of epidemics in Sudan were typical of a disease newly
introduced in a previously non-immune population, in that all age groups were
affected.
Migrants from western Sudan (endemic for zoonotic cutaneous leishmaniasis)
to Khartoum Province probably contributed to the epidemic that affected this
area between 1985 and 1987.
Overcrowding Yes Overcrowding can increase the risk of contact with animal reservoir
Poor access to health No
services
Food shortages No However, malnourished people are more susceptible to the infection due to a
weakened immune response. Many of the patients seeking treatment are also
malnourished.

Lack of safe water Yes Open sewage systems and lack of garbage or rubble collection favour the
and poor sanitation proliferation of breeding site for vectors.

Others Yes Great expansion of towns and villages, establishment of new settlements,
and consequent development of previously uninhabited areas
Interruption of control measures: discontinuation of insecticide spraying for the
control of malaria in Sudan in the years before the epidemics might have
contributed to an increase in the population of the vector.
Increase in the rodent population: in 1976 and in 1986 this coincided with
the 2 epidemics of cutaneous leishmaniasis in Sudan
Prolonged low rainfall: the dry soil cracks and becomes waterlogged,
creating ideal breeding conditions for the sandfly.
Risk assessment The disease is known as hashara ("insect") in Sudan.
conclusions

Case Management Cutaneous leishmaniasis is a self-limiting disease. Self-healing usually occurs
within 6 months, but skin scarring and changes in pigmentation always follow.
There is at present no uniform protocol for treating cutaneous leishmaniasis in Sudan.
Patients with minor lesions are usually reassure and left to heal spontaneously.
Patient with severe or multiple lesions (>5), diabetics with lesions, and patients with
sporothrycoid spread are treated.
Treatment is based on:
Pentavalent antimonials (the drug used in Sudan is sodium stibogluconate) as first line
drug, except when resistance exists. They can be administered systemically (IM or IV),
or locally (intralesional infiltrations). WHO recommends the following course: 20
mg/kg/day for 20 days.
In the presence of resistance, second-line drugs must be used. Standard
amphotericin-B, aminosidine plus pentavalent antimonials or pentamidine isethionate
are the main alternatives.
Other therapeutic options are available:
Antifungal drugs (e.g. Ketoconazole)
Cryotherapy
Patients with mucosal leishmaniasis respond well to treatment with pentavalent
antimony compounds (sodium stibogluconate).
Epidemic control CL epidemics can be controlled by an integrated, feasible and efficient strategy
based on:
Provision of first line drug (pentavalent antimonials) to improve cure-rate
Provision of long-lasting bednets (Insecticide Treated Nets - ITNs) to limit
contact between human and vector
Health education and social interventions to increase awareness and improve early
diagnosis

Prevention
Personal protective measures are effective in preventing contact between
sandflies and man. Such measures include skin repellents, vaporizing liquids,
bednets impregnated or sprayed with pyrethroids, screened doors and windows.
Vector control: application of residual insecticides on surfaces where sand flies rest,
such as indoor and outdoor walls, tree trunks, rock crevices, water wells,
and flowering plants, could be effective in reducing the size of the sand fly
population over time and thus decrease the risk of infection, but is not
recommended since it produces a transient effect only.
Reservoir controlcontrol methods must be adapted to the biology of the reservoir
species (anticoagulants, poison baits, deep ploughing to eliminate plants on
which the rodents feed, use of artificial canals or barriers to prevent colonization o
reinvasion). No definitive control method against Arvicanthis is currently
known.
control measure of cutanious lieshmaniasis is integrated with mlaria control.
Work is in progress to evaluate the use of mosquito nets impregnated with insecticide
to reduce human-fly contact.

11. VISCERAL LEISHMANIASIS (KALA AZAR)
DESCRIPTION
Infectious agent
Protozoan: Leishmania donovani.
An illness with prolonged irregular fever, splenomegaly and weight loss as its main
symptoms.
Post kala-azar dermal leishmaniasis (PKDL) is increasingly recognized in Sudan as a
complication of visceral leishmaniasis, occurring in about 55% of patients during
treatment or within 0-6 months after treatment. It is characterized by a rash
that may be macular, maculopapular, nodular or plaque-like.
Sudanese mucosal leishmaniasis is a chronic infection of the upper respiratory
tract and/or oral mucosa caused mainly by L. donovani (see Cutaneous
leishmaniasis). The disease occurs in areas of the country endemic for visceral
leishmaniasis. In most cases it is a primary mucosal disease, not preceded or
accompanied by a cutaneous lesion, but less frequently the condition may
develop during or after an attack of visceral leishmaniasis. In this case the
disease represents a phenomenon similar to PKDL.
Laboratory criteria
Positive parasitology
stained smears from bone marrow, spleen, liver, lymph node, blood or
culture of the organism from a biopsy or aspirated material
Positive serology (immunofluorescent assay, ELISA, Direct Agglutination Test)
WHO operational definition
A case of visceral leishmaniasis (VL) is a person showing clinical signs
(prolonged irregular fever, splenomegaly and weight loss) with serological (at
peripheral geographical level) and/or (when feasible at central level)
parasitological confirmation of the diagnosis. The main differential diagnosis is
malaria. In endemic malarious areas, visceral leishmaniasis must be suspected
when fever lasts for more than 2 weeks and no response has been achieved with
anti-malarial drugs (assuming drug-resistant malaria has also been considered).
Mode of Vector-borne, through the bite of infective female phlebotomines (sand flies).
transmission
Phlebotomus orientalis is the vector of L. donovani in Sudan, most abundant where
Acacia seyal and Balanites aegyptiaca vegetation is common and where the soil is
rich in clay.
Transmission dynamics have not been elucidated fully; the large numbers of patients
with post kala-azar dermal leishmaniasis (PKDL) in heavily affected villages may
indicate a human reservoir and anthroponotic transmission, whereas heavy
transmission in scarcely populated areas suggests zoonotic transmission. The
presence of Leishmania parasites was found in several species of animals.
Incubation Usually between 2 and 6 months. Intensity of infection, partial immunity resulting from
previous exposure, intercurrent illness, malnutrition and other factors may play a role in
determining the acuteness or slowness of the course.
Period of An infected subject is susceptible to transmit the parasite to sandflies as long as it
communicability persists in the circulating blood or skin. Infectivity for sandflies may persist even after
clinical recovery of human patients.

EPIDEMIOLOGY
Burden Number of cases reported (July to June):
2001-2002: 2413
2000-2001: 2308
1999-2000: 3922
1998-1999: 4804
1997-1998: 6182
Geographical The disease is historically endemic in a wide belt extending from the western bank
distribution of the White Nile and the Sudan-Ethiopian border. This area includes the southern
areas of Central and Eastern provinces, and the north-eastern part of Upper Nile
Province. Since 1989 VL has spread in the western part of Upper Nile province,
where VL had not ever been reported before.
Cases have also been reported from Darfour province in west Sudan, from Nuba
mountains area (Kordofan), from the Kapoeta area in eastern Equatoria.
Seasonality It is likely that the peak of transmission occurs towards the end of the dry season
(March to June), especially just before the rainy season begins (May, June), when
large numbers of P. Orientalis appear. Most individuals report with illness after the
rains in October and November.
Number of cases reported in the period 1997-2002 (monthly basis):
January: 2335 July: 934
February: 2094 August: 870
March: 1883 September: 1083
April: 1554 October: 1856
May: 1376 November: 2384
June: 1122 December: 2138
Recent epidemics 2002
in the country A severe increase in cases of VL has been reported in October and November from
communities in southern Sudan. The overlap of areas affected by VL and areas of
conflict suggests that insecutity, malnutrition, and poor access to health care lower
the people's natural resistance, and create an epidemic-prone environment.
1997-1998
A dramatic upsurge in cases of VL has been reported from eastern Sudan (Atbarra river
area): over 2500 confirmed cases were registered in a MSF-run treatment centre in
Gedaref State from October to December 1997 (+439% compared to the same
period in 1996).
Cumulative factors played a role: influx of displaced and non-immune population from
southern States and overall decline in the nutritional status of the population.
1984-1994
Upper Nile province (southern Sudan): because of the isolation of the area caused
by the war, the epidemics was not noticed until 1988. Between 1984 and 1994, an
estimated 100 000 died. A number of causes has been proposed for this outbreak in a
previously non-endemic area:
Regeneration of Acacia seyal and Balanites aegyptiaca forests after they had
been destroyed in the 1960s.
Introduction of the parasite from VL endemic areas along the Ethiopian border by
movement of military personnel
Discontinuation of residual insecticide spraying for malaria because of the war.
Malnutrition of the people
From 1990 onwards the epidemics reached the southern part of Kordofan province,and
in 1995-1996 the eastern part of Upper Nile province.

Population Yes Movements of population such as internal migration (displaced people) or
movement movements of refugees (repatriation programme) contribute to the
maintenance of the epidemics, bringing non immune people in endemic areas and
infected people in non-endemic areas where the vector is widespread.
The characteristics of epidemics in Sudan were typical of a disease newly
introduced in a previously non-immune population, in that all age groups were
affected.
Migrants from western Sudan (endemic for zoonotic cutaneous leishmaniasis) to
Khartoum province probably contributed to the epidemics.
Overcrowding Yes Persons with PKDL act as reservoirs of Leishmania parasites in anthroponotic
foci.
Poor access to Yes Multifactorial:geographical ,economical &cultural .poor transportation
health services ,most of the service is not free of charge &most of patient seek for
traditional measures .
Food shortages No However, poor nutritional status increases susceptibility to VL infection and
disease.
Lack of safe No
water and poor
sanitation
Others Yes Acacia seyal and Balanites aegyptiaca woodland: the disease vector was
found only in forests where these trees were present and in villages in or near
these forests.
Black cotton soils: this soil rich in clay shrinks and swells with drying and
wetting to the extent that very few woody plants can survive in it. However,
certain trees survive and even thrive on this soil - including A. seyal and B.
aegyptiaca.
Termitaria: they are thought to provide the insects with a relatively low,
stable temperature and high humidity during the heat of the day. Termitaria
have been found to be resting sites for P. orientalis in eastern Sudan, but
many localities which harbour P. orientalis have no or small termitaria.
Interruption of control measures: discontinuation of insecticide spraying for the
control of malaria in Sudan might have led to an increase in the population
of the vector and contributed to the VL epidemics in southern Sudan.
Prolonged low rainfall: the dry soil cracks and becomes waterlogged,
creating ideal breeding/resting sites for the sandfly. P. orientalis is most
abundant towards the end of the dry season (March to June).
Risk assessment VL is known to be endemic in Sudan: the first case was reported in 1904. High
conclusions mortality in the country is mainly due to the absence of diagnostic facilities, the
unavailability of first-line drugs at the peripheral level, and increasing resistance
to pentavalent antimonials.
The majority of cases are found in children and teenagers (up to 75%) as
transmission occurs early in the life. Prognosis is usually severe due to
frequent malnourishment and associated diseases, such as TB, respiratory
and/or intestinal infections.
Case Management VL is a severe and fatal disease in the absence of treatment.
1st line treatment: pentavalent antimonials (Sodium stibogluconate was

introduced in Sudan in 1947). WHO recommends the following course: 20
mg/kg/day for 30 days
2nd line treatment: liposomal amphotericin B, aminosidine, pentamidine
Three lipid-associated amphotericin B formulations (liposomal, colloidal
dispersion, lipid complex) are highly effective against visceral leishmaniasis and
better tolerated than the conventional preparation. Liposomal amphotericin B is
an expensive drug and therefore cannot be recommended as a first-line drug, but if
available it should be the drug of choice in cases resistant or unresponsive to
antimonials due to its high effectiveness and lower toxicity.
Treatment for PKDL is needed only for those who have severe and prolonged
disease; sodium stibogluconate is usually sufficient. Liposomal amphotericin B is
also effective.
Patients with mucosal leishmaniasis respond well to treatment with pentavalent
antimony compounds (sodium stibogluconate).
Resistance to pentavalent antimonials has been reported from Eastern Sudan. It has
not been reported from Southern Sudan.
Epidemic control VL epidemics can be controlled by an integrated, feasible and efficient strategy based on:
Provision of first line drug (pentavalent antimonials) to improve cure rate and, in
zoonotic foci, reduce transmission
Provision of long-lasting bednets (Insecticide Treated Nets - ITNs) to limit contact
between human and vector
Health education and social interventions to increase awareness and improve early
diagnosis, early health-seeking and good treatment compliance.
Prevention
Personal protective measures are effective in preventing contact of sand flies and
man. Such measures include skin repellents, vaporizing liquids, bednets
impregnated or sprayed with pyrethroids, and screened doors and windows.
Usually the mesh used for leishmaniasis control is the same used for malaria
control: therefore, it has to be impregnated with insecticide, otherwise sandflies
will pass through.
Vector control: application of residual insecticides on surfaces where sand flies rest,
such as indoor and outdoor walls, tree trunks, rock crevices, water wells,
and flowering plants, could be effective in reducing the size of the sand fly
population over time and thus decrease the risk of infection, but is not
recommended due to its high cost, low sustainability, and logistic constraints.
Reservoir control: control methods must be adapted to the biology of each
species (anticoagulants, poison baits, deep ploughing to eliminate plants on
which the animal feed, use of artificial canals or barriers to prevent colonization
o reinvasion). The animal reservoir for L. donovani has not been identified yet.
Systematical case detection and rapid treatment: this applies to anthroponotic foci
There is control programme integrated with the malaria control for L . Work is in
progress to evaluate the use of vaccine against L. donovani and of mosquito nets
impregnated with insecticide to reduce human-fly contact.

12. LEPROSY
DESCRIPTION
Infectious agent Bacterium: Mycobacterium leprae (Hansen's bacillus)
Case definition WHO operational definition:
A case of leprosy is defined as a person showing one or more of the following
features, and who as yet has to complete a full course of treatment:
Hypopigmented or reddish skin lesion(s) with definite loss of sensation
Involvement of the peripheral nerves, as demonstrated by definite thickening with
loss of sensation
Skin smear positive for acid-fast bacilli
The operational case-definition includes:
Retrieved defaulters with signs of active disease
Relapsed cases who have previously completed a full course of treatment
Case Classification (clinical):
Paucibacillary leprosy: 1 to 5 patches or lesions on the skin.
Multibacillary leprosy: more than 5 patches or lesions on the skin.
Laboratory criteria for confirmation:
In practice, laboratories are not essential for the diagnosis of leprosy.
Mode of Not clearly established: probably organisms enter the human body through the
transmission mucous membranes of upper respiratory tract and possibly through broken skin,
during close and frequent contact with untreated, infected persons.
Incubation 9 months to 40 years; on average 4 years for tuberculoid and 8 years for lepromatous form.
Period of
If not treated: infectivity is possible as long as bacilli are demonstrated in a patient.
communicability
Treated: infectivity vanishes within 3 days of treatment with muitidrug therapy
(MDT).

EPIDEMIOLOGY
Registered cases at the end of 2001 (point prevalence): 1452
Prevalence (2001): 0.5/10.000
New cases detected in the year 2001: 1299
(890 MB adult; 2 MB child; 405 PB adult; 2 PB child)
Detection rate (2001): 4.3/100.000/year
Data on southern Sudan only are also provided to WHO by NGOs and relief
agencies operating in the field as follows:
New cases detected in the year 2001: 2468
(1505 MB adult; 156 MB child; 595 PB adult; 212 PB child)
Geographical Cases of leprosy are widespread all over the country. New cases (2001):
distribution
Khartoum: 175 (151 MB; 24 PB)
Northern: 20 (13 MB; 7 PB)
Eastern: 38 (18 MB; 20 PB)
Kordofan: 110 (90 MB; 20 PB)
Darfor: 263 (168 MB; 95 PB)
Central: 395 (220 MB; 175 PB)
Bahr El Gazal: 234 (180 MB; 54 PB)
Equatoria: 36 (32 MB; 4 PB)
Upper Nile: 28 (20 MB; 8 PB)
Seasonality No seasonality registered
Recent epidemics The disease has no epidemic potential
in the country

Population No
movement
Overcrowding No
Poor access to No
health services
Food shortages
No
Lack of safe No
water and poor
sanitation
Others
No

Risk assessment At the end of 2001, Sudan, with a prevalence rate of 0.5/10.000, was not among the
conclusions countries in which leprosy is considered a public health problem (prevalence rate>1 per
10.000 and population above 1 million).
However, Sudan is the country with the second highest leprosy burden in EMRO after
Egypt.
Data are likely to be not complete due to lack of coverage in southern Sudan: In the effort to
eliminate leprosy, a particular approach is needed for southern States of Sudan due to the
ongoing complex emergency, with implementation of MDT in as many areas as
possible, sound involvement of NGOs, community sensibilization and direct
involvement in case-finding and case-management.
Differential diagnosis between leprosy and Post Kala-azar Dermal Leishmaniasis
should always be considered, since any form of leprosy may be confused with PKDL.
However, if the 3 cardinal signs of leprosy are always kept in mind (anaesthetic lesions,
nerve enlargement and the demonstration of Mycobacterium leprae), there should not be
any confusion between PKDL and leprosy.
Case Management Treatment by multidrug therapy (MDT) according to case classification:
Multibacillary leprosy: the standard regime is a combination of the following for 12

months:
Adults:
Rifampicin: 600 mg once a month
Dapsone: 100 mg once a day
Clofazimine: 50 mg once a day and 300 mg once a month
Children must receive appropriately scaled-down doses (in child blister-packs)
Paucibacillary leprosy: the standard regimen is a combination of the following for 6
months:
Adults:
Rifampicin: 600 mg once a month
Dapsone: 100 mg once a day
Children must receive appropriately scaled-down doses (in child blister-packs)
A core element of the Elimination strategy is to make leprosy diagnosis and MDT
available at all health centres, to all existing leprosy patients. MDT is provided free of
charge by WHO.
Prevention
Early detection and treatment of cases.
Reducing contact with known leprosy patients is of dubious value and can lead to
stigmatization.
Immunization
BCG vaccination can induce protection against the tuberculoid form of the disease; this
is part of the control methods against tuberculosis and must not be undertaken
specifically against leprosy.

13. LYMPHATIC FILARIASIS
DESCRIPTION
Infectious agent Helminth: Wuchereria bancrofti, a filarial worm belonging to the class Nematoda. Other
genera not present in Angola.
Case definition Clinical case definition:
Hydrocoele or lymphoedema in a resident of an endemic area for which other causes of
these findings have been excluded.
Laboratory criteria for diagnosis:
Positive parasite identification by:
Direct blood examination or
Ultrasound or
Positive antigen detection test
Suspected: Not applicable.
Probable: A case that meets the clinical case definition.
Confirmed: A person with positive laboratory criteria even if he/she does not meet
the clinical case definition.
The burden of Lymphatic Filariasis, as measured in disability-adjusted life years
(DALYs), is the highest of all tropical diseases after malaria.
Mode of Bite of infected blood-feeding female mosquitoes (mainly Anopheles spp, also Culex spp.)
transmission which transmit immature larval forms of the parasitic worms from human to human.
Incubation
1 month to 1 year and more: recidivant attacks of "filarial fever" (pain and inflammation
of lymph nodes and ducts, often accompanied by fever, nausea and vomiting)
5 to 20 years: chronic illness manifestations may include elephantiasis (swelling of
limbs), hydrocoele (swelling of the scrotum in males), and enlarged breasts in females.
Period of As long as microfilariae are present in the peripheral blood (6-12 months to 5-10 years
communicability after the infective bite).
EPIDEMIOLOGY
Burden Sudan is included in the Afrotropical endemic region ,no other data available .
Geographical Lymphatic filariasis is endemic in the southern part of the country. It is not present in the
distribution northern part.
Lymphatic filariasis is a focal disease, and an important feature is that it tends to occur
in circumscribed zones. Observed prevalence rates vary greatly from one geographical
area to another, and even between one village and another within the same district.
Seasonality No clearly evident seasonal pattern .

Recent epidemics The disease is not outbreak-prone.
in the country

Population Yes
Disease-free population can be displaced in endemic areas.
movement
Overcrowding Yes
Population crowding increases the risk of transmission
Poor access to Yes
Increased risk of transmission, especially where no services exist for providing
health services treatment for lymphatic filariasis
Food shortages No
Lack of safe Yes
Providing safe water is a measure of secondary prevention (prevention of the
water and poor disease, not of the infection) since it enables some of the hygienic
sanitation measures recommended for the affected body parts.
Poor sanitation may contribute to create breeding sites for mosquito
vectors (especially Culex spp.).
Others Yes
Established link between the grade of poverty and the prevalence of LF
Risk assessment The complex emergency situation of Sudan is one of the reasons why this country
conclusions has not been included so far in the Global Programme to Eliminate Lymphatic
Filariasis (GPELF). This results not only in a scourge for the country under
consideration, but also poses a risk for elimination of LF in neighbouring countries
since Angola can represent a source of transmission.
Health Mapping for Lymphatic Filariasis will be completed in next years, in order to
localize exactly populations at risk. After that, it will be possible to implement the
control programme, to monitor drug coverage over time, and to monitor the
elimination of the disease in space and time.
The introduction of GPELF in Sudan would bring "beyond filariasis" benefits, as
albendazole is an effective and safe drug for treating soil-transmitted helminths as
well; ivermectin is effective against many intestinal parasites and even against
scabies and lice.

Case
Hygiene measures for the affected body parts (and, when necessary, antibiotics
Management
and antifungal agents) can decrease the risk of adenolymphangitis:
Washing the affected parts twice daily with soap and water.
Raising the affected limb at night.
Exercising to promote lymph flow.
Keeping nails short and clean.
Wearing comfortable footwear.
Using antiseptic or antibiotic creams to treat small wounds or abrasions, or in severe
cases systemic antibiotics.
Drug regimen:
DEC 6 mg/kg single dose for 12 days, repeated at 1-6 months interval if necessary, or
DEC 6-8 mg/kg/day for 2 days each month for 12 months.
Since the use of DEC in patients with either onchocerciasis or loiasis can be unsafe, it is
important that patients with bancroftian filariasis who live in areas endemic for
these other infections be examined for co-infection with these parasites before being
treated with DEC.
In alternative, ivermectin and albendazole can be used: ivermectin, though very
effective in decreasing microfilaraemia appears not to kill adult worms (i.e., be
macrofilaricidal) and thus can be expected not to cure infection completely.
Albendazole can be macrofilaricidal for W. bancrofti if given daily for 2-3 weeks, but
optimization of its usage has not been attempted.
Prevention and Prevention of infection can only be achieved either by decreasing contact between
Control humans and vectors or by decreasing the amount of infection the vector can acquire,by
treating the human host.
A - Population level:
Filariasis control through reducing the number of vectors has proven largely
ineffective. Even when good mosquito control can be put into place, the long life-span of the
parasite (4-8 years) means that the infection remains in the community for a long
period of time, generally longer than the intensive vector control efforts can be
sustained.
More recently, with the advent of the extremely effective single-dose, once-yearly
drug regimen, an alternative approach has been taken; this made possible the launch of the
Global Programme to Eliminate Lymphatic Filariasis (GPELF) in 1998.
When Angola will be included in the GPELF, the following steps will apply:
1. The national territory will be divided in areas called Implementation Units (IUs)
2. In lUs known to be endemic, mass drug administration (MDA) will be implemented if the
prevalence in the IU is greater than 1 %.
3. In each IU where lymphatic filariasis status is uncertain, a village will be selected which has
the most likelihood of transmission (if no information at all, randomly selected).
In the selected villages a sample of 250 persons aged 15 and plus should be examined,
using the ICT card test. If any person has a positive result, the IU should be classified as
endemic.
It is required to collect for each village the number of persons examined and the number of
persons positive, so that it will be possible to calculate the prevalence.
MDA will be implemented if the prevalence in the IU is greater than 1 %.

The GPELF has two main goals: (1) to interrupt transmission of infection; (2) to
alleviate and prevent both the suffering and disability caused by the disease:
1. To interrupt transmission of infection, the entire at-risk population must be
treated for a period long enough to ensure that levels of microfilariae in the blood
remain below those necessary to sustain transmission. Therefore, a yearly, 1
dose regimen (Mass-drug administration or MDA) of the following drugs must be
given:
Areas with concurrent onchocerciasis:
Albendazole 400 mg + Ivermectin 150 micrograms/kg of body weight once a year
for 4-6 years.
Areas with no concurrent onchocerciasis:
Albendazole 400 mg + Diethylcarbamazine (DEC) 6 milligrams/kg of body weight once
a year for 4-6 years, or
Diethylcarbamazine (DEC) fortified salt for daily use for at least 6-12 months
In areas with concurrent loiasis mass interventions cannot at present be
envisaged systematically because of the risk of severe adverse reactions in
patients with high-density Loa loa infections (about 1 in 10 000 treatments).
Loiasis is present in the north-western part of Angola, in Cabinda, Cuanza Norte, Zaire,
Uige, and Luanda Provinces.
2. To alleviate and prevent suffering and to reduce the disability and handicap
caused by the chronic consequences of lymphatic filariasis, the principal
strategy focuses on: (1) increasing lymph flow through elevation and exercise of the
swollen limb; (2) decreasing secondary bacterial and fungal infections of limbs
or genitals where the lymphatic function has already been compromised by filarial
infection. Secondary infection is the primary determinant of the worsening of
lymphoedema and elephantiasis.
Scrupulous hygiene and local care are dramatically effective in preventing
painful, debilitating and damaging episodes of lymphangitis. These consist of
regular washing with soap and water, daily exercising of the limbs, wearing of
comfortable footwear and carrying out other simple procedures at home, and at a
very low cost (see Case-Management for details).
Whereas MDA can be generally expected to reduce or interrupt transmission of LF,
the goal of GPELF could be achieved more rapidly through additional vector control in
some situations. Where MDA coverage rates or duration are limited, the added
impact of effective vector control can most usefully augment the GPELF.
B - Individual level:
Lymphatic filariasis vectors usually bite between the hours of dusk and dawn.
Contacts with infected mosquitoes can be decreased through the use of repellents,
bednets, or insecticide-impregnated materials.
Epidemic control Because of relatively low infectivity and long incubation, outbreaks of lymphatic filariasis
are unlikely

14. MALARIA
DESCRIPTION
Infectious agent In Sudan, about 90% of all malaria cases are caused by the protozoan parasite
Plasmodium falciparum. This causes the most life threatening form of the disease.
Both P. vivax and P. ovale are responsible of the remaining malaria burden.
Uncomplicated Malaria
Patient with fever or history of fever within the last 48 hours (with or without other
symptoms such as nausea, vomiting and diarrhoea, headache, back pain, chills,
myalgia) in whom other obvious causes of fever have been excluded.
Severe Malaria
Patient with symptoms as for uncomplicated malaria, as well as drowsiness with
extreme weakness and associated signs and symptoms related to organ failure such
as disorientation, loss of consciousness, convulsions, severe anaemia, jaundice,
haemo-globinuria, spontaneous bleeding, pulmonary oedema and shock.
Confirmed case
Demonstration of malaria parasites in blood film by examining thick or thin smears, or
by rapid diagnostic test kit for P. falciparum.
Mode of Vector-borne, through mosquito bite.
transmission
In Sudan, primary malaria vectors include: An.arbinanses,gamiac,funestus .
Malaria may also be transmitted by injection of infected blood. Rarely, infants may
contract malaria in utero due to trans-placental transfer of parasites, or during
delivery.
Incubation Incubation period for mosquito-transmitted infection is approximately 7-14 days for
P. falciparum, 8-14 days for P. vivax, and 7-30 days for P. malariae.
However, malaria should be considered in all cases of unexplained fever that starts
at any time between one week after the first possible exposure to malaria risk and 2
months (or even later in rare cases) after the last possible exposure.
Period of Communicability is related to the presence of infective Anopheles mosquitoes
communicability and presence of infective gametocytes in the blood of patients. Untreated or insufficiently
treated patients may be a source of mosquito infection for more than 3 years in
P.malariae malaria, 1-2 years in P. vivax malaria, and usually not more than 1 year
in P. falciparum malaria.

EPIDEMIOLOGY
Burden Number of malaria cases (2001):
Reported: 4,250,000 (only 371,633 laboratory confirmed)
Estimated: 7,500,000
Number of estimated deaths per year: 35,000
Geographical Malaria risk is present all over the country but is predominant in southern Sudan.
distribution Endemicity ranges from holo-endemicity in the South, hypo-endemicity in the North
and epidemic-prone in north, central Sudan.
Seasonality Malaria risk exists from May to November
Alert threshold Any increase in the number of cases above what is expected for the time of the year
in a defined area.
Recent epidemics

Population Yes The potential for epidemics can increase due to the influx of non-immune
movement populations moving from areas of no malaria/low transmission to highly
endemic areas.
Overcrowding Yes Due to increased population density and increased exposure to mosquito bites
in temporary shelters
Poor access to Yes Delays in access to effective treatment increase the likelihood of severe
health services disease and death
Delays in access to effective treatment also increase the pool of malaria
gametocyte carriers (the mature sexual stage of the parasite in humans,
that once picked up in the blood feed of a mosquito then develops into the
infective stage for transmission to another human)
Food shortages No However, malnutrition increases vulnerability to severe malaria once infected.
Case management also becomes more complicated, resulting in increased
mortality
Lack of safe No However, temporary surface water bodies may increase malaria vector
water and poor breeding opportunities
sanitation
Others Yes Breakdown of control measures, and lack of preventive interventions such as
insecticide treated materials (bed nets, sheeting etc.) and residual insecticide
spraying of shelters

Risk assessment Epidemiological situation
conclusions
Malaria is the major health problem in the Sudan and the whole country is now
considered endemic, with varying degrees. The malaria endemicity ranges from holo-
endemic in the South to hypoendemic in the North with epidemic
outbreaks. Plasmodium falciparum infection is overwhelmingly predominant
(90%); Anopheles arabiensis is the main vector. 32% of the outpatient attendance
and 20% of all hospital deaths are due to malaria, with an estimated rate of 7.5
million cases per year. (1998, Ministry of Health data). Malaria case fatality for
paediatric hospitals ranges between 5 and 15%. The situation is further aggravated
by the spread of chloroquine-resistant P. falciparum, increasing insecticide
resistance of vectors and inaccessibility of many areas, particularly in the South.
Sudan has a history of malaria control activities pre-dating colonial time. As
early of 1903 there was an aerial mapping of Khartoum with details of mosquito
breeding sites. A volunteer programme of "mosquito men" was very successful at
the time and heightened environmental management; strict sanitary laws and
public education on prevention led to the near elimination of malaria in most of the
country except southern and central regions. With the establishment of the Blue
Nile health project in 1978 (supported by WHO, WB, Kuwait, Japan and USA),
malaria was successfully controlled for ten years. In this period the prevalence of the
disease reduced to less than 1 % of what it had been.
Unfortunately, continuous civil strife in the south associated with massive
population movement, coupled with the drought and desertification in 1984-88, have
combined to reverse many of Sudan's earlier advancements. As there was no
sustainability plan built into the Blue Nile project, it collapsed after the withdrawal of
donor funding and epidemics have broken out on and off since then, most notably
in 1993-94.
It is expected that the malaria situation will improve due to strong political
commitment from the country toward that end, as well as the support generated
from the RBM partnership.
Recently, the training of health workers in case management and vector control
has led to an improvement in malaria control activities. Epidemic preparedness
and malaria information system have markedly improved and helped in early detection
and abortion of the expected malaria epidemic following the floods of 1998. Thousands
of Insecticide Treated Nets (ITNs) have been distributed all over the country in 2002.
The management system for malaria control in Sudan includes National Malaria
Administration (NMA) at central level and Malaria units active in some provinces.
Constraints
The expansion of irrigation schemes and poor maintenance of drainage systems.
A lack of intersectoral and intrasectoral co-operation
Massive population movement within the country
A complex emergency situation in the southern region
Inadequacies in surveillance systems
Frequent turnover and emigration of technical staff to Arabian Gulf countries
Priority actions
Intensify malaria control in selected states 8initiatives include Khartoum,
Gezira and Sennan)
Reduce malaria mortality in the priority states
Prevent epidemics in the country as a whole
Support malaria control in complex emergency situation territories
Control malaria in pregnancy by presumptive intermittent treatment

Protect high-risk groups by insecticide-treated material
National programme objectives

To reduce incidence, morbidity of severe and complicated malaria cases, and
prevent mortality.
To prevent, early detect and contain malaria epidemics.

Case Management NATIONAL RECOMMENDED TREATMENT (?)
Prevention and At present malaria control includes environmental management, distribution of
Control Gambusia fish, larviciding, indoor residual spraying with pyrethroids. Moreover, free of
charge drugs are provided at all levels in endemic areas.
Insecticide treated bednets (ITN) have proved their efficacy in reducing

morbidity and mortality per year for individual and family protection. They also
have the potential for reducing transmission when used on a large scale.
Periodic spraying of shelters with residual insecticide reduces transmission and is
recommended in refugee camps, particularly among populations with low
immunity occupying mud huts or houses. When large numbers of dwellings are
sprayed, a mass effect on the density of vector population can result.
Environmental control may be difficult during the acute phase except on a local
scale, and impact is often limited. To reduce the number of vector breeding sites:
Drain clean water around water tap stands and rain water drains
Use larvicides in vector breeding sites if these are limited in number (seek
expert advice).
Drain ponds, but may not be acceptable if used for washing.
Chemoprophylaxis: in complex emergencies, chemoprophylaxis for malaria
should be limited to pregnant women, expatriate staff, and special groups such
as the army. The recommended drug is chloroquine. Chemoprophylaxis must be
complemented by personal protection. It is not recommended on a mass scale
because it is extremely difficult to implement and to monitor on a large scale and
because it can accelerate the development of drug resistance.
Preventive Intermittent Treatment (P.I.T.) at least twice during pregnancy (2nd and
3`d trimester) is advisable for pregnant women living in areas where
transmission is high. National policy has recently changed to P.I.T. in pregnancy with
Sulphadoxine-Pyrimethamine, once in the 2nd trimester and again in the 3rd
trimester. This is yet to be introduced.
Cattle sponging with insecticides can be another approach, especially against
vectors showing some degree of zoophily, such as An.funestus.
Vigorous health education at community level to improve rapid treatment
seeking behaviour for fever cases during the transmission season

15. MEASLES
DESCRIPTION
Infectious agent Measles virus (genus Morbillivirus, family Paramyxoviridae)
Any person with:
Fever and
Maculopapular (i.e. non vesicular) rash, and
Cough or coryza (i.e. runny nose) or conjunctivitis (i.e. red eyes);
or
Any person in whom a clinical health worker suspects measles infection
Presence of measles-specific IgM antibodies
Clinically confirmed: A case that meets the clinical case definition
Laboratory-confirmed (only for outbreak confirmation and during the outbreak
prevention/elimination phase):
A case that meets the clinical case definition and is laboratory-confirmed
or
A case meeting clinical definition and epidemiologically linked by direct contact to
a laboratory-confirmed case in which rash onset occurred 7-18 days earlier.
Mode of Airborne by droplet spread; or
transmission
Direct contact with the nasal and throat secretions of infected persons or via object (e.g.
toys) that has been in close contact with an infected person
Incubation After infection there is an asymptomatic incubation period of 10-12 days, with a range
from 7 to 18 days from exposure to the onset of fever
Period of Measles is most infectious from 4 days before the rash until 1-2 days after rash onset
communicability
EPIDEMIOLOGY
2003 : 4,523 cases 1997: 350 cases

2002 : 4,529cases 1990: 14,075 cases
2001: 4,362 cases 1980: 50,168 cases
2000: 2,875 cases
1999: 3,347 cases
1998: 550 cases
Geographical Measles is highly endemic throughout the region and the expected number of
distribution measles cases is high.
Seasonality Higher incidence during the colder months .some state has tow beaks (februrary
april) , (September desumber ) .

Alert threshold
-One case must lead to an alert in state that conducted the measeals
catchup campaign (northan ,river nile ,red sea & kasala ).
-mean alert threshold to sudan 4489cases .
Laboratory confirmation of all cases is not required
Only few cases from each outbreak should be laboratory confirmed

Recent It is reported that in Sudan one-third of all deaths in children under three years of age is
epidemics due to measles
October-November 2002:40 cases with 3 deaths are reported from Nimule (Magwe
county, Eastern Equatoria)
October-November 2002: 45 cases (no deaths) are reported from Gomjuer (Aweil West
county, Southern Bahr-al-Gazal)
September-October 2002: 118 cases and 3 deaths are reported from Labone and Yei
(Bahr-al-Jabal)
July-August 2002: 260 cases with 6 deaths are reported from areas of Nuba mountains
including Jullud, Timen and Tima (STATE)
March-April 2002:13 cases with 3 deaths are reported from Ruweng (STATE)
March April 2001: An outbreak involving 158 cases of measles is reported from Buoth
and Mayoum (Upper Nile)
April-May 2001: 14 cases are reported from Niemni (Upper Nile)
January-February 2001: 101 cases and 26 deaths were reported from Nyimboli (Aweil
West county, Southern Bahr-al-Gazal)

Population
Yes Importation of virus
movement
Overcrowding Yes Crowded conditions facilitate transmission
Poor access to Yes Case-fatality rates can be reduced by effective case management, including the
health services administration of vitamin A supplements
Food shortages No However, disease is more severe among children with malnutrition and vitamin A
deficiency
Lack of safe No
water and poor
sanitation
Others Yes Low immunization coverage in the area of origin of the refugees or internally
displaced people, and/or the host area.
Risk assessment Routine immunization services have been hampered for a long time by civil unrest.
conclusions This implied low reported coverage rates, especially in the southern states.
Measles is still common in various areas of the country, including the capital's area: the
disease is the most common diagnosis among vaccine-preventable diseases in febrile
children who present at the emergency hospitals in Khartoum.
MCV (measles-containing vaccine) coverage:

2001: 80% (official country estimates); 67% (WHO-UNICEF estimates)
1997: 92%
1990: 57%
1980: N.A.

Sudan has a routine immunization policy (see Annex 7) which requires a dose
of single antigen measles vaccine at 9 months.
However, supplementary measles immunization campaigns may be required in order
to reduce the risk of a measles outbreak
Routine Immunize the population at risk as soon as possible. The priority is to immunize
Immunization children 6 months to 15 years old, regardless of vaccination status or history
of disease. Expansion to older children is of less priority and should based
on evidence of high susceptibility among this age group
Children who are accinated against measles before 9 months of age must
receive a second measles vaccination. This should be given as soon as possible
after 9 months, with at least 1 month as a minimum interval with the
previous dose.
All children 6 months - 5 years of age should also receive prophylactic
Vitamin A supplementation. If evidence of clinical vitamin A deficiency in older
age groups, treatment with Vitamin A should be initiated as per WHO
guidelines.
To ensure safety of injection during immunization, auto-disable syringes and
safety boxes are recommended. Safe disposal of used sharps should
be ensured
Outbreak response
Inform the Health Authorities if one or more suspected cases are identified
Confirm the suspected outbreak, following WHO guidelines
Investigate suspected case: check if it fulfils the case definition, record date of
onset, age and vaccination status
Confirm the diagnosis: collect blood specimen from 3-5 initial reported cases
Assess the extent of the outbreak and the population at risk
Implement outbreak response measures as follows:
Give priority to proper case-management and immunization of groups at
highest risk (e.g. children 6 months - 5 years) as soon as possible even
in areas not yet affected where the outbreak is likely to spread.
Promote social mobilization of parents in order to assure previously
unvaccinated children 6 months - 5 years of age are immunized.
The presence of several cases of measles in an emergency setting does not
preclude a measles immunization campaign. Even among individuals
who have already been exposed to, and are incubating the natural virus,
measles vaccine, if given within 3 days of exposure, may provide protection
or modify the clinical severity of the illness.
Isolation is not indicated and children should not be withdrawn from
feeding programmes.

Case management For uncomplicated cases
Give Vitamin A immediately upon diagnosis and ensure the child receives a
second dose the next day (can be given to mother to administer at home)
Advise the parent to treat the child at home (control fever and provide
nutritional feeding)
For cases with non-severe eye, mouth or ear complications:
Children can be treated at home
Give Vitamin A immediately upon diagnosis and ensure that the child receives
a second dose the next day (can be given to mother to administer at home)
If pus draining from the eyes, clean eyes and treat with 1 % tetracycline
eye ointment
If mouth ulcers, treat with gentian violet
If pus draining from the ear, clean ear discharge and treat with antibiotics for
5 days (amoxycillin-1st line- or cotrimoxazole-2" line-, as per national ARI
policy and IMCI guidelines currently under development)
Treat malnutrition and diarrhoea, if present, with sufficient fluids and high
quality diet
For cases with severe, complicated measles (any general danger signs*,
clouding of cornea, deep or extensive mouth ulcers, pneumonia):
Refer urgently to hospital
Treat pneumonia with an appropriate antibiotic
If clouding of the cornea or pus draining from the eye, clean eyes and apply 1
tetracycline eye ointment
If the child has any eye signs indicating Vitamin A deficiency (i.e. night blindness,
Bitot spots, conjunctival and corneal dryness, corneal clouding or corneal
ulceration), then he or she should receive a third dose of Vitamin A 2-4
weeks later
* inability to drink or breastfeed, vomiting everything, convulsions, lethargy or unconsciousness

16. MENINGOCOCCAL DISEASE (MENINGITIS AND SEPTICAEMIC
FORM)
DESCRIPTION
Infectious agent Bacterium: Neisseria meningitidis serogroups A,B,C,Y,W135
An illness with sudden onset of fever (>38.5 C rectal >38.0 C axillary)
And one or more of the following:
neck stiffness
altered consciousness
other meningeal sign or petechial or purpural rash
In patients under one year of age, suspect meningitis when fever is accompanied
by bulging fontanelle.
Positive CSF antigen detection, or
Positive culture
Suspected: a case that meets the clinical case definition above.
Probable: a suspected case as defined above and:
Turbid CSF (with or without positive Gram-stain), or
Ongoing epidemic and epidemiological link to a confirmed case.
Mode of Confirmed: a suspected or probable case with laboratory confirmation.
Direct contact with respiratory droplets
transmission
Incubation Incubation period varies between 2 to 10 days, most commonly 4 days
Period of From the beginning of the symptoms till 24 hours after the institution of the therapy, but
communicability the most important source of infection are asymptomatic carriers.
EPIDEMIOLOGY
Burden Cases and deaths of meningococcal meningitis reported to WHO:
2002: no data reported
2001: no data reported
2000 (week 25): 4 031 cases, 328 deaths
1999: 33 313 cases, 2 410 deaths
1998: 697 cases, 82 deaths
1997: 297 cases
1996: 340 cases
Geographical Epidemics occurred in Sudan between 1980 and 1999 affected the following regions: Blue
distribution Nile, Darfur, Gezira, Kassala, Khartoum, Kordofan, Omdurman, Rombeik, Sennar,
White Nile.
Seasonality Outbreaks tend to occur during the dry season (December to January)

Alert thresholdt1 Intervention: (1) inform authorities; (2) Investigate; (3) Confirm; (4) Treat cases; (5)
Strengthen surveillance; (6) Prepare.
Population > 30,000: 5 cases per 100,000 inhabitants per week or a cluster of
cases in an area.
Population < 30,000: 2 cases in 1 week or an increase in the number of cases
compared to previous non-epidemic years
Epidemic Intervention: (1) Mass vaccination; (2) Distribute treatment to health centres; (3)
threshold
treat according to epidemic protocol; (4) Inform the public.
Population > 30,000:
10 cases per 100,000 inhabitants per week if:
1- no epidemic for 3 years and vaccination coverage <80%;
2- alert threshold crossed early in the dry season.
15 cases per 100,000 inhabitants per week in other situations
Population < 30,000:
5 cases in 1 week or
Doubling of the number of cases in a 3-week period or
For mass gatherings, refugees and displaced persons, 2 confirmed cases in 1
week are enough to vaccinate the population
Other situations should be studied on a case-by-case basis.
1
Detecting meningococcal meningitis epidemics in highly-endemic African countries. Weekly Epidemiological Record, 2000, 38: 306-9.
Recent epidemics 2002: As of February 11, a total of 330 cases including 49 deaths were reported from
in the country Limun, Kauda and Hieman, in the Nuba mountains (South Kordofan). Serogroup A has
been confirmed. (CFR=14.8%)
January-March 2002: as of 21 March 2003, 126 cases and 7 deaths were reported
from Isoke (Torit county, Eastern Equatoria), and 104 cases and 14 deaths from
Ikotos, in the same county
February-March 2002: as of 15 March 2003, 8 cases and 1 death were reported from
Padak (Boma county, East Equatoria)
March 2001: 42 admission cases and 2 deaths were reported from Jaibor (Keew
county, Upper Nile)
February-March 2001: as of 26 March, 19 cases and 1 death were reported from
Chuil (Latjor county, Upper Nile). N. meningitidis serogroup A was identified.
February-March 2001: as of 22 March, 67 cases and 13 deaths were reported from
Paluer (Bor county, Upper Nile)
February 2001: 117 cases and 1 death were reported from Narus (Eastern Equatoria)
2000: a total of 2,549 cases of meningococcal disease, of which 186 were fatal, were
reported to the national health authorities between 1 January and 31 March 2000.
Bahr-al-Jabal State resulted to be the most affected, with 1.437 cases (including 99
deaths) reported in the Juba city area. Other States affected included White Nile (197
cases, 15 deaths), South Kordofan and Sennar (where incidence was lower). Epidemic
response activities included vaccination of a total of 70,000 people in early March.
1998-1999: an outbreak of meningococcal meningitis was reported in the Northern
Darfur region. An increase in the number of cases had already been observed in
December 1998. As far as May 1999, about 22 000 cases of meningococcal disease
had been notified from 19 of the 26 States of Sudan, out of which 1600 had died.
More than 10 million doses of meningococcal vaccine had been distributed for mass
vaccination campaigns. A total of 33 313 cases and 2 410 deaths have been reported in
1999 from Sudan to WHO.
1988: following the returns of pilgrims from Mecca (Haji) in August 1987 many
countries in EMR faced an unusual spread of meningococcal infection. In Sudan, the
1987 introduction developed into epidemic spread in the meningitis season of 1988.
32 016 cases of meningococcal disease have been reported in 1988 from Sudan to
WHO.

Population Yes Travel, migration and displacement facilitate the circulation of virulent strains
movement inside a country or from country to country.
Overcrowding Yes High density of susceptible people is an important risk factor for outbreaks.
IDP/Refugee camps, crowding due to cattle or fishing-related activities, military
camps, schools facilitate spread of the disease.
Poor access to Yes Cases identification is crucial to rapidly implement control measures
health services
Case fatality ratio in absence of treatment is very high (50%)
Food shortages No
Lack of safe No
water and poor
sanitation

Others No Concurrent infections: upper respiratory tract infections may contribute to
some meningococcal outbreaks.
Dry and windy/dusty seasons increase transmission of the disease
Risk assessment Central and southern Sudan is included in the African meningitis belt,
Conclusions extending from Ethiopia in the East, to Senegal in the West, mainly within the
range of 300 mm to 1 100 mm annual rainfall. In this area sporadic infections
occur in seasonal annual cycles, while large-scale epidemics occur at greater
intervals with irregular patterns. These usually begin during the dry season
from December to February, and can sometimes last more than a year.
Since the early 1990s, Sudan has been practising preventive vaccination,
mainly directed to high-risk groups. However, this was not sufficient to prevent
the 1999 epidemics.
High risk of epidemics in overcrowded refugee camps

Case Management Meningococcal disease (either meningitis or septicaemia) is potentially fatal and should
always be viewed as a medical emergency.
NON-EPIDEMIC CONDITIONS:
Admission to a hospital or health centre is necessary for diagnosis (lumbar
puncture and CSF examination). Lumbar puncture must be done as soon as
meningitis is suspected, prior to starting antibacterials.
As infectivity of patients is moderate and disappears quickly following antimicrobial
treatment, isolation of the patient is not necessary.
Antimicrobial therapy must be instituted as soon as possible after lumbar puncture
(without waiting for laboratory results), and should be combined with supportive
treatment.
Initial antimicrobial therapy should be effective against the three major causes of
bacterial meningitis until bacteriological results are available:
AGE GROUP PROBABLE ANTIBIOTIC THERAPY
PATHOGENS
FIRST CHOICE ALTERNATIVE
Adults and children >5 S. pneumoniae Penicillin G Ampicillin or
Amoxicillin
Chloramphenicol
Ceftriaxone or
Cefotaxime
Children I month H. influenzae Ampicillin or Chloramphenicol

5 years of age S. pneumoniae Amoxicillin (1) Ceftriaxone or
N. meningdidis Cefotaxime
Neonates Gram-negative bacteria Ampicllin and Ceftriaxone or

Group B streptococci Gentamycin Cefotaxime (2)
Listeria Chloramphenicol
(at reduced doses)
1 If H. influenzae is highly resistant to Ampicillin, chloramphenicol should be given with Ampicillin.
2 No effect on Listeria
Once diagnosis of meningococcal disease has been established many

antimicrobials can be used: either penicillin or ampicillin is the drugs of choice.
Chloramphenicol is a good and inexpensive alternative. The third-generation
cephalosporins, Ceftriaxone and Cefotaxime, are excellent alternatives but are
considerably more expensive.
A seven-day course is still the general rule for the treatment of meningococcal
disease (beyond the neonatal period), However there id good evidence that a
four-day course of penicilin G is as effective as any longer course of
treatment .The long-acting (oily) form of chloramphenicol has also been shown to
be effective.
EPIDEMIC CONDITIONS:
During epidemics of confirmed meningococcal disease, case management needs to
be simplified to permit the health system to respond to rapidly expanding numbers
of cases.
Diagnosis: as the flood of patients could make the routine use of lumbar puncture
to confirm meningitis impossible, every suspected case of meningitis should
be considered and treated as one of meningococcal meningitis.
Treatment: simplified treatment protocols are appropriate: long-acting o
chloramphenicol intramuscularly (100 mg/kg up to 3 grams in a single dose) is the
drug of choice for all age groups, particularly in areas with limited health facilities.

For patients who do not improve rapidly, an additional dose of the same
antimicrobial is recommended 48 hours later.
Prevention NON-EPIDEMIC CONDITIONS:
Vaccination: to prevent secondary cases around a sporadic case of meningococcal
disease, vaccine can be used for close contacts of patients with meningococcal
disease due to A, C, Y, or W135 serogroups.
Chemoprophylaxis: the aim of chemoprophylaxis is to prevent secondary cases
by eliminating nasopharyngeal carriage. To be effective in preventing
secondary cases, chemoprophylaxis must be initiated as soon as possible (i.e.
not later than 48 hours after diagnosis of the case). Its use should be restricted
to close contacts of a case, which are defined as:
Household members (i.e. persons sleeping in the same dwelling as the
case)
Institutional contacts who shared sleeping quarters (i.e. for boarding-school
pupils, roommates; for military camps, persons sharing a barracks);
Nursery school or childcare centre contacts (i.e. children and teachers who
share a classroom with the case);
Others who have had contact with the patient's oral secretions through
kissing or sharing of food and beverages.
The drugs recommended by the Federal Ministry of Health are injectable oily
choloranphenicol during an outbreacks single dose 3gm &penzyle penicillin .
EPIDEMIC CONDITIONS
Vaccination: a mass vaccination campaign, if appropriately carried out, is able to
halt an epidemic of meningococcal disease. Laboratory diagnosis and
confirmation of epidemic serogroups will guide the type of vaccine needed, either
meningococcal polysaccharide bivalent A/C (if serogroup A or C is confirmed as
the epidemic serogroup), or meningococcal polysaccharide tetravalent
vaccine A/C/Y/W135 (if serogroup Y or W135 is confirmed). Vaccination will
be concentrated in the area where the epidemic is maximal.
Refugee camp population: Following confirmation (serogroup identified) of
two cases, mass vaccination is recommended if the serogroup/s identified
is/are included in either the bivalent (A/C) or tetravalent (A/C/Y/W135)
vaccine. At risk populations (e.g. 2-30 years of age) should be given priority.
General population: If an outbreak is suspected, vaccination should only be
considered after careful investigation (including confirmation and serogroup
identification) and the assessment of the population group at highest risk.
Chemoprophylaxis: chemoprophylaxis of contacts of meningitis patients is NOT
warranted during an epidemic for several reasons. In small clusters or
outbreaks among closed populations (e.g. extended household, boarding
schools), chemoprophylaxis may still be appropriate

17. ONCHOCERCIASIS (RIVER BLINDNESS)
DESCRIPTION
Infectious agent Onchocerca volvulus, a filarial worm belonging to the class Nematoda
Persons suffering from onchocerciasis may experience:
(A) Skin lesions: dermal changes are secondary to tissue reaction to motile larvae
as they migrate subcutaneously, or to their destruction in the skin.
- Itching: the pruritus of onchocerciasis is the most severe and intractable that is
known. In lightly infected persons, this may persist as the only symptom.
- Rashes: the rash usually consists of many raised papules, which are due to
icroabscess formation, and may disappear within a few days or may spread.
Sowda, from the Arabic for black or dark, is an intensely pruritic eruption usually
limited to 1 limb and including oedema, hyperpigmented papules, and regional
lymphadenopathy. It is common in Yemen, but can also be found in Sudan.
- Depigmentation of the skin: areas of depigmentation over the anterior shin with
islands of normally pigmented skin, commonly called "leopard skin", are found in
advanced dermatitis
- Subcutaneous nodules: these are 0.5 to 3.0 cm asymptomatic subcutaneous
granulomas resulting from a tissue reaction around adult worms. They occur
most often over bony prominences: in Africa the nodules are often located over
the hips and lower limbs.
- Lymphadenopathy: it is frequently found in inguinal and femoral areas, and can
result in "hanging groin" (especially when associated with skin atrophy and loss of
elasticity), and elephantiasis of the genitalia.
(B) Eye lesions: ocular onchocerciasis is related to the presence of live or dead
microfilariae. Involvement of all tissues of the eye has been described, and many
changes in both anterior and posterior segments of the eye can occur. The more
serious lesions lead to serious visual impairment including blindness.
(C) General debilitation: onchocerciasis has also been associated with weight loss
and musculoskeletal pain
Clinical case definition
In an endemic area, a person with fibrous nodules in subcutaneous tissues. These
must be distinguished from lymph nodes or ganglia.
Laboratory criteria
Presence of one or more of the following:
- Microfilariae in skin snips taken from the iliac crest (Africa) or scapula (Americas)
- Adult worms in excised nodules
- Typical ocular manifestations, such as slit-lamp observations of microfilariae in
the cornea, the anterior chamber, or the vitreous body
- Serology (especially for non-indigenous persons)
Case classification
- Suspected: A case that meets the clinical case definition
- Probable: Not applicable
- Confirmed: A suspected case that is laboratory-confirmed

Mode of Vector-borne, by the bite of infected female blackflies belonging to the genus
transmission Simulium (mainly S.damnosum complex). Larvae of the vector for onchocerciasis live in
fast-running water - this has led to the name "river blindness".
Microfilariae are ingested by a black fly feeding on an infected person, and penetrate
thoracic muscles of the fly. Here a few of them develop into infective larvae after
several days, migrate to the cephalic capsule, are liberated on the skin and enter the bite
wound during a subsequent blood meal. Infective larvae develop into adult parasites
in the human body, where adult forms of O. volvulus can live for up to 14-15 years and
are often found encased in fibrous subcutaneous nodules. Each adult female
produces millions of microfilariae that migrate under the skin and through the eyes,
giving rise to a variety of dermal and ocular symptoms.
Humans are the only reservoir. Other Onchocerca species found in animals cannot
infect humans but may occur together with O. volvulus in the insect vector.
Incubation Larvae take at least 6 to 12 months to become adult worms. Adult worms are usually
innocuous, apart from the production of the subcutaneous nodules (these can
develop as early as 1 year after infection). The main pathologic sequelae of O.
volvulus infection are due to the microfilariae in skin and ocular tissue, where they
can be found after a period of 7 to 34 months.
Microfilariae are found in the skin usually only after 1 year or more from the time of the
infective bite.
Period of Man->Blackfly
communicability Infected individuals can infect blackflies as long as living microfilariae occur in their
skin. Microfilariae are continuously produced by adult female worms (about 700 per
day), and can be found in the skin after a prepatent period of 7 to 34 months
following introduction of infective larvae. They may persist for up to 2 years after the
death of the adult worms.
Blackfly=Man
Blackfly vectors become infective (i.e. able to transmit infective larvae) 7 to 9 days
after the blood meal.
EPIDEMIOLOGY
Burden There are an estimated two million persons at risk of onchocerciasis in Sudan, and
10,000 cases of onchocerciasis-related blindness.
Southern focus: in Western Bahr-al-Gazal, more than 80% of subjects in some
villages had palpable nodules in 1998.
Northern focus: Rapid Epidemiological Assessment (REA) in 1995 revealed that
16% of the local inhabitants had palpable nodules. Skin-snip positivity reaches
33.6%.
Eastern focus: skin-snip positivity may reach 50% in some villages, but nodule rates are
low (1998).
Western focus: Rapid Epidemiological Assessment (REA) in 1996 revealed that
22% of subjects in this area had palpable nodules and 28% had onchocercal skin
lesions or itching

Geographical Infection with Onchocerca volvulus is known to occur in four main regions, known as
distribution
the southern, northern, eastern and western foci.
Southern focus: this is the largest focus and includes all the southern States from
Western Bahr-al-Gazal in the west to Upper Nile in the east. The rate of infection is
highest in the South-West, in Western Bahr-al-Gazal state, especially among
communities living along the Jur river (Nahr-al-Jur) and its tributaries.
Northern focus: the rocky ground and river bed between the fourth and fifth Nile
cataracts create breeding sites for S. damnosum. The river level reaches its peak in
late summer (August-September), and ideal conditions for Simulium breeding occur
when the water recedes and rocks and vegetation emerge, creating surface
turbulence. This focus is located in the Abu Hamad area of the Nubian desert in the
Northern state. This is the most northerly focus in Africa, and probably in the world.
Eastern focus: this focus is located in Gedarif state, along the upper Atbarra river,
close to the Ethiopian border.
Western focus: this focus is contiguous to the southern one and includes the
communities living along the Umbellasha, Adda and Bahr-al-Arab River in Southern
Darfur. This is a sudan savanna region where seasonal rainfalls (May-September)
give rise to fast flowing rivers which, during the dry months, become parched or
stagnant
Seasonality Southern focus: transmission from July to October
Northern focus: transmission between November and January
Eastern focus: transmission from July to October
Western focus: transmission from May to September
Recent epidemics (?)

Population Yes Infections in the Bahr-al-Arab area (western focus) are probably the result of
movement individuals from the southern focus migrating northwards during the civil war
in the 1950s.
Overcrowding Yes
Poor access to Yes CDTI is an effective tool for transmission control.
health services
Food shortages No
Lack of safe No
water and poor
sanitation
Others No

Risk "Craw-craw" (itchy skin due to onchocerciasis) was reported for the first time in
assessment Sudan in 1908 from Bahr-al-Ghazal.
conclusions
The Global 2000 River Blindness Program of The Carter Center estimates the crude
ultimate treatment goal for Sudan (total number of people in need of treatment) at
743,230. Of the several endemic areas in the country, the southern focus is the most
significant and is characterized by high prevalence of blinding onchocerciasis. Some of
the highest rates of blindness due to onchocerciasis in the world occur in southwest
Sudan.
The cost per treatment in 2001 was considerably above that recommended by APOC,
and calculated at US$ 0.74. The high cost underscores the principle that distribution
in conflict areas will be more expensive.
In general, communities are committed to the distribution of ivermectin. The
onchocerciasis control programme is viewed at the highest governmental levels as
an example of a successful health delivery system and is well integrated into the
Sudanese primary health care system.
Among the constraints encountered in Sudan:
Accessibility problems due to the civil unrest, flood, famine, drought, and mass
population displacement (in southern Sudan)
Continuous reshaping of the population and the community-directed drug
distributors
Impaired treatment activities in areas devoid of any health infrastructure, or in
areas where the Primary Health Care system is not operational.
Co-endemicity for Onchocerca volvulus and Loa loa in some areas of
southwestern Sudan. Guidelines for Loa loa coendemic areas still need to be
implemented.
It seems likely that there has been a decrease in the prevalence of infection in the
last one or two decades in the Western focus. This reduction might be the result of
population mass migration and reduced vector density following a period of drought in
1987, and also of annual ivermectin treatment. The prevalence of infection
appeared to be reduced also in the northern focus in 1995 when compared to 1985,
thanks to the five annual rounds of ivermectin treatment carried out in this area.
Case Management Administration of ivermectin once a year over a period of at least 15 to 20 years will
reduce infection to insignificant levels and prevent the appearance of clinical
manifestations. The recommended dosage is equivalent to 150 microgrammes per
kg of body weight (in practice, dosage is according to height, using 1 to 4 tablets of
3 mg). Established clinical manifestations are also treated by ivermectin.
Treatment with ivermectin is contraindicated in:
Children under 5 years (age), less than 15kg (weight), or less than 90cm (height).
Pregnant women
Lactating mothers of infants less than one week old
Severely ill persons
NB: ivermectin should be used with extreme caution in areas co-endemic with Loa loa.
Epidemic control Recrudescence of transmission may occur and can be managed by the
administration of ivermectin if mass treatment programmes can maintain good
treatment coverage.

Prevention Vector Control:
Distruction of Simulium larvae by application of insecticides such as Temephos
(Abate) through aerial spraying to breeding sites in fast-flowing rivers, in order
to interrupt the cycle of transmission of the disease. Once the cycle has been
interrupted for 14-15 years, the reservoir of adult worms dies out in the human
population, thus eliminating the source of the disease. This was the basic strategy of
the Onchocerciasis Control Programme (OCP) in West Africa.
In the West African savanna zone, onchocerciasis was a severely blinding
disease. It was also responsible for the depopulation of fertile river valleys in the
OCP countries and hence had become a major impediment to economic development.
For these reasons, the large-scale vector control operations of the OCP-
based on the aerial application of insecticides and aiming at the virtual elimination
of the disease-were considered economically justified. OCP has been successful
in eliminating onchocerciasis as a public health and socioeconomic problem.
The African Programme for Onchocerciasis Control (APOC), that includes Sudan
and other 18 African countries, considers focal vector eradication as a control
option. This implies that the whole focus is covered at once resulting in the total
eradication of the vector over a very short time scale.
Community-Directed Treatment with Ivermectin (CDTI):
Course: Once-a-year administration of 150 micro grammes of ivermectin per kg
of body weight
The introduction of ivermectin in 1987 provided for the first time a feasible
chemotherapy for large-scale treatment of onchocerciasis. Ivermectin is an
effective microfilaricide which greatly reduces the numbers of skin microfilariae to
low levels for up to a year, thus:
(1) alleviating many symptoms: since the microfilariae cause the severe morbidity
of onchocerciasis, ivermectin treatment is an effective tool for morbidity control,
able to prevent the development of ocular lesions and blindness;
(2) making the recipient less infective for the vector: ivermectin is an effective tool for
onchocerciasis transmission control.
Ivermectin treatment greatly reduces transmission of the parasite, but does not
halt it within the period of a decade or more, and the adult worm may live for as long
as 14-15 years. Annual large-scale treatment will therefore have to continue for a
very long time. Current predictions with a simulation model indicate that annual
treatment at the current level of coverage may have to continue for at least two
decades. The main challenge facing ivermectin-based control, therefore, is
to develop and implement simple methods of ivermectin delivery which can be
sustained by the communities themselves. The current APOC strategy consists of
distribution house to-house or at central meeting points in villages.
CDTI is the main strategy adopted by APOC. In the 19 countries included this
programme, onchocerciasis remains a major cause of blindness, but does not
appear to be the cause of major depopulation of fertile lands. Partly for this
reason, largescale vector control operations are not likely to be as cost-effective as
they have been in the OCP area.

18. PERTUSSIS (WHOOPING COUGH)
DESCRIPTION
Infectious agent Bordetella pertussis, the pertussis bacillus
The initial stage, the catarrhal stage, is characterized by the insidious onset of
coryza (runny nose), sneezing, low-grade fever, and a mild, occasional cough, similar to
the commom cold. The cough gradually becomes more severe and irritating, and after
1-2 weeks, the second, or paroxysmal stage, begins. The patient has bursts, or
paroxysms, of numerous, rapid coughs, apparently due to difficulty expelling thick
mucus from the tracheobronchial tree. At the end of the paroxysm, a long inspiratory
effort is usually accompanied by a characteristic whoop.
In younger infants, periods of apnoea may follow the coughing spasms, and the
patient may become cyanotic (turn blue). Pneumonia is a relatively common
complication (reported 21.7% of cases in developed countries); otitis, haemorrhages
(subconjunctival petechiae and epistaxis), convulsions, encephalopathies and death
occur more rarely). The disease lasts 4 to 8 weeks. Complications are more frequent
and severe in younger infants. In developed countries the case fatality ratio among
infants less than 1 month has been reported to be around 1 %. Older persons (i.e.
adolescent and adults), and those partially protected by the vaccine, may become
infected with B. pertussis, but usually have milder disease.
In the convalescent stage, recovery is gradual. The cough becomes less
paroxysmal and disappears over 2 to 3 weeks. However, paroxysms often recur with
subsequent respiratory infections for many months after the onset of pertussis. Fever is
generally minimal throughout the course of pertussis.
Clinical case definition:
A case diagnosed as pertussis by a physician, or
A person with a cough lasting at least 2 weeks with at least one of the following
symptoms:
Paroxysms (i.e. fits) of coughing
Inspiratory "whooping"
Post-tussive vomiting (i.e. vomiting immediately after coughing)
Isolation of Bordetella pertussis, or
Detection of genomic sequences by polymerase chain reaction (PCR)
Positive paired serology
Clinical case: A case that meets the clinical case definition
Confirmed case: A clinical case that is laboratory-confirmed
Mode of Primarily by direct contact with discharges from respiratory mucous membranes of
transmission infected persons via the airborne route. Humans are the only hosts.
Even though the disease may be milder in older persons, these infected persons may
transmit the disease to other susceptible persons, including un-immunized or under
immunized infants. Adults are often found to be the first case in a household with
multiple pertussis cases.

Incubation The incubation period usually lasts 7 to 10 days and rarely more than 14 days.
Period of Pertussis is highly communicable in the early catarrhal stage. Communicability

communicability gradually decreases after the onset of the paroxysmal cough.
Untreated patients may be contagious for up to 3 weeks after the onset of
paroxysmal cough in the absence of treatment or up to 5 days after onset of
treatment
EPIDEMIOLOGY
2001: 645 1997: 418 cases
2000: 80 1990: 566 cases
1999: 51 1980: 28,631 cases
1998: 169
Geographical No data available
distribution
Seasonality Pertussis has no distinct seasonal pattern, but may increase in the summer and fall.
Alert threshold
Recent epidemics 2002 December: 5 cases (no deaths) are reported from Akob Payam (Tonj county,
in the country Lakes state)
2002 October-December: 127 cases with 2 deaths were reported from Akon (Gogrial
county, Western Bahr-al-Gazal)
2002 August-September: 68 cases and 5 deaths were reported from several villages in
Oriny and Shilluk counties (Upper Nile state). All cases, except 5, were children <5 years
of age.

Population Yes Importation and spreading of B. pertussis.
movement
Overcrowding Yes Crowded conditions facilitate transmission. The disease is usually brought
home by an older sibling or a parent.
Poor access to Yes No access to routine immunization services. Susceptibility of non-immunized
health services individuals is universal, and vaccination is the mainstay of pertussis control.
Food shortages N
Lack of safe N
water and poor
sanitation
Others Yes Low DTP3 coverage (<80%).

Risk assessment Yearly fluctuations in the number of reported cases reflect a weak surveillance system.
conclusions
Pertussis is a potential problem if introduced into crowded refugee settings with
many unimmunized children
DTP3 coverage:
2001: 71% (official country estimates); 46% (WHO-UNICEF estimates)

Case
Erythromycin or erythromycin estolate or - in case of allergies to erythromycin
Management trimethoprimsulfamethoxazole (contraindicated during pregnancy) should be
administered for 7-14 days to all cases and close contacts of persons with
pertussis, regardless of age and vaccination status. Drug administration both (1)
modifies the course of illness (if initiated early), and (2) eradicates the organism
from secretions, thereby decreasing communicability.
Symptomatic treatment and supportive case-management
Immunization The administration of vaccines is the most rational approach to pertussis control. Active
primary immunization against B. pertussis infection with the whole-cell vaccine (wP)
is recommended in association with the administration of diphtheria and tetanus toxoids
(DTP). No single antigen pertussis vaccine is available.
Although the use of acellular vaccines (al?) is less commonly associated with adverse
reactions, price considerations affect their use, and wP vaccines are the vaccines of
choice for most countries, including Iraq.
In general, pertussis vaccine is not given to persons 7 years of age or older, since
reactions to the vaccine (convulsions, collapse, high temperature) may be increased in
older children and adults.
The efficacy of the vaccine in children who have received at least 3 doses is estimated to
be 80%: protection is greater against severe disease and begins to wane after about 3
years.
Epidemic control The highly contagious nature of the disease leads to large numbers of secondary cases
among non-immune contacts. Prophylactic antibiotic treatment (erythromycin) in the
early incubation period may prevent disease, but difficulties of early diagnosis, costs
involved and concerns related to the occurrence of drug resistance all limit prophylactic
treatment to selected individual cases. Priority must be given to:
Protecting children less than 1 year old and pregnant females in the last 3 weeks of
pregnancy because of the risk of transmission to the newborn.
Stopping infection among household members, particularly if there are children
aged less than 1 year and pregnant women in the last 3 weeks of pregnancy.
The strategy relies on chemoprophylaxis of contacts within a maximum delay of 14 days
following the first contact with the index case. Index cases must avoid contact with day care
centres, schools and other places regrouping susceptible individuals for up to 5
days after the beginning of treatment or up to 3 weeks after onset of paroxysmal cough, or till
the end of cough, whichever comes first.
All contact cases must have their immunization status verified and brought up to date.

19. POLIOMYELITIS
DESCRIPTION
Infectious agent
Poliovirus (Enterovirus group): types 1, 2, 3
Case definition and Clinical description:
classification
All 3 types of wild poliovirus may cause paralysis, although most infections (at least
95%) remain asymptomatic.
Most symptomatic cases report merely a non-specific febrile illness lasting a few
days, and corresponding to the viremic phase of the disease. In a few cases the
fever can be followed by the abrupt onset of meningitic and neuro-muscular
symptoms, such as stiffness in the neck, and pain in the limbs. Initial symptoms can also
include fatigue, headaches, vomiting, constipation (or less commonly diarrhoea). In a very
small percentage of cases (1 or less per 100 infected susceptible persons), the gradual
onset (2-4 days) of flaccid paralysis can then follow. Paralytic disease usually
affects the lower limbs, and is typically asymmetric and more severe proximally.
Bulbar paralysis may also occasionally occur, leading to respiratory muscle
involvement and death unless artificial respiration is resorted to. The mortality from
paralytic poliomyelitis is between 2 and 10%, mainly due to bulbar involvement
and/or respiratory failure.
Risk factors for paralytic disease are a large inoculum of virus, increasing age,
pregnancy, recent tonsillectomy, strenuous exercise and intramuscular injections
during the incubation period.
After the acute illness there is often a degree of recovery of muscle function. 80% of
eventual recovery is attained within 6 months, although recovery of muscle function
may continue for up to 2 years.
After many years of stable neurologic impairment, in 25-40% of patients new
neuromuscular symptoms (weakness, pain and fatigue) develop (post-polio
syndrome).
Clinical case definition:
Acute flaccid paralysis (AFP) in a child aged <15 years, including Guillain Barre
syndrome*; or
Any paralytic illness in a person of any age when polio is suspected.
(*) For practical reasons, Guillain-Barre syndrome will be considered as poliomyelitis until proven otherwise
Suspected: a case that meets the clinical case definition
Confirmed: AFP with laboratory-confirmed wild poliovirus in stool sample
Polio-compatible: AFP clinically compatible with poliomyelitis, but without
adequate virological investigation
Mode of Poliovirus is highly communicable. Transmission is primarily person-to-person via the
transmission fecal-oral route
Incubation The time between infection and onset of paralysis is 4-30 days
Period of From 36 hours after infection, for 4-6 weeks
communicability

EPIDEMIOLOGY
2002: 0 wild-virus confirmed polio cases
2001: 1 wild-virus confirmed polio case
Geographical
distribution
Seasonality
Alert threshold Any AFP case must be notified and investigated.
Recent epidemics 1993 - the earliest cases of a large outbreak were reported from Darfur state in May,
in the country reaching a peak in July, and spreading to eight of nine states (since then
administrative division of the country has changed) by December, 1993. The
highest reported incidence was from Darfur and Equatoria, where infant coverage for the
third dose of oral poliomyelitis vaccine was reported to be 29% and 23%
respectively, in 1993. In all, 252 cases were confirmed as poliomyelitis according to
WHO criteria; 85% were under 5 years of age, 53% were male, and 57% were from
urban areas. Only 26% of cases had received the third dose of OPV, suggesting that
the outbreak was largely due to an accumulation of susceptible children and was
accelerated by low immunization coverage.

Population Yes Importation of virus
movement
Poor access to Yes No access to routine immunization services
health services
Risk of undetected poliovirus circulation
Food shortages No
Lack of safe Yes Generally poor sanitation.
water and poor
sanitation
Others No

Risk assessment The civil war in southern Sudan has hampered routine immunization services
conclusions for more than 20 years, however high-quality supplementary immunization
activities have been implemented in the country, especially in recent years.
Sub-NIDs targeting children <5 year old in southern Sudan held in October
and November 2002 reached an unprecedented number of children. During
the first round, 755,877 children were vaccinated (they had been 539,845 in
2001). In the second round, 1,108,316 children were vaccinated. Unimpeded
access throughout southern Sudan allowed the polio programme to reach
some areas for the first time.
Management of polio eradication efforts has been split foe a long time between
government-controlled zones and rebel-dominated territories.
The last reported wild poliovirus-positive case in Sudan occurred in April 2001
(type 1).
Supplementary immunization activities began in 1994 in Sudan.
Sudan held its first NID in 1998 (?).
Po13 vaccination coverage:
2001: 71 % (official country estimates); 47% (WHO-UNICEF estimates)

Case Management of the acute phase of paralytic poliomyelitis is supportive and
Management symptomatic:
Bedrest
Close monitoring of respiration: respiratory support in case of respiratory failure or
pooling of pharyngeal secretions
Moist hot packs for muscle pain and spasms
Passive physical therapy to stimulate muscles and prevent contractures
Anti-spasmodic drugs
Frequent turning to prevent bedsores
Hospitalization may be required: in this case the patient should be isolated.
Disinfection of discharges, faeces and soiled articles, and immediate reporting of further
cases are essential.
Immunization Two types of poliovirus vaccine are available:
Oral poliovirus vaccine (OPV):
OPV is a live vaccine including live attenuated strains of all three virus types,
administered orally. It is easily administered by health workers or volunteers,
induces a good humoral (antibody) and mucosal (intestine) immune response
and is 4 times cheaper than inactivated poliovirus vaccine (IPV). OPV is the only
vaccine of choice for poliomyelitis eradication because it achieves much better
mucosal immunity than IPV and can therefore disseminate in the community
whilst limiting the dissemination of wild poliovirus.
Inactivated poliovirus vaccine (IPV):
IPV, which can only be given by intramuscular injection and requires trained
health workers, elicits an excellent antibody response, but only minimal intestinal
mucosal response; it is much more expensive than IPV.
Sudan has a routine immunization policy, which requires 4 doses of OPV (see
Annex 7).
However, supplementary immunization activities are also conducted in the country in
order to increase the immunization coverage as much as possible: these consist of
National Immunization Days (NlDs), sub-NIDs (mass campaigns similar to NIDs but in
a smaller area), and mop-up campaigns, during which two OPV doses are given at
an interval of 1 month to all children under 5 years, preferably during the season of
low transmission for enteroviruses (cooler season).
Supplementary immunization activities in Sudan: NIDs started 1994 for polio eradication
activity :
- 11 national campaign was conducted two round for each .
- 5 sub NIDs in slected high risk areas conducted two round for each .
- MNT(maternal &neonatel tetanous elimination campaigns were conducted in high risk
localities ( 28 ) from 2000 -2003 .
In refugee camps, all children 0-59 months should be vaccinated on arrival.
Any AFP case must be notified and investigated.

Epidemic In case of suspected outbreak:
Control Investigation response
Clinical and epidemiological investigation
Rapid virological investigation (specimens prioritized in a WHO accredited
laboratory)
Outbreak confirmation will be based on the isolation of wild poliovirus.
Surveillance response
House to house mop-up campaign with OPV in a wide geographic area (at least
province involved and relevant neighbours) if no NIDs or sub-NIDs covering the
area are planned within the next 3 months. If NIDs/sub-NIDs are planned, a major
quality focus should be set on the area of the outbreak and adjacent districts.
Enhancing the surveillance (intensive monitoring of all reporting units, ensuring active
surveillance and zero reports, extensive retrospective record reviews, active case
search in surrounding areas).

20. RABIES (SUDAN)
DESCRIPTION
Infectious agent Rabies virus, a Rhabdovirus of the genus Lyssavirus
Paresis or paralysis, delirium, convulsions
Without medical attention, death in about 6 days, usually due to respiratory
paralysis.
Clinical case definition
An acute neurological syndrome (encephalitis) dominated by forms of hyperactivity
(furious rabies) or paralytic syndrome (dumb rabies) that progresses toward coma
and death, usually by respiratory failure, within 7-10 days after the first symptom.
Laboratory criteria
One or more of the following:
Detection of rabies viral antigens by direct fluorescent antibody (FA) in clinical
specimens, preferably brain tissue (collected post mortem)
Detection by FA on skin or corneal smear (collected ante mortem)
FA positive after inoculation of brain tissue, saliva or CSF in cell culture, in mice or in
suckling mice
Detectable rabies-neutralizing antibody titre in the CSF of an unvaccinated person
Identification of viral antigens by PCR on fixed tissue collected post mortem or in a
clinical specimen (brain tissue or skin, cornea or saliva)
Isolation of rabies virus from clinical specimens and confirmation of rabies viral
antigens
Case classification
HUMAN RABIES:
Suspected: A case that is compatible with the clinical case definition
Probable: A suspected case plus history of contact with a suspected rabid animal
Confirmed: A suspected case that is laboratory-confirmed
HUMAN EXPOSURE TO RABIES:
Possibly exposed: A person who had close contact (usually a bite or a scratch)
with a rabies-susceptible animal in (or originating from) a rabiesinfected area.
Exposed: A person who had close contact (usually a bite or a scratch) with a
Mode of laboratory-confirmed rabid animal.
Usually by the bite of an infected mammalian species (dog, cat, fox, etc.): bites or
transmission scratches introduce virus-laden saliva into the human body.
No human to human transmission has been documented
Incubation The incubation period usually ranges from 2 to 10 days but may be longer (up to 7
years).
Period of In dogs and cats, usually for 3-7 days before onset of clinical signs (rarely over 4
communicability days) and throughout the course of the disease. Longer periods of excretion before
onset of clinical signs have been observed with other animals.

EPIDEMIOLOGY
Burden In the year 2000:
Total number of rabies deaths in human: 32 (diagnosed on clinical grounds only)
Human rabies diagnosis in Sudan is usually based on clinical grounds only.
Laboratory confirmation is very rare.
8934 persons received post-exposure treatment. 100% of them received
vaccine alone.
Total number of animal rabies cases:
35 (confirmed by laboratory examination)
189 (diagnosed on clinical grounds only)
In 2002, 42 unprovoked bites with suspected rabid dogs, and 3 deaths from rabies were
confirmed in southern Sudan.
In Sudan canine rabies remains the most important epidemiological type of
thedisease: dogs represent more than 90% of human exposure. Also present wildlife
rabies.
The spread of rabies in Sudan increased in 2000 by more than 10% when compared to
1999. Rabies foci occur in most parts of the country.
Dog vaccination is optional in Sudan. Total number of dogs vaccinated is 2,946 (100%
vaccinated by Government staff during State-organized campaigns).
The estimate of the dog vaccination coverage is 5%. Vaccine is also applied to cats,
monkeys and bovines.
Geographical Foci of human disease occur in limited areas within the country.
distribution
Foci of animal disease occur in most part of the country.
Seasonality No seasonality reported
Alert threshold One case in a susceptible animal species and /or human must lead to an alert
Recent epidemics August-October 2002: suspected rabies outbreak in Rumbek, Twic, and Ikotos/Torit
(Lakes and Western Equatoria states). A total of 38 unprovoked dog bites, and 3
deaths with manifestations consistent with rabies among people were reported.
Suspected rabid dogs were killed but no specimen was tested. Bitten people was
vaccinated.

Population
No
movement
Overcrowding Yes An infected animal has the possibility to bite more people
Poor access to Yes Prompt administration of vaccine post exposure (plus immunoglobulin if heavy
health services exposure) is the only way to avoid death for an infected person
Food shortages No
Lack of safe No
water and poor
sanitation
Others Yes Availability of food sources for the dogs and wild susceptible animals increases
their number
Children of 5 to 15 years are the group at major risk
Risk assessment Risk of epidemics for humans is significant if cases of rabies are reported in dogs or other
conclusions susceptible animals in the same zone

Case Management There is no specific treatment for rabies, which is a fatal disease.
The most effective mechanism of protection against rabies is to wash and

flush a wound or point of contact with soap and water, detergent or plain water,
followed by the application of ethanol, tincture or aqueous solution of iodine.
Anti-rabies vaccine should be given for Category II and III exposures, as soon
as possible according to WHO recognized regimens. Anti-rabies
immunoglobulin should be applied for Category III exposures only. Suturing
should be postponed, but if it is necessary immunoglobulin must first be
applied. Where indicated, anti-tetanus treatment, antimicrobials and drugs
should be administered to control infections other than rabies.
Recommended treatments according to type of contact with suspect animal
Category Type of contact with suspect animal Recommended treatment
I Touching or feeding an animal None, if reliable case history is available
Licks on intact skin
II Nibbling of uncovered skin Administer vaccine immediately,

Minor scratches or abrasions and stop if 10-day observation or laboratory
without bleeding techniques confirm suspect animal
Licks on broken skin to be rabies negative
III Single or multiple trans-dermal Administer rabies immunoglobulin

bites or scratches and vaccine immediately and stop if
Contamination of mucous membrane suspect animal confirmed as rabies negative
with saliva
If a person develops the disease, death is inevitable.
Universal nursing barrier practices are necessary for the sick people.
Epidemic control
Immediate notification if one or more suspected cases are identified
Confirm the outbreak, following WHO guidelines
Confirm diagnosis and insure prompt management
Prevention WHO promotes:
Human rabies prevention through:
Well-targeted post exposure treatment using modern vaccine types and,
when appropriate, antirabies immunoglobulin
Increased availability of modern rabies vaccine
Dog rabies elimination through mass vaccination of dogs and dog population
management
Immunization
Human preventive mass vaccination is generally not recommended but can
be considered under certain circumstances for the age group 5 to 15 years

21. SCHISTOSOMIASIS
DESCRIPTION
Infectious agent Helminths: Schistosoma haematobium (agent of Urinary Schistosomiasis) and
Schistosoma mansoni (agent of Intestinal Schistosomiasis), blood fluke worms
belonging to the class Trematoda.
Other Schistosoma species are not present in Sudan.
Case definition URINARY SCHISTOSOMIASIS
1. ENDEMIC AREAS (MODERATE OR HIGH PREVALENCE)
Suspected: Not applicable.
Probable: Not applicable.
Confirmed: A person with:
visible haematuria or
with positive reagent strip for haematuria or
with eggs of S. haematobium in urine (microscope).
2. NON ENDEMIC AREAS AND AREAS OF LOW PREVALENCE
Suspected: A person with:
visible haematuria or
with positive reagent strip for haematuria, and
possibly infective water contact.
Confirmed: A person with eggs of S. haematobium in urine (microscope)
INTESTINAL SCHISTOSOMIASIS
1. ENDEMIC AREAS (MODERATE OR HIGH PREVALENCE)
Suspected: A person with non-specific abdominal symptoms, blood in stool,
hepato(spleno)megaly
Probable: A person who meets the criteria for presumptive treatment, according to the
locally applicable diagnostic algorithms.
Confirmed: A person with eggs of S. mansoni in stools (microscope).
2. NON-ENDEMIC AREAS AND AREAS OF LOW PREVALENCE
Suspected: A person with non-specific abdominal symptoms, blood in stool,
hepatosplenomegaly and possibly infective water-contact.
Confirmed: A person with eggs of S. mansoni in stools (microscope).
Mode of Water-based disease :
transmission
Penetration of human skin by larval worms (Cercariae) developed in snail after that
eggs have been discharged in urine (S. haematobium ) or faeces (S. mansoni) into
a body of fresh water by patients with chronic schistosomiasis.
Incubation within 4 days: localized dermatitis at the site of cercarial penetration
within 2-8 weeks: acute febrile reaction (Katayama fever; almost completely absent in
S.haematobium infection )
3 months to several years : chronic illness manifestations
Period of As long as eggs are discharged by patients: 10-12 weeks to more than 10 years after
communicability infection.

EPIDEMIOLOGY
Burden S. haematobium Prevalence of Infection:
Gezira: 0.5-30%
Khartoum: 10-24.9%
White Nile: 12-46%
Southern Sudan: a school-based survey conducted in Lui (Mundri county,
Western Equatoria) in 2002 on 200 schoolchildren, found no cases of S.
haematobium infection. Another survey conducted in Nyal (Upper Nile) found
that the prevalence among 200 schoolchildren was 73%.
Other regions: no data available
S. mansoni Prevalence of Infection:
Gezira : 2.2-75%
Khartoum: 0-39.9%
River Nile: 25-49.9%
White Nile: 4.6-24.9%
Southern Sudan:
Eastern Equatoria: 0-9.9%
Bahr-al-Jabal: in Juba area, a study conducted in 1998on 2789 children found
that the prevalence of S. mansoni was 6.9%.
Western Equatoria: a school-based survey conducted in Lui, Mundri
county (2002) among 200 schoolchildren, obtained the following results:
Prevalence of infection: 51.5%
Patients with low intensity of infection (1-99 eggs/g): 52.5%
Patients with moderate intensity of infection (100-399 eggs/g): 32%
Patients with high intensity of infection (more than 399 eggs/g):
15.5%
Upper Nile: a school-based survey conducted in Nyal (2002) found that the
Geographical The endemic area of S. haematobium is located in the middle part of Sudan, between
distribution the ninth and the sixteenth parallels. The most affected areas include:
The southern two-thirds of Northern Darfur, except in the heart of the Jebel Marra
mountains
Southern Darfur
Southern Kordofan
South of 9N latitude foci of transmission are sporadic. North of 16N latitude is found
only in the Nile valley.
S. mansoni is especially present in the southern edge of Sudan, and in the area
between the two branches of the Nile (Gezira-El Manaqil area). In the east of
the country, there are a few foci of transmission in the zone of Khasm el Girba. In
the west, some foci are found in the Jebel Marra mountains. Foci of transmission
are also present along the White Nile. Few data are available on the epidemiology of S.
mansoni in southern Sudan, but prevalence is known to be high.
Generally speaking, the most humid and the coolest regions(river nile ,trubiraties
&the irrigated scheus) would appear to be more susceptible to the spread of intestinal
schistosomiasis, and arid areas to the spread of urinary schistosomiasis. The major foci
of transmission are invariably in the savanna zone.
Seasonality Dry periods tend to increase transmission of the disease due to higher
cercarial densities in bodies of water and to drying of wells with consequent increased
use of unsafe water.

Recent epidemics Schistosomiasis is usually an endemic disease, with little likelihood of rapid changes in
in the country incidence. Surveys may identify areas of particularly high endemicity where mass
treatment will be warranted.

Population Yes Population displacement in Somalia and Angola is known to have led to the
movement introduction of S. mansoni in areas previously endemic for S.
Haematobium only.
Overcrowding Yes Higher human densities increase the chances for snails to be penetrated and
colonised by miracidia.
Poor access to Yes Regular treatment of cases has proven effective in reducing or preventing
health services introduction of Schistosoma spp. into "Schistosoma-free" areas.
Food shortages No
Lack of safe Yes Use of surface water infested by cercariae and contamination of water by
water and poor urination/defecation are essential for transmission of Schistosomiasis.
sanitation
Others No
Risk assessment Also in "chronic" complex emergencies such as the one that affects Sudan,
conclusions case-management and control of schistosomiasis should be a priority
intervention due to the effect that this disease plays on the general status of
infested individuals and on the increased severity of concomitant infections.
Notwithstanding this, no large-scale programmes are currently implemented
in Sudan.
Praziquantel is locally produced and is available on the market.
However, the quality of the drug is not always good, and should be tested
before being used in control programmes.

Case Management Praziquantel is the drug of choice against all schistosome parasites. A single oral
dose of 40 mg/kg is generally sufficient to give cure rates of between 80% and 90%
and dramatic reductions in the average number of eggs excreted.
Praziquantel treatment for 1 person requires on average 3 tablets of 600 mg in 1
dose. The cost of a tablet is now less than US$ 0.10, bringing the total drug cost of
a treatment to about US$ 0.35.
Prevention 1. Regular treatment of individuals according to the following community categories
Community diagnosis (through primary school surveys) and treatment regimen for
Schistosome infections
Community Category Prevalence
I - high prevalence >=30% visible haematuria (S. haematobium by
questionnaire) OR
>=50% infected (S. mansoni, S. haematobium by
parasitological methods)
II - moderate prevalence <30% visible haematuria (S. haematobium, by
questionnaire) OR
>=10% but <50% infected (S. mansoni,
S. haematobium, by parasitological methods)
III - low prevalence <10% infected (S. haematobium, S. mansoni, by
parasitological methods)
Category 1:
Intervention in schools (enrolled and non-enrolled children): Targeted treatment of
school-age children, once a year.
Health services and community based intervention: Access to Praziquantel for
passive case-treatment + Community Directed Treatment for high-risk groups*
recommended .
*Such groups include preschool children, school-age children, pregnant women and workers with
occupations involving contact with fresh water.
Category 2:
school-age children, once every 2 years.
Health Services and community based intervention: Access to Praziquantel for
passive case treatment.
Category 3:
school age children twice during primary schooling (once on entry, again on leaving).
Community based intervention: Access to Praziquantel for passive case treatment
For the definition of classes of intensity and further information, see:Prevention and
Control of Schistosomiasis and Soil-transmitted helminthiasis, First Report of the
Joint WHO Expert Committees, WHO Technical Report Series, WHO, Geneva, 2002.
2. Creation of alternative, safe water sources to reduce infective water contact.
3. Proper disposal of faeces and urine to prevent viable eggs from reaching bodies
of water containing snail hosts.
4. Health education to promote early care-seeking behaviour, use of safe water (if
available) and proper disposal of excreta.
5. Reduction of snail habitat and snail contact (in irrigation and agriculture
practices) - environmental management.
6. Treatment of snail-breeding sites with molluscicides (if costs permit).

22. SOIL - TRANSMITTED HELMINTHIASES (ASCARIASIS, HOOKWORM
INFECTION, TRICHURIASIS)
DESCRIPTION
Infectious agent
Helminths: Ascaris lumbricoides, Hookworm, Trichuris trichiura
Case definition
Ascariasis:
Suspected: Abdominal or respiratory symptoms and History of passing worms.
Confirmed: Suspected case and Passage of A. lumbricoides (anus, mouth, nose),
or Presence of A. lumbricoides eggs in stools (microscope examination).
Hookworm infection:
Suspected: Severe anemia for which there is no other obvious cause.
Confirmed: Suspected case and Presence of hookworm ova in stools (microscope
examination).
Trichuriasis:
Suspected: bloody, mucoid stools.
Confirmed: Suspected case and
Presence of T. trichiura eggs in stools.
Mode of - Ingestion of eggs, mainly as a contaminant of food: A. lumbricoides and T. trichiura
transmission
- Active penetration of skin by larvae in the soil (Hookworm)
Incubation - 4 to 8 weeks for A. lumbricoides
- a few weeks to many months for hookworm disease
- unspecified for T. trichiura
Period of - A. lumbricoides: eggs appear in the faeces 45-75 days after ingestion and become
communicability infective in soil after 2-3 weeks. They can remain viable in soil for years. Infected
people can contaminate soil as long as mature fertilized female worms live in the
intestine (life span of adult worms can be up to 12-24 months).
- Hookworm: eggs appear in the faeces 6-7 weeks after infection. As larvae they
become infective in soil after 7-10 days and can remain infective for several weeks.
Infected people can contaminate soil for several years.
- T trichiura: eggs appear in the faeces 70-90 days after ingestion and become
infective in soil after 10-14 days. Infected people can contaminate soil for several
years.

EPIDEMIOLOGY
Burden 1992:
A survey carried out in Juba (Bahr-al-Jabal) gave the following results (241 fecal
samples):
Ascaris lumbricoides prevalence: 1.2%
Trichuris trichiura prevalence: 0.8%
Hookworm prevalence: 36%
1994:
A survey conducted in 6 different localities in the Sudan covering all climatic
conditions gave the following results (2489 fecal samples):
Geohelminths: 53 cases (2.12%). 50 out of 53 cases were from Juba (Bahr-al-Jabal)
Another survey conducted in Juba, Bahr-al-Jabal (2789 stool samples) found a
prevalence of geohelminthic infections of 20.6%
1998:
A study performed in Chukudum and Kimatong (Eastern Equatoria) gave the
following results (274 fecal samples):
Ascaris lumbricoides: not detected
Trichuris trichiura: 5 cases (1.8%)
Hookworm: 36 cases (13.1 %)
Geographical STH are mainly present in southern Sudan
distribution
Seasonality No data available
Recent epidemics Soil-transmitted helminthiases are usually endemic diseases, with little likelihood of
in the country rapid changes in incidence. Surveys may identify areas of particularly high endemicity
where mass treatment will be warranted.

Population
Yes Strictly linked to insufficient sanitation resources. Not a risk factor if people
movement remain in the same place for a period shorter than the time needed for eggs to
be discharged by an infected patient and become infective themselves (at
least 45-50 days).
Overcrowding Yes Linked to the number of people defecating and unsafe faeces disposal.
Poor access to Yes No treatment provided.

health services
Food shortages No
Lack of safe water Yes The ratio between number of people and available sanitation is the most
and poor sanitation important risk factor.
Others No

Risk assessment Control of helminthic infestations can play a major role in the reduction of the
conclusions communicable disease burden shouldered by populations in complex
emergency situations.
Soil-transmitted helminths can be controlled with low-cost, highly effective
interventions that can remarkably increase the quality of life of affected
populations.
Moreover, due to their simplicity and feasibility, intestinal helminth control
activities can represent a starting point for the reconstruction of health care
systems in complex emergency-affected countries.
All S-TH compete with the host for nutrients, causing malabsorption of fats,
proteins, carbohydrates and vitamins, and directly synergising malnutrition. They
can cause growth retardation.
A. lumbricoides infestation synergises vitamin A deficiency. Elimination of
Ascarids may result in rapid clinical improvement in night blindness and
dryness around the eye. Infection from measles in a patient already infected with
A. lumbricoides can result in a very severe disease. Hookworm infestation is
strongly associated with chronic anemia. Significant correlations between intensity
of worm infestation and haemoglobin level have been demonstrated.
Heavy T. tric hi ura infection may cause diarrhoea and severe malabsorption.
Currently no programmes for the control of S-TH are implemented in Angola.
As stated above, it is important to remark that S-TH can be controlled with very cheap
interventions. The average cost in a school distribution campaign (including
drugs, distribution, and monitoring activities) is approximately US$ 0.05 per child.
Case Management For treatment, WHO recommends the following 4 drugs:
400 mg albendazole, or
2.5 mg/kg levamisole, or
500 mg mebendazole, or
10 mg/kg pyrantel (less commonly used because it is less easy to administer)
Note 1: These drugs must not be given during the first trimester of pregnancy
Note 2: Where mass treatment with albendazole for filariasis is envisaged, chemoterapy of intestinal
helminths will take place as part of the antifilarial chemoprophylaxis
Note 3: Iron supplementation is also recommended if required
Prevention and Overall:
control
Personal hygiene, disposal of faeces, hand-washing, and clean food
Improvements in sanitation standards (see Safe water and Sanitation)
Community-wide treatment according to the following categories:
Community diagnosis (through primary school surveys) and treatment regimen for S-TH:
Community category prevalence % of moderate to
of any infection heavy intensity infections
I (high prevalence-high intensity) >=70% >=10%
II (high prevalence-low intensity) >=50% but <70% <10%
III (low prevalence-low intensity) <50% <10%

Category 1:
Intervention in schools (enrolled and non-enrolled children): Targeted treatment
of school-age children, 2-3 times a year.
Health services and community-based intervention: Systematic treatment of
pre-school children and women of child-bearing age in mother and child
health programmes.
Category 2:
Intervention in schools (enrolled and non-enrolled children): Targeted treatment
of school-age children, once a year.
Health services and community-based intervention: Systematic treatment of
pre-school children and women of child-bearing age in mother and child
health programmes
Category 3:
Intervention in schools (enrolled and non-enrolled children): Selective
treatment
Community based intervention: Selective treatment
For the definition of classes of intensity and further information, see:
Prevention and Control of Schistosomiasis and Soil-transmitted helminthiasis, First
Report of the Joint WHO Expert Committees, WHO Technical Report Series,
WHO, Geneva 2002.
In case of suspected or confirmed hookworm infection in addition:
In highly endemic areas, wear shoes
Consider drug treatment and iron supplementation in pregnancy

23. TUBERCULOSIS
DESCRIPTION
Infectious agent Bacterium: Mycobacterium tuberculosis. This complex includes M. tuberculosis and
M. africanum primarily from humans, and M. Bovis primarily from cattle.
Case definition and A case of tuberculosis:
Classification A patient in whom tuberculosis has been bacteriologically confirmed, or has been
diagnosed by a clinician.
A definite tuberculosis case:
A patient with culture positive for the M. tuberculosis complex
If culture is not routinely available, a patient with two sputum smears positive for acid-
fast bacilli (AFB) is also considered a "definite case".
TB suspect:
Any person who presents with symptoms or signs suggestive of pulmonary TB, in
particular cough of long duration
May also have haemoptysis, chest pain, breathlessness, fever/night sweats,
tiredness, loss of appetite and significant weight loss
All TB suspects should have three sputum samples examined by light
microscopy, early morning samples are more likely to contain the TB
organism than a sample later in the day
Classification by localisation and bacteriology:
Smear-positive pulmonary tuberculosis (PTB+):
Diagnostic criteria should include:
two or more initial sputum smear examinations positive for acid fast
bacilli (AFB),
or
one sputum smear examination positive for AFB plus radiographic
abnormalities consistent with active pulmonary TB as determined by a
clinician,
or
one sputum smear examination positive for AFB plus sputum culture positive
for M. tuberculosis
Smear-negative pulmonary tuberculosis (PTB ):
A case of pulmonary tuberculosis that does not meet the above definition for
smear-positive TB.
Diagnostic criteria should include:
at least three sputum smear specimens negative for AFB,
and
radiographic abnormalities consistent with active pulmonary TB,
and
no response to a course of broad spectrum antibiotics,
and
decision by a clinician to treat with a full course of anti-tuberculosis
chemotherapy.
Extra-Pulmonary TB:
TB of organs other than the lungs: e.g. pleura, lymph nodes, abdomen, genito-urinary
tract, skin, joints and bones, meninges, etc. Diagnosis should be based on one
culture-positive specimen, or histological or strong clinical evidence consistent with
active extra-pulmonary TB, followed by a decision by a clinician to treat with a full
course of anti-TB chemotherapy. Note: a patient diagnosed with both pulmonary and
extra-pulmonary TB should be classified as a case of pulmonary TB.
Mode of Exposure to tubercle bacilli in airborne droplet nuclei produced by people with
transmission pulmonary or laryngeal tuberculosis during expiratory efforts, such as coughing
and sneezing. Extra-pulmonary tuberculosis (other than laryngeal) is usually
non-infectious.
Bovine tuberculosis results from exposure to tuberculous cattle, usually by
ingestion of unpasteurized milk or dairy products, and sometimes by airborne
spread to farmers and animal handlers
Progression to Progression to active disease can take from weeks to years; latent infections may
active disease persist throughout life. The risk of TB occurrence is relatively high during the first year following
TB infection, then progressively decreases by half within the 4-5 following years.
Only 10% of infected people with normal immune system will develop clinically evident
TB at some point in life; 5% will have an early progression of the disease (primary
tuberculosis); the remaining 5% will have a late progression of the disease (post-primary
tuberculosis) after a period of initial containment.
Period of As long as viable tuberculosis bacilli are being discharged in the sputum. Effective
communicability treatment usually eliminates communicability within 2 weeks
EPIDEMIOLOGY
Burden Estimated number of new cases:
2001: 59,897 (of which 23,997 (40.0%) were notified)
Estimated number of new cases of smear positive (ss+) TB:
Geographical Even if specific data are not available, tuberculosis is known to be widespread in the
distribution country.
Seasonality No specific seasonality is reported
Alert threshold An increase in number of cases in crowded settings must lead to an alert
Recent epidemics No data available
in the country
Population Yes Mainly due to the interruption in treatment and increased duration of
movement communicability
Overcrowding Yes Overcrowding is recognized as one of the most important factors leading
to increase risk of transmission
Poor access to Yes People affected by TB who cannot access health services and be
health services treated, remain infectious for a longer period
The fatality rate is high (about 50%) without proper treatment
The interruption of treatment is the most important cause of
development of multi-drug resistant TB (MDR-TB)
Food shortages No However, poor nutritional status increases vulnerability to TB infection and
development of active disease.
Lack of safe water
and poor sanitation

Others No
Risk assessment Sudan is in a phase of routine implementation of DOTS strategy, the TB policy
conclusions based on WHO recommendations. DOTS was introduced in 1990, and the
DOTS population coverage increased from 80% in 2000 to 97% in 2001.
The smear-positive TB case-detection rate (new ss+ notified/new ss+
estimated) decreased from 46% in 2000 to 41 0/c, in 2001. All TB
cases detection rate (all cases notified/all cases estimated) decreased from
41% to 40% in 2001. The target is to detect 70% of all cases and successfully
treat 85% of them by 2005.
BCG vaccination coverage:
2001: 71 % (official country estimates); 51 % (WHO-UNICEF estimates)

Case Management Standardized short-course chemotherapy using regimens of 6 to 8 months.
Good case management includes directly observed therapy (DOT) during the
intensive phase for all new sputum-smear positive cases, the continuation phase of
rifampicin-containing regimens and the whole of the retreatment regimen.
There are primarily three types of regimens: category 1 regimen for new smear
positive (infectious) pulmonary cases, category 2 regimen for retreatment cases, and
category 3 regimen for smear negative pulmonary or extra-pulmonary cases.
The chemotherapeutic regimens are based on standardized combinations of 5
essential drugs: Rifampicin (R), Isoniazid (H), Pyrazinamide (P), Ethambutol (E) and
Streptomycin (S).
Each of the standardized chemotherapeutic regimens consist of 2 phases:
Initial (intensive) phase: 2-3 months, with 3-5 drugs given daily under direct
observation
Continuation phase: 4-6 months, with 2-3 drugs given 3 times a week under
direct observation, or in some cases (e.g. during repatriation of refugees) 2
drugs for 6 months given daily unsupervised, but in fixed dose combination
form.
Staff should observe all doses of rifampicin containing regimens. Actual swallowing
of medication should be checked.
Hospitalized patients should be kept in a separate ward for the first two weeks of
treatment.
See also:
1. WHO guidelines for Recommended Treatment Regime
2. Treatment of Tuberculosis: Guidelines for National Programmes (WHO/TB/97.220)
3. Tuberculosis Control in Refugee Situations: an Inter-Agency Field Manual
(WHO/TB/97.221)
4. An Expanded DOTS Framework for Effective Tuberculosis Control
(WHO/CDS/TB/2002.297)

Immunization BCG has been shown to be effective in preventing severe forms of TB such as
meningitis in children.
BCG is strongly recommended for all newborn children and any children up to the age of 5
years who have not already received it.
The vaccination of newborns should be incorporated into the immunization
programme for all children. Re-vaccination is not recommended.
Prevention and Detection and treatment of smear positive (infectious) TB cases is the most effective
control preventive measure.
To ensure the appropriate treatment and cure of TB patients, strict implementation of the
DOTS strategy is important. DOTS is the recommended strategy for TB control, and
has the following components:
Government commitment to ensuring sustained, comprehensive TB control activities
Case detection by sputum smear microscopy among symptomatic patients self
reporting to health services
Standardized short-course chemotherapy using regimens of 6 to 8 months, for at least
all confirmed smear positive cases (see Case Management )
A regular, uninterrupted supply of all essential anti-TB drugs
A standardized recording and reporting system that allows assessment of casefinding
and treatment results for each patient and of the TB control programme's performance
overall
Complementary control strategies:
Health education to improve awareness and reduce stigma
Maintaining good ventilation and reducing overcrowding in health clinics, and
ensuring hospitalized patients are kept in a separate ward for the first two
weeks of treatment.
Isoniazid prophylaxis is not recommended in refugee situations, except for
children being breast-fed by smear positive mothers. If the child is well, BCG
vaccination should be postponed and isoniazid should be given to the child for
6 months. In the event of a sudden disruption to the programme, isoniazid may be
stopped, and BCG should be given before the child leaves the refugee camp
(preferably after a one week interval)

24. TYPHOID FEVER
DESCRIPTION
Infectious agent Bacterium: Salmonella typhi
Clinical diagnosis is difficult. In absence of laboratory confirmation, any case with fever
of at least 38 for 3 or more days is considered suspect if the epidemiological
context is conducive
Confirmed case
Isolation of S. typhi from blood or stool cultures
Mode of Fecal oral route, particularly contaminated water and food
transmission
Incubation Incubation period is usually 8-14 days but may be from 3 days up to one month
Period of From the symptomatic period for 2 weeks. 2-5% of infected cases remain carriers for
communicability several months. Chronic carriers are greatly involved in the spread of the disease
EPIDEMIOLOGY
Burden No data available.
Geographical No data available
distribution
Seasonality No data available.
Alert threshold Two or more linked cases
Recent epidemics No data available
in the country

Population Yes Dissemination of multi-drug resistant strains of S. typhi
movement
health services dissemination
Case fatality rate is high (10-20%) in absence of a proper treatment
Food shortages No
Lack of safe water The most important risk factor
and poor sanitation
Others Yes Multi-drug resistant strains of S. typhi, including resistance to
ciprofloxacin
Milk and dairy products are an important source of infection

Risk assessment In the general population the risk is related to the availability of safe food and water
conclusions
Case Management Early antimicrobial treatment, selected according to the antimicrobial
resistance pattern of the strain
Quinolones (e.g. ciprofloxacin), cotrimoxazole, chloramphenicol and ampicillin
are usually used for typhoid fever
Dehydration prevention and case management using ORS also plays an
important role
Epidemic control Inform the Health Authorities if one or more suspected cases are identified
Confirm the outbreak, following WHO guidelines
Confirm the diagnosis and insure prompt treatment
Prevention See prevention of diarrhoeal diseases
See Annex 3: Safe Water and Sanitation
Immunization Mass immunization may be an adjunct for the control of typhoid fever during a
sustained, high incidence epidemic. This is especially true when access to well
functioning medical services is not possible or in the case of a multi-drug
resistant strain
A parenteral vaccine containing the polysaccharide Vi antigen is the vaccine of
choice amongst displaced populations. An oral, live vaccine using S. typhi strain
Ty21 a is also available
Neither the polysaccharide vaccine nor the Ty21 a vaccine is licensed for children
under two years old. The Ty21 a vaccine should not be used in patients receiving
antibiotics

25. YELLOW FEVER
DESCRIPTION
Infectious agent
Yellow fever virus, belonging to Flavivirus group
Characterized by acute onset of fever followed by jaundice within 2 weeks of onset
of first symptoms. Haemorrhagic manifestations and signs of renal failure may occur.
There are 2 disease phases for yellow fever.
Acute phase: while some infections have no symptoms whatsoever, this first phase
is normally characterized by fever, muscle pain (with prominent backache),
headache, shivers, loss of appetite, nausea and/or vomiting. Often, the high fever is
paradoxically associated with a slow pulse (Faget's sign). Most patients improve after 3 to
4 days and their symptoms disappear, but 15% enter the following phase.
Toxic phase: fever reappears, the patient rapidly develops jaundice and complains of
abdominal pain with vomiting. Bleeding can occur from mouth, nose, eyes and/or
stomach. Once this happens, blood appears in the vomit and faeces. Kidney function
deteriorates; this can range from abnormal protein levels in the urine (albuminuria)
to complete renal failure with no urine production (anuria). Half the patients in the
"toxic" phase die within 10-14 days. The remainder recover without significant organ
damage.
Isolation of yellow fever virus, or
Presence of yellow fever specific IgM or a 4-fold or greater rise in serum
IgG levels in paired sera (acute and convalescent), or
Positive post-mortem liver histopathology, or
Detection of yellow fever antigen in tissues by immunohistochemistry, or
Detection of yellow fever virus genomic sequences in blood or organs by
PCR.
Suspected: a case that is compatible with the clinical description.
Probable: not applicable
Confirmed: a suspected case that is laboratory-confirmed (national
reference laboratory) or epidemiologically linked to a confirmed case or
outbreak.
Mode of Bite of infective mosquitoes.
transmission
The vectors of yellow fever in forest areas in Africa are Aedes africanus and other
Aedes species. In urban areas, the vector is Aedes aegypti (all day biting
Incubation species).
From 3 to 6 days
Period of Blood of patients is infective for mosquitoes shortly before onset of fever and for the
communicability first 3-5 days of illness. The disease is highly communicable where many susceptible
people and abundant vector mosquitoes coexist; not communicable by contact or
common vehicles. Once infected, mosquitoes remain so for life.

EPIDEMIOLOGY
Burden
2001: 0 cases reported 1997: no data available
2000: no data available 1990: no data available
1999: no data available 1980: no data available
1998: no data available
Geographical The southern half of the country territory was officially endemic in the year 2000.
distribution
Seasonality In forest areas, where the yellow fever virus circulates between mosquitoes and
monkeys or chimpanzees, the disease is continuously present throughout the year.
In field or savannah areas outside the forest areas, the virus remains dormant in the
infected mosquito eggs throughout the dry season and emerges in the rainy season
when eggs hatch.
Alert threshold One confirmed case must lead to alert.
An outbreak of yellow fever is at least one confirmed case.
Recent epidemics The country is known to be endemic.
in the country
No cases have been officially reported in recent years, but sporadic cases and small
outbreaks are likely to occur.
No cases officially reported in recent times.

Population
Yes Unvaccinated people moving to areas of endemicity is at risk.
movement
Changes in land use is a risk factor.
Overcrowding Yes Due to increased population density and increased exposure to mosquito bites in
temporary shelters
Poor access to Yes Collapse of vaccination programmes.
health services
Increased fatality due to unavailability of case management
Food shortages No
Lack of safe water
No
and poor sanitation
Yes Open water storage provides favourable habitat for Ae. aegypti
Others
Old tyres, old water containers, etc. increase vector breeding
Temporary surface water bodies (poor drainage leading to pools and
open channels of water) may increase vector breeding opportunities.

Risk assessment Even if no official cases are reported from Angola, the risk of transmission exists.
conclusions Reduced coverage rates for yellow fever immunizations and abandonment of
mosquito-control programmes are likely to have increased this risk. Moreover,
the movement of people from rural to urban areas has resulted in large numbers
of people living in conditions of poverty, crowded housing and poor sanitation, all
conditions that amplify the risk of transmission.
The precise extent of illness and death due to yellow fever is not known.
Disease surveillance is not adequate to detect cases of sylvatic yellow fever that
often occur in remote areas. Moreover, an outbreak of yellow fever can go
undetected because the signs and symptoms of yellow fever have a wide spectrum
and overlap with many other diseases, and it is difficult for health workers to make
a definitive diagnosis based on the signs and symptoms alone. Mild cases can go
undetected because the patient is likely to be treated at home and does not seek care in
a health facility.
YFV (yellow fever virus vaccine) coverage:

Case Management No specific treatment for yellow fever is available.
Dehydration and fever can be corrected with oral rehydration salts.
Intensive supportive care may improve the outcome but is rarely available.
Epidemic control An infected mosquito spreads yellow fever when it bites non-infected humans. When
human-to-human transmission is established, the conditions for an epidemic are in
place. Depending on the travel patterns of infected humans or infected mosquitoes, the
epidemic spreads from village to village and into cities.
Under epidemic conditions, the following must be implemented:
Mass vaccination
Emergency mosquito control measures:
- Eliminating potential mosquito breeding sites (the most important measure)
- Spraying to kill adult mosquitoes (less important due to small impact)
Prevention Vaccination is the single most important measure for preventing yellow fever:
- In endemic areas, vaccination must be given routinely through the
incorporation of yellow fever vaccine in routine child immunization
programmes and mass preventive campaigns. Yellow fever vaccine is
not recommended for symptomatic HIV-infected persons or other
immunosuppressed individuals; for theoretical reasons, it is not
recommended for pregnant women.
Routine mosquito control measures:
- Eliminating potential mosquito breeding sites.

ANNEX 1: FLOWCHARTS FOR THE DIAGNOSIS OF COMMUNICABLE
DISEASES
Suspected outbreak ACUTE DIARRHOEAL SYNDROME
Definition of syndrome Acute onset of diarrhoea AND severe illness AND absence of
known predisposing factors
Watery
Viral gastroenteritis
Faeces Cholera Enterotoxigenic E. coli
Giardiasis Cryptosporidium
Possible diseases/pathogens
Dysentery
Shigellosis
Salmonellosis
Campylobacteriosis
Amoebic dysentery
Enterohaemorrhagic E. coli
Clostridium difficile
Ebola and other haemorrhagic fevers*
Specimens required Faeces
Bacterial: Viral: Parasite:

Faecal leukocytes Culture Macro and microscop
Laboratory studies Culture Antigen detection examination
Antimicrobial susceptibility Genome detection
Serotyping
Toxin identification
*Ebola and other haemorrhagic fevers may initially present as bloody diarrhoea. If such an aetiology is suspected, refer to "Acute
Haemorrhagic Fever Syndrome" for appropriate specimen collection guideline.

Suspected outbreak ACUTE HAEMORRHAGIC FEVER SYNDROME
Acute onset of fever of less than 3 weeks duration AND

any two of the following:
Haemorrahgic or purpuric rash
Definition of syndrome Epstaxis
Haemoptysis
Blood in stool
Other haemorrhagic symptom
AND absence of known predisposing factors
Dengue haemorrhagic fever and shock syndrome

Yellow fever
Other arboviral haemorrhagic fevers (e.g. Rift Valley, Crimean Congo,
Tick-borne flaviviruses)
Possible diseases/pathogens Lassa fever and other arenoviral haemorrhagic fevers
Ebola or Marburg haemorrhagic fevers
Haemorrhagic syndrome (hantaviruses)
Malaria
Relapsing fever
Blood
Blood smear
Specimens required Serum
Post-mortem tissue specimens (e.g. skin
biopsy and/or liver biopsy)
Laboratory studies
Viral: Parasitic:
Culture Demonstration of
Antigen detection pathogen
Antibody levels
Genome detection

Suspected outbreak ACUTE JAUNDICE SYNDROME
Acute onset of jaundice AND severe illness AND

absence of known predisposing factors
Definition of syndrome
Yellow fever Hepatitis A-E Leptospirosis and

Possible diseases/pathogens other spirochaetal
diseases
Post mortem Serum Blood culture

Specimens required liver biopsy (urine)*
Viral: Leptospiral:
Culture Culture
Laboratory studies Antigen detection Antibody levels
Antibody levels Serotyping
Genome analysis
* Requires specialized media and handling procedures

Suspected outbreak ACUTE NEUROLOGICAL SYNDROME
Acute neurological dysfunction with one or more of the following:

Deterioration of mental function
Acute paralysis
Definition of syndrome Convulsions
Signs of meningeal irritation
Involuntary movements
Other neurological symptons
AND severe illness AND absence of predisposing factors
Poliomyelitis or Viral, bacterial, fungal, or Rabies

Possible diseases/ pathogens Guillain Barr parasitic meningo-encephalitis
syndrome
Faeces CSF Serum

Specimens required Blood Culture Post mortem
Blood smears specimens (e.g.
Serum corneal impressions,
Throat swab brain tissue, skin
biopsy from necl
Viral: Bacterial Viral:

Culture (including Leptospiral): Culture
Laboratory studies Gram stain and other Antigen detection
microscopic techniques Antibody levels
Culture Genome analysis
Antimicrobial susceptibility
Antigen detection
Serotyping

Suspected outbreak ACUTE RESPIRATORY SYNDROME
Definition of syndrome Acute onset of cough OR respiratory distress AND severe illness AND
absence of known predisposing factors
Possible diseases/pathogens
Influenza Hantavirus Pertussis Bacterial

Diphtheria pulmonary Respiratory syncytial pneumonia
Streptococcal syndrome virus (RSV) including:
pharyngitis Pneumococcal
and Scarlet Legionellosis
Haemophilus
influenzae
Mycoplasma
Respiratory
anthrax
Pneumonic plague
Specimens required Throat Serum Blood

Nasopharyngeal
swab swab cultureSerum
Sputum
Urine (for
Legionella)
Bacterial or viral:
Culture
Antimicrobial susceptibility (for
Laboratory studies bacteria)
Antigen detection
Antibody levels
Genome analysis
Serotyping
Toxin identification
Adapted from: Guidelines for the collection of clinical specimens during field investigation of outbreaks. WHO/CDS/CSR/EDC/2000.4

ANNEX 2: STEPS FOR MANAGEMENT OF A COMMUNICABLE DISEASE
OUTBREAK
1. PREPARATION
Health Co-ordination meetings
Surveillance system - Weekly Health Reports to WHO
Stockpiles - specimen kits, appropriate antibiotics, IV fluids
Epidemic Investigation kits
Contingency plans for isolation wards in hospitals
Laboratory support
2. DETECTION
If you diagnose a case of the following diseases/syndromes:
Bloody diarrhoea
Acute watery diarrhoea
Suspected
cholera
Measles
Meningitis
Acute haemorrhagic fever syndrome
Acute jaundice syndrome
Or a cluster of deaths due to unknown origin
Inform your Health Co-ordinator as soon as possible
Health Co-ordinator shall inform WHO
Take a clinical specimen for laboratory confirmation (e.g. stool, serum, CSF)
Include the case in Weekly Health Report
3. CONFIRMATION
MoH will investigate cases reported to verify that a outbreak exists, in collaboration with WHO
where appropriate
Clinical specimens will be sent for testing
MoH will set up an Outbreak Control Team with membership from relevant organizations - WHO,
UNICEF health NGOs, water and sanitation NGOs, veterinary experts
4. RESPONSE
Investigation
Collect/analyse descriptive data to date (e.g. age, date of onset, location of cases)
Develop hypothesis for pathogen/source/transmission
Develop outbreak case definition
Follow up of cases and contacts
Conduct further investigation/epidemiological studies
Control
Implement control measures specific for the disease
Treat cases with recommended treatment as in WHO guidelines
Prevent exposure (e.g. isolation of cases in viral haemorrhagic fever outbreak)
Prevent infection (e.g. immunization in measles outbreak)
5. EVALUATION
Assess timeliness of outbreak detection and response, cost
Change public health policy if indicated (e.g. preparedness)
Write outbreak report and disseminate

ANNEX 3: SAFE WATER AND SANITATION
The following are effective methods to obtain safe drinking water:
Boiling
To make water safe for drinking and hygiene purposes, bring water to a vigorous, rolling boil and keep it boiling
for 1 minute. This will kill, or inactivate, most of the organisms that cause diarrhoea.
Household filtration
Household filtration should considerably reduce the pathogens in the water. It should be followed by
disinfection through chlorination or boiling.
Disinfection through chlorination
The following guidelines should be translated into messages that take into account locally available products
and measuring devices. To make water safe by chlorination, the first step is to make a stock solution of chlorine.
A stock solution can be prepared by adding the following products to one litre of water:
Product (% concentration b y weight of available chlorine) Amount for 1 litre
Calcium hypochlorite (70 %); or 15g

Bleaching powder or chlorinated lime (30%); or 33g
Sodium hypochlorite (5%); or 250 ml
Sodium hypochlorite (10 %); or 110 ml
The stock solution must be stored in a closed container, in a cool dark place and used within one month. It should be used to
prepare safe water as follows:
Stock solution Added volume of Water

0.6 ml or 3 drops l litre
6 ml 10 litres
60 ml 100 litres
Mix by stirring and allow the chlorinated water to stand for at least 30 minutes before using it. The free residual
chlorine level after 30 minutes should be between 0.1 to 0.5 mg/litre. If the free residual chlorine is not within
this range the number of drops of the stock solution should be adjusted so the final product falls within this
range.
If the water is cloudy or turbid it must either be filtered before chlorination or boiled vigorously rather than
chlorinated. Chlorination of turbid water might not make it safe.
See: Guidelines for Cholera Control, WHO 1993 and Fact Sheets on Environmental Sanitation for Cholera Control, WHO 1996
Sanitation
Good sanitation can markedly reduce the risk of transmission of intestinal pathogens, especially where its
absence may lead to contamination of clean water sources. High priority should be given to observing the basic
principles of sanitary human waste disposal, as well as to ensuring the availability of safe water supplies.
Appropriate facilities for human waste disposal are a basic need of all communities; in the absence of such
facilities there is a high risk of water-related diseases. Sanitary systems that are appropriate for the local
conditions should be constructed with the co-operation of the community.
People will need to taught how to use latrines, about the dangers of defecating on the ground, or in or
near waters, and about the importance of thorough hand-washing with soap or ash after any contact with
excreta. The disposal of children's excreta in latrines needs to be emphasized.
See Fact Sheets on Environmental Sanitation for Cholera Control, WHO 1996 and A Guide to the Development of On-site Sanitation,
WHO 1992

ANNEX 4: INJECTION SAFETY
Analysis of data collected as part of the Comparative Risk Assessment component of the Global Burden of
Disease study suggests that the Region which includes Angola faces substantial challenges in terms of
unsafe injection practices and transmission of blood-borne pathogens through injections. In this region, the
proportion of new infections with Hepatitis B, Hepatitis C, and HIV that are attributable to unsafe injections
practices are 58.3%, 81.7% and 7.1 % respectively.
In Sudan, only 50% of EPI injections are administered safely (clean preparation, safe reconstitution and use
of sterile syringe and needle), while therapeutic injections are safe in 30%. Sharps are presently collected in
safety boxes in 130% of immunization and 0% of therapeutic settings, while they are found in open
containers in 84% of health facilities.
Thus, in any relief efforts to assist the population and the refugees in this region of the world, safe and
appropriate use of injections should be ensured through the following actions:
PATIENTS:
State a preference for oral medications when visiting health care facilities
Demand a new, single-use syringe for every injection
HEALTH WORKERS:
Avoid prescribing injectable medication whenever possible
Use new, single-use syringe for every injection
Do not recap syringes and immediately discard them in a sharp box to prevent needlestick injury
Dispose of by open-air incineration and burial of full sharp boxes
IMMUNIZATION SERVICES:
Deliver vaccines with matching quantities of auto-disable syringes and sharp boxes
Make sterile syringes and sharp boxes available in every health care facility
ESSENTIAL DRUGS:
Build rational use of injections in the National drug policy
Make single-use syringes available in quantities that match injectable drugs in every health care facility
HIV-AIDS PREVENTION:
Communicate the risk of HIV infection associated with unsafe injections
HEALTH CARE SYSTEM:
Monitor safety of injections as a critical quality indicator for health care delivery
MINISTRY of HEALTH:
Coordinate safe and appropriate National policies with appropriate costing, budgeting and financing
REMEMBER:
Observe the "ONE SYRINGE/ONE NEEDLE SET-ONE INJECTION" rule
A safe injection is one that:
Does no harm to the recipient
Does not expose the health worker to avoidable risk
Does not result in waste that puts other people at risk
An unsterile injection is usually caused by:
Reusable syringes that are not properly sterilised before use
Single-use syringes that are used more than once
Used syringes and needles which are not disposed of properly

ANNEX 5: KEY CONTACTS FOR SUDAN
Table 1: World Health Organization - Sudan
Office of the WHO Representative Dr Guido Sabatinelli

PO Box 2234 The WHO Representative ([email protected])
Khartoum - Sudan
Location
Federal Ministry of Health Nile Avenue,
Eastern Gate, Khartoum, Sudan
Tel: +249-11-776-471 (office)
+249-11-780-190 (direct)
+249-11-781-707
Fax: +249-11-776-282
+873-382-420-336 (UNDP satellite in case of need)
E-mail: [email protected]
Table 2: Relevant WHO Regional Offices and Headquarters Technical Staff
Areas of work EMRO contact HQ contact

CD Control Dr Ezzedine Mohsni
Dr Maire Connolly
[email protected]
[email protected]
Outbreak Alert and Response
Dr Nadia Teleb Dr Mike Ryan
[email protected] [email protected]
Mr Pat Drury
[email protected]
Acute Lower Respiratory Dr Suzanne Farhoud
Dr Shamim Qazi
Infections [email protected]
[email protected]
African Trypanosomiasis
Dr Jean Jannin
[email protected]
Bacillary Dysentery - Cholera Dr Nadia Teleb
Dr Claire-Lise Chaignat
- [email protected]
[email protected]
Typhoid Fever - Other
Dr Suzanne Farhoud
Diarrhoea) Dr Frederique Marodon
[email protected]
Diseases [email protected]
Diphtheria Dr Ezzedine Mohsni
Dr Julian Bilous
[email protected]
[email protected]
Dracunculiasis
Dr Mark Karam
[email protected]
Dr Ahmed Tayeh
[email protected]
HIV/AIDS Dr Jihane Tawilah
Dr Andrew Ball
[email protected]
[email protected]
Dr Hany Ziady
Dr Brian Pazvakavambwa
[email protected]
[email protected]
Leishmaniasis Dr Riadh Ben-Ismail
Dr Philippe Desjeux
[email protected]
[email protected]

Leprosy Dr Denis Daumerie
[email protected]
Dr Myo Thet Htoon
[email protected]
Lymphatic Filariasis Dr Francesco Rio

[email protected]
Dr Sergio Yactayo
[email protected]
Malaria
Dr Hoda Atta Dr Aafje Rietveld
Dr Suzanne Farhoud Dr Allan Schapira
Measles
Dr Ezzedine Mohsni Dr Brad Hersh
Meningococcal disease
Dr Nadia Teleb Dr Maria Santamaria
Dr William Perea
[email protected]
Onchocerciasis
Dr Markus Behrend
[email protected]
Pertussis (whooping cough) Dr Ezzedine Mohsni Dr Philippe Duclos

Poliomyelitis Dr Faten Kamel Mr Chris Maher

Ms Claire Chauvin
[email protected]
Rabies Dr Riadh Ben-Ismail Dr Frangois-Xavier Meslin

Schistosomiasis Dr Riadh Ben-Ismail Dr Lorenzo Savioli

Dr Dirk Engels
[email protected]
Soil-transmitted helminths Dr Riadh Ben-Ismail Dr Lorenzo Savioli

Dr Antonio Montresor
[email protected]
Tuberculosis Dr Akihiro Seita Dr Salah-Eddine Ottmani

Dr Samiha Baghdadi Dr Malgosia Grzemska
Viral Haemorrhagic Fevers Dr Nadia Teleb Dr Cathy Roth

Health aspects of biological Dr Ottorino Cosivi

agents [email protected]

Injection Safety Dr Nadia Teleb Dr Yvan Hutin
Safe Water Dr Houssain Abouzaid Mr Jose Hueb


ANNEX 6: LIST OF WHO GUIDELINES ON COMMUNICABLE DISEASES
Title Publication No./Date
FACT SHEETS
Anthrax Fact Sheet No 264 October 2001
http://www.who.int/inf-fs/en/fact264.html
Cholera Fact Sheet No 107 Revised March 2000

http://www.who.int/inf-fs/en/factl07.html
Crimean-Congo Haemorrhagic Fever Fact Sheet No 208 December 1998

http://www.who.intlinf-fs/en/fact208.htmi
Dengue and Dengue Haemorrhagic Fever Fact Sheet No 117 Revised November 1998
http://www.who.int/inf-fs/en/factl 17.html
Diphtheria Fact Sheet No 89 Revised September 2000

http://www,who.int/inf-fs/en/fact089.html
Epidemic Dysentery Fact Sheet No 108 Revised October 1996

http://www. who. int/inf-fs/enlfactl08.htmI
Escherichia coli 0157:H7 Fact sheet No 103 Revised December 2000

http://www.who.int/inf-fs/en/factl 03.html
Food Safety and Foodborne Illness Fact Sheet No 237 revised January 2002
http://www.who.int/inf-fs/en/fact237.htmi
Hepatitis B Fact Sheet WHO/204 Revised October 2000

http://www.who.int/inf-fs/en/fact204.htmI
Hepatitis C Fact Sheet No 164 Revised October 2000

http://www.who.intlinf-fs/en/factl64.html
Influenza Fact Sheet No 211 February 1999

http://www.who.int/inf-fs/en/fact2l 1.html
Influenza A(H5N1) Fact Sheet No 188 January 1998

Injection Safety: Background Fact Sheet No 231 Revised April 2002

http://www.who.intlinf-fs/en/fact231.html
Injection Safety: Facts & Figures Fact Sheet No 232 October 1999
Injection Safety: a Glossary Fact Sheet No 233 October 1999

http://www.who.intlinf-fs/en/fact233.htm]
Injection Safety: Questions & Safety Fact Sheet No 234 October 1999
http://www.who.intlinf-fs/en/fact234,htmI
Malaria Fact Sheet no 94

http://www,who.intlinf-fs/en/factO94.html
Plague Fact Sheet No 267 January 2002
Poliomyelitis Fact Sheet No 114 Revised August 2002

http://www.who.int/mediacentre/factsheets/fs114/en/
Rabies Fact Sheet No 99 Revised June 2000

Salmonella Fact Sheet No 139 January 1997
Smallpox October 2001

http://www.who.intlemc/diseases/smallpox/factsheet.html
Tuberculosis Fact Sheet no 104 Revised August 2002

http://www.who.intlmediacentre/factsheets/whol04/en!
Typhoid Fever Fact sheet No 149 March 1997

http://www.who.int/inf-fs/en/factl49.html
The World Health Organization Fact Sheet No 126 August 1996

http://www.who.int/inf-fs/en/factl 26.htm
GUIDELINESIPUBLICATIONSIREPORTS
Protocol for the Assessment of National Communicable Disease Surveillance and WHO/CDS/CSRIISR/2001.2
Response Systems. Guidelines for Assessment Teams English only
http://www.who.int/emc-documents/surveillance/whocdscsrisr20012c.htmI
Strengthening Implementation of the Global Strategy for Dengue Fever/Dengue WHO/CDS/(DEN)/IC/2000.1

Haemorrhagic Fever Prevention and Control English only
http://www.who.intlemc-documents/dengue/whocdsdenic2000l c.html
WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases WHO/CDS/CSRII SR/2000.1

http:/Iwww.who.int/emc-documents/surveillance/whocdscsrisr2000lc.html English only
Guidelines for the collection of clinical specimens during field investigation of outbreaks WHO/EDC/2000.4
http://www.who.intlemc-documents/surveillance/docs/whocdscsredc2004.pdf English only
Hepatitis A WHO/CDS/EDC/2000.7
http://www.who.int/emc-documents/hepatitis/whocdscsredc20007c.htmI English only
WHO Guidelines for Epidemic Preparedness and Response to Measles Outbreaks WHO/CDS/CSRIISR/99.1
http://www.who.intlemc-documents/measles/whocdscsrisr991c.html English only
Influenza Pandemic Preparedness Plan. The Role of WHO and Guidelines for National and WHO/CDS/CSR/EDC/99.1
Regional Planning English only
http://www.who. int/emc-documents/influenza/whocdscsredc991 c.html
Plague Manual: Epidemiology, Distribution, Surveillance and Control WHO/CDS/CSR/EDC/99.2

http://www.who.int/emc-documents/plaguelwhocdscsredc992c.html English and French
Laboratory methods for the diagnosis of meningitis caused by Neisseria meningitidis, WHO/CDS/CSR/EDC/99.7
Streptococcus pneumoniae, and Haemophilus influenzae English and French
http://www.who.int/emc-documents/meningitis/whocdscsredc997c.htmI
Laboratory methods for the diagnosis of epidemic dysentery and cholera, 1999 WHO/CDS/CSR/EDC//99.8
http://www.who.intlemc/diseases/cholera.html English and French
Infection Control for Viral Haemorrhagic Fevers in the African Health Care Setting WHO/EMC/ESR/98.2
http://www.who.int/emc-documents/haem fevers/whoemeesr982c.html English and French
Control of epidemic meningococcal disease. WHO practical guidelines 2nd edition
http://www.who.intlemc-documents/meningitis/whoemcbac983c.html
Guidelines for the Surveillance and Control of Anthrax in Human and Animals. 3rd edition
Cholera and other epidemic diarrhoeal diseases control - Technical cards on environmental
sanitation, 1997
http://www.who.intlemc-documents/cholera/whoemcdis976c.html

WHO/EMC/97.3 Rev.1
Epidemic diarrhoeal disease preparedness and response - Training and practice, 1998
English, French and Spanish
(Participant's manual)
http://www.who.int/emc-documents/cholera/whoemcdis973c.html
Epidemic diarrhoeal disease preparedness and response - Training and practice, 1998 WHO/EMC/97.4 Rev.1
(Facilitator's guide) English, French and Spanish
http://www.who.int/emc-documents/cholera/whoemcdis974c.html
Dengue haemorrhagic fever: Diagnosis, treatment, prevention and control. 2nd edition 1997
http://www.who.intlemc/diseases/ebola/Denguepublication/index.html English only
Guidelines for the control of epidemics due to Shigella dysenteriae type 1 WHO/CDR/95.4
http://www.who.int/emc-documents/cholera/whocdr954c.html English only
Guidelines for Cholera Control, WHO 1993 1993

http://www.who.int/emc/diseases/cholera.htm English and French
VIDEOS
Protecting ourselves and our communities from cholera (41 min) 2000
http://www.who.int/emc/diseases/cholera/videos.html English and French
WEB SITES
WHO/EMRO Roll Back Malaria website http://208.48.48.190/rbm/Index.htm

ANNEX 7: IMMUNIZATION SCHEDULE FOR SUDAN
VACCINE SCHEDULE
BCG Birth or 1 St contact

DTP 6, 10, 14 weeks
OPV Birth, 6, 10, 14 weeks
Measles 9 months
Vitamin A
6-59 months
TT 1St contact for CBAW, 14th week of pregnancy, +4-6
weeks
CBAW = child bearing age women

ANNEX 8: MAP OF SUDAN

ANNEX 9: POPULATION OF SUDAN,2000
Northern and Centra SUDAN
STATE CAPITAL
AREA (SqKm) Population, 2000
Blue Nile (An Nil al Azraq) Al-Damazin 45,844 633,129
Gedarif (AI-Qadarif)
Gedarif 75,263 1,414,531
Gezira (Al-Jazirah)
Wad Medani 23,373 3,310,928
Kassala (Kassala)
Kassala 36,710 1,433,730
Khartoum (Al Khartum)
Khartoum 22,142 4,740,290
North Darfur (Shamal Darfur)
Al-Fashir 296,420 1,409,894
North Kordufan (Shamal Kurdufun) Al-Obeid 185,302 1,439,930
Northern (Ash Shamaliyah) Dongula 348,765 578,376
Red Sea (Al Bahr al Ahmar) Port Sudan 218,887 709,637
River Nile (Nahr an Nil)
Al-Damar 122,123 895,893
Sennar (Sinnar)
Sennar 37,844 1,132,758
South Darfur (Janub Darfur) Nyala 127,300 2,708,007
South Kordufan (Janub Kurdufun) Kadugli 79,470 1,066,117
West Darfur (Gharb Darfur) Geneina 79,460 1,531,682
West Kordufan (Gharb Kurdufun) Al-Fula 111,373 1,078,330
White Nile (An Nil al Abyad) Rabak 30,411 1,431,701
Sub-Total
1,840,687 25,514,933
Southern SUDAN
Bahr-al-Jabal Juba 22,956 1,342,943

East Equatoria (Sharq al Istiwa'iyah) Kapoita 82,542 1,234,486
Jungoli (Junqali) Bor 122,479 --
Lakes (Al Buhayrat) Rumbek 40,235 --
North Bahr-al-Gazal (Shamal Bahr-al-Gazal) Awil 33,558 --
Unity (Al Wahdah) Bantio 35,956 --
Upper Nile (A'ali an Nil) Malakal 77,773 1,342,943
Warap (Warab)
Warap 31,027 --
West Bahr-al-Gazal (Gharb Bahr-al-Gazal) Wau 93,900 --
West Equatoria (Gharb al Istiwa'iyah) Yambio 79,319 --
Sub-Total
619,745 3,920,372
Grand-Total
2,460,432 29,435,305
no compete: t e popu ation o southern Sudan is estimated at about six million
ANNEX 10: BASIC HEALTH INDICATORS IN SUDAN
Life Expectancy at Birth (in years)
55 (male) 58 (female) (2000)
Infant Mortality Rate 81 deaths per 1,000 live births (2000)
Mortality Rate for Children <5 years old 108 deaths per 1,000 live births (2000)
Maternal Mortality Ratio 500 deaths per 100,000 live births (1990-1998)
Population Growth Rate 2 . 4 % (1980-2000)
Access to an Improved Water Source 75% of population (2000)

Sudan Communicable Disease Profile

Uploaded by

Copyright:

Available Formats

Sudan Communicable Disease Profile

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Sudan Communicable Disease Profile

Uploaded by

Copyright:

Available Formats

WHO/CDS/2004.

COMMUNICABLE DISEASE TOOLKIT

1. COMMUNICABLE DISEASE PROFILE

Communicable Disease Working Group on Emergencies, WHO/HQ

All rights reserved.

World Health Organization 3

World Health Organization 4

World Health Organization 5

Case definition Clinical case definition

Children 2 months up to 5 years old

Severe Pneumonia or Very Severe Disease

General danger signs: unable to drink or breast feed; vomiting everything;

[Source: National guidelines on Integrated Management of Childhood Illness - IMCI

World Health Organization 6

RISK FACTORS FOR INCREASED TRANSMISSION

World Health Organization 7

PREVENTION AND CONTROL MEASURES

World Health Organization 8

2. AFRICAN TRYPANOSOMIASIS (AFRICAN SLEEPING SICKNESS)

Possible protracted course of several years in T.b. gambiense infection.

Rapid and acute evolution in T.b. rhodesiense infection.

Both diseases are always fatal without treatment.

Laboratory tests available:

Suspected*: any case without direct demonstration of the parasite

World Health Organization 9

World Health Organization 10

Overcrowding No Tsetse density is not related to the density of population.

World Health Organization 11

World Health Organization 13

RISK FACTORS FOR INCREASED TRANSMISSION

World Health Organization 14

PREVENTION AND CONTROL MEASURES

World Health Organization 15

Mode of Fecal oral route.

World Health Organization 16

RISK FACTORS FOR INCREASED TRANSMISSION

World Health Organization 17

World Health Organization 18

Seasonality Diarrhoea rates are higher in summer than in winter.

RISK FACTORS FOR INCREASED TRANSMISSION

World Health Organization 19

PREVENTION AND CONTROL MEASURES

Safe disposal of human excreta

World Health Organization 20

Hand washing with soap

World Health Organization 21

RISK FACTORS FOR INCREASED TRANSMISSION

PREVENTION AND CONTROL MEASURES

World Health Organization 22

World Health Organization 23

World Health Organization 24

World Health Organization 25

RISK FACTORS FOR INCREASED TRANSMISSION

World Health Organization 26

World Health Organization 27

World Health Organization 28

World Health Organization 29

RISK FACTORS FOR INCREASED TRANSMISSION

World Health Organization 30